


Supplementary Information:

Figure S1 Biomarkers Validation in Suicide Completers (A) Validating of top AP candidate biomarkers for suicidality. 47 out of the 153 with top-scoring CFG (31%) showed stepwise significant change between no SI, high SI, and validation suicide completers. 17 (11%) remained significant after strict Bonferroni correction. (B) Validating of top DE candidate biomarkers for suicidality. 124 out of the 418 with top-scoring CFG (30%) showed stepwise significant change between no SI, high SI, and validation suicide completers. 68 (16%) remained significant after strict Bonferroni correction.






Figure S2. SASS and snapshot of apps screen display.

Simplified Affective State Scale (SASS)

For each item, mark the scale with a vertical line where you think you are at this moment in time, compared to lowest and highest you ever remember being:

Mood Subscale

1) Mood

How good is your mood right now?

[-----]
Lowest Highest

2) Motivation to do things

How is your motivation, your drive, your determination to do things right now?

[-----]
Lowest Highest

3) Movement activity

How high is your physical energy and the amount of moving about that you feel like doing right now?

[-----]
Lowest Highest

4) Thinking activity

How high is your mental energy and thinking activity going on in your mind right now?

[-----]
Lowest Highest

5) Self-esteem

How good do you feel about yourself and your accomplishments right now?

[-----]
Lowest Highest

6) Interest in pleasurable activities

How high is your interest to do things that are fun and enjoyable right now?

[-----]
Lowest Highest

7) Appetite

How high is your appetite and desire for food right now?

[-----]
Lowest Highest

Anxiety Subscale

1) Anxiety

How anxious are you right now?

[-----]
Lowest Highest

2) Uncertainty

How uncertain about things do you feel right now?

[-----]
Lowest Highest

3) Fear

How frightened about things do you feel right now?

[-----]
Lowest **Highest**

4) Anger

How angry about things do you feel right now?

[-----]
Lowest **Highest**

Comments (optional):

Describe events or actions that you think are influencing how you feel now. Describe any additional feelings you might have at this moment in time:

--

SASS App

SASS

SASS - Enter Ratings

SASS - Enter Ratings

Simplified Affective State Scale

Lab Version

Current Subject ID: 001

Mood and Anxiety

Enter Ratings

View Ratings

Send Ratings

Export Ratings

Set Subject ID

Simplified Affective State Scale

Subject ID: 001

Mood Subscale

For each item, slide the scale to where you think you are at this moment in time, compared to lowest and highest you ever remember being:

1) Mood: 16/100

How good is your mood right now?

Lowest Highest

2) Motivation to do things: 20/100

How is your motivation, your drive, your determination to do things right now?

Lowest Highest

3) Movement activity: 41/100

How high is your physical energy and the amount of moving about that you feel like doing right now?

Lowest Highest

4) Thinking activity: unset

Anxiety Subscale

For each item, slide the scale to where you think you are at this moment in time, compared to lowest and highest you ever remember being:

1) Anxiety: 82/100

How anxious are you right now?

Lowest Highest

2) Uncertainty: 66/100

How uncertain about things do you feel right now?

Lowest Highest

3) Fear: 80/100

How frightened about things do you feel right now?

Lowest Highest

4) Anger: 37/100

How angry about things do you feel right now?

Lowest Highest

CFI-S App

CFI-S

Suicide Risk Assessment

Suicide risk assessment

CFI-S

Current Subject ID: 001

Last CFI-S Assessment: 11:47 AM, 04/20/2015

Set Subject ID

Select saved Subject ID

Perform CFI-S Assessment

View past assessment results

Take CFI-S without saving score

Settings

Export via excel

Export via email

Ask and answer the following questions. If you don't understand a question, you can tap the question text for more info.

Item 1.

Do you have a mood disorder?

Yes No Not sure

Comments (optional):

If so, has it been diagnosed and treated?

Yes No Not sure

Comments:

Do you have any other kind of psychiatric diagnosis?

Yes No Not sure

Comments:

CFI-S Score = 0.64

(64% of possible points)

Figure S3. mTOR signaling. The top KEGG pathway in our 76 Bonferroni corrected validated markers for suicide. Boxed in black are our suicide biomarkers present in this pathway.




Figure S4. Reproducibility and diagnosis differences in levels of biomarkers.




Table S1. Detailed Demographics

Cohort 1: Discovery Cohort (n=37) (106 visits)					
Subject ID visit	Diagnosis	Age	Gender	Ethnicity	HAMD SI
phchp016v1	SZ	54	M	African American	2
phchp016v2	SZ	54	M	African American	0
phchp016v3	SZ	54	M	African American	0
phchp023v1	BP	52	M	Caucasian	0
phchp023v2	BP	52	M	Caucasian	3
phchp023v3	BP	52	M	Caucasian	0
phchp042v1	SZA	43	M	Caucasian	3
phchp042v2	SZA	43	M	Caucasian	0
phchp042v3	SZA	44	M	Caucasian	0
phchp047v1	SZA	57	M	African American	2
phchp047v2	SZA	57	M	African American	0
phchp047v3	SZA	58	M	African American	0
phchp072v1	SZA	60	M	Caucasian	0
phchp072v2	SZA	60	M	Caucasian	0
phchp072v3	SZA	60	M	Caucasian	2
phchp088v2	BP	45	M	Caucasian	0
phchp088v3	BP	45	M	Caucasian	0
phchp088v4	BP	49	M	Caucasian	3
phchp088v5	BP	50	M	Caucasian	4
phchp089v1	SZA	33	M	Caucasian	0
phchp089v2	SZA	33	M	Caucasian	0
phchp089v4	SZA	38	M	Caucasian	3
phchp093v1	BP	51	M	Caucasian	0
phchp093v2	BP	51	M	Caucasian	0
phchp093v3	BP	52	M	Caucasian	3
phchp095v1	BP	28	M	Caucasian	3
phchp095v2	BP	29	M	Caucasian	0
phchp095v3	BP	29	M	Caucasian	2
phchp109v1	BP	22	M	Caucasian	0
phchp109v2	BP	25	M	Caucasian	3
phchp122v1	BP	51	M	Caucasian	0
phchp122v2	BP	51	M	Caucasian	2
phchp128v1	BP	45	M	Caucasian	2
phchp128v2	BP	45	M	Caucasian	0
phchp136v1	BP	41	M	Caucasian	0
phchp136v2	BP	41	M	Caucasian	0

phchp136v3	BP	41	M	Caucasian	3
phchp140v2	BP	38	M	Caucasian	3
phchp140v3	BP	38	M	Caucasian	2
phchp140v4	BP	40	M	Caucasian	0
phchp142v1	BP	55	M	Caucasian	0
phchp142v2	BP	55	M	Caucasian	0
phchp142v3	BP	55	M	Caucasian	0
phchp142v4	BP	57	M	Caucasian	2
phchp142v5	BP	57	M	Caucasian	0
phchp142v6	BP	58	M	Caucasian	0
phchp150v1	SZA	61	M	Caucasian	2
phchp150v2	SZA	61	M	Caucasian	0
phchp150v3	SZA	62	M	Caucasian	0
phchp153v1	BP	55	M	Caucasian	0
phchp153v2	BP	55	M	Caucasian	2
phchp153v3	BP	56	M	Caucasian	0
phchp153v4	BP	57	M	Caucasian	0
phchp153v6	BP	58	M	Caucasian	0
phchp155v1	MDD	37	M	Caucasian	3
phchp155v2	MDD	37	M	Caucasian	0
phchp161v1	MDD	54	M	African American	3
phchp161v2	MDD	54	M	African American	0
phchp161v3	MDD	54	M	African American	0
phchp179v1	BP	36	M	Caucasian	0
phchp179v2	BP	37	M	Caucasian	0
phchp179v4	BP	37	M	Caucasian	3
phchp182v1	MDD	39	M	Caucasian	2
phchp182v2	MDD	39	M	Caucasian	0
phchp182v3	MDD	40	M	Caucasian	3
phchp183v1	BP	48	M	Caucasian	3
phchp183v2	BP	48	M	Caucasian	0
phchp194v1	MDD	47	M	Caucasian	2
phchp194v2	MDD	47	M	Caucasian	0
phchp194v3	MDD	47	M	Caucasian	0
phchp198v1	MDD	61	M	Caucasian	4
phchp198v2	MDD	61	M	Caucasian	0
phchp198v4	MDD	62	M	Caucasian	0
phchp236v1	MDD	51	M	Caucasian	0
phchp236v2	MDD	51	M	Caucasian	3
phchp243v1	PTSD	50	M	African American	3
phchp243v2	PTSD	50	M	African American	0
phchp243v3	PTSD	52	M	African American	0
phchp248v1	SZ	52	M	African American	0

phchp248v2	SZ	52	M	African American	3
phchp248v3	SZ	53	M	African American	2
phchp266v1	MoodNOS	41	M	Caucasian	3
phchp266v2	MoodNOS	42	M	Caucasian	0
phchp266v3	MoodNOS	42	M	Caucasian	0
phchp277v1	SZ	49	M	Caucasian	0
phchp277v2	SZ	50	M	Caucasian	3
phchp277v3	SZ	50	M	Caucasian	0
phchp293v1	BP	43	M	Caucasian	0
phchp293v2	BP	44	M	Caucasian	2
phchp296v1	BP	48	M	Caucasian	0
phchp296v2	BP	49	M	Caucasian	2
phchp300v1	SZA	47	M	Caucasian	2
phchp300v2	SZA	47	M	Caucasian	0
phchp300v3	SZA	48	M	Caucasian	2
phchp304v1	MDD	52	M	Caucasian	2
phchp304v2	MDD	52	M	Caucasian	0
phchp304v3	MDD	52	M	Caucasian	2
phchp308v1	SZ	47	M	African American	3
phchp308v2	SZ	47	M	African American	0
phchp310v1	Mood NOS	54	M	African American	2
phchp310v2	Mood NOS	54	M	African American	0
phchp310v3	Mood NOS	54	M	African American	2
phchp319v1	PTSD	42	M	African American	0
phchp319v2	MDD	42	M	African American	4
phchp325v1	PTSD	44	M	Caucasian	3
phchp325v2	PTSD	44	M	Caucasian	0

Cohort 2: Coroner's Office Validation Cohort -gene expression data (n=26) and CFI-S data (n=35)

SubjectID- Visit	Dx	Age	Gender	Ethnicity	Method	CFI-S Score	Gene Expression
INBRAIN09	Bipolar/Schizophrenia	59	M	Caucasian	Hanging	0.5	Y
INBRAIN011	Depression/ADHD	26	M	Caucasian	GSW to chest	0.55	Y
INBRAIN012	Unknown	39	M	Caucasian	GSW - Head	0.5	Y
INBRAIN013	Depression	68	M	African American	GSW - Head	0.4	Y
INBRAIN014	None	27	M	Caucasian	Hanging	0.2	Y
INBRAIN015	None	40	M	Caucasian	Hanging	0.272	Y
INBRAIN016	Anxiety/TBI	68	M	Caucasian	GSW- head	0.684	Y
INBRAIN017	Depression	56	M	Caucasian	GSW to chest	0.7	Y
INBRAIN018	None	65	M	Caucasian	deep cut to wrist	0.786	Y

INBRAIN019	Depression	55	M	Caucasian	GSW to head & chest	0.45	Y
INBRAIN021		23	M	African American	Hanging	0.375	Y
INBRAIN022	Bipolar depression	38	M	Hispanic	GSW - Head	0.55	Y
INBRAIN023		18	M	Caucasian	Hanging	0.35	Y
INBRAIN024		23	M	Caucasian	Hanging	0.45	Y
INBRAIN025		31	M	African American	GSW - Head	0.4	Y
INBRAIN028	Alcoholism	67	M	Caucasian	GSW to chest	0.5	Y
INBRAIN030		22	M	African American	GSW- head	0.55	Y
INBRAIN033	Depression	26	M	Caucasian	GSW to chest	0.4	Y
INBRAIN035	Depression	58	M	Caucasian	Electrocution	0.5	Y
INBRAIN036		59	M	Caucasian	GSW to chest	0.444	Y
INBRAIN039		53	M	Caucasian	Hanging	0.6	Y
INBRAIN040		36	M	Caucasian	GSW- head	0.5	Y
INBRAIN044		23	M	Caucasian	Hanging	0.7	Y
INBRAIN048	Psychosis	26	M	Caucasian	GSW- head	0.762	Y
INBRAIN055	Depression	18	M	Caucasian	GSW - Head		Y
INBRAIN056	Depression	37	M	Caucasian	Hanging		Y
INBRAIN07	Depression/anxiety	57	M	Caucasian	CO Poisoning	0.615	N
INBRAIN08	Bipolar, untreated	31	M	Caucasian	Drug overdose	0.556	N
INBRAIN031		56	M	Caucasian	Drug overdose	0.563	N
INBRAIN037	Depression	24	M	Asian	Jump	0.368	N
INBRAIN041	Depression	76	M	Caucasian	GSW - Head	0.75	N
INBRAIN042		25	M	Caucasian	GSW - Head	0.545	N
INBRAIN043	None	28	M	Caucasian	GSW - Head	0.65	N
INBRAIN045		20	M	Caucasian	GSW - Head	0.6	N
INBRAIN046	Depression	65	M	Caucasian	GSW - Chest	0.667	N
INBRAIN047	Depression	57	M	Caucasian	GSW - Head	0.5	N
INBRAIN049	Depression, untreated	41	M	Caucasian	GSW - Head	0.55	N

Coroner's Office Validation Cohort -Toxicology

Subject ID	Toxicology
INBRAIN09	NA
INBRAIN011	ALPRAZOLAM 3.2 NG/ML TRAMADOL 331 NG/ML NORTRAMADOL 179 NG/ML BUPROPION 136 NG/ML CITALOPRAM/ESCITALOPRAM 229 NG/ML CAFFEINE COTININE
INBRAIN012	NEGATIVE
INBRAIN013	CAFFEINE
INBRAIN014	ETHANOL 0.15 % (W/V) CAFFEINE
INBRAIN015	ETHANOL 0.119 % (W/V) CAFFEINE
INBRAIN016	DIAZEPAM 155 NORDIAZEPAM 61.9 ALPRAZOLAM 6.8 ATENOLOL WARFARIN CAFFEINE
INBRAIN017	CLONAZEPAM 6.6 7-AMINOCLONAZEPAM 73.7 Glucose positive urine THC 2.0 THC-COOH 10.5 ETHANOL 0.130 FLUOXETINE 636 NORFLUOXETINE 359 VENLAFAXINE 1641 NORVENLAFAXINE 136 CAFFEINE
INBRAIN018	ETHANOL 0.057 % (W/V) AMIODARONE CAFFEINE COTININE

INBRAIN019	ALPRAZOLAM 169 CAFFEINE
INBRAIN021	THC 8.9 THC 60.2 ISOPROPANOL 0.042
INBRAIN022	ETHANOL 0.185 CAFFEINE
INBRAIN023	CAFFEINE POSITIVE
INBRAIN024	CAFFEINE POSITIVE
INBRAIN025	THC 1.2 THC-COOH 12.0 CAFFEINE
INBRAIN028	ETHANOL 0.354 ANTIHISTAMINES DIPHENHYRAMINE 178 AMLODIPINE 19.9 CAFFEINE
INBRAIN030	CAFFEINE POSITIVE
INBRAIN033	ETHANOL 0.128 CITALOPRAM 294 CAFFEINE
INBRAIN035	VENLAFAXINE 231 NORVENLAXFAXINE 452 AMLODIPINE 45.3 CAFFEINE
INBRAIN036	NEGATIVE
INBRAIN039	ETHANOL 0.158 CAFFEINE
INBRAIN040	IBUPROFEN 8.2 CAFFEINE
INBRAIN044	THC 10.3 THC-COOH 143
INBRAIN048	CARBOXY THC 78 ng/ml CAFFEINE
INBRAIN055	THC-COOH 4.3 ng/ml CARBOXY THC 69 ng/ml
INBRAIN056	NEGATIVE

Cohort 3: Test Cohort for Suicidal Ideation (n=108) (223 visits)

Subject ID visit	Diagnosis	Age	Gender	Ethnicity	SI
phchp003v1	SZ	50	M	African American	0
phchp005v1	SZA	45	M	Caucasian	0
phchp005v2	SZA	45	M	Caucasian	0
phchp005v3	SZA	45	M	Caucasian	0
phchp006v1	SZA	52	M	African American	0
phchp006v2	SZA	52	M	African American	0
phchp008v1	SZ	47	M	African American	0
phchp010v1	SZA	45	M	Caucasian	0
phchp010v2	SZA	45	M	Caucasian	0
phchp010v3	SZA	45	M	Caucasian	0
phchp013v1	SZA	53	M	African American	0
phchp013v3	SZA	54	M	African American	0
phchp015v1	SZ	48	M	African American	0
phchp015v2	SZ	49	M	African American	0
phchp017v2	SZA	53	M	African American	0
phchp017v3	SZA	54	M	African American	0
phchp019v1	SZ	50	M	African American	0
phchp019v2	SZ	51	M	African American	0
phchp019v3	SZ	51	M	African American	0
phchp021v1	SZA	48	M	Hispanic	0
phchp021v2	SZA	49	M	Hispanic	0
phchp021v3	SZA	49	M	Hispanic	0
phchp022v1	SZ	48	M	Caucasian	0
phchp022v2	SZ	48	M	Caucasian	0
phchp024v1	SZA	49	M	African American	0
phchp025v1	SZ	42	M	Caucasian	0
phchp026v1	SZA	49	M	African American	1
phchp026v2	SZA	49	M	African American	0
phchp026v3	SZA	49	M	African American	0
phchp027v1	SZA	40	M	Caucasian	0
phchp029v1	MDD	56	M	Caucasian	3
phchp030v1	BP	49	M	Caucasian	0
phchp030v3	BP	49	M	Caucasian	0
phchp031v1	BP	51	M	Caucasian	0
phchp031v2	BP	51	M	Caucasian	0
phchp031v3	BP	52	M	Caucasian	0

phchp033v1	SZA	48	M	Caucasian	3
phchp039v1	BP	52	M	Caucasian	0
phchp039v3	BP	52	M	Caucasian	0
phchp040v1	SZA	50	M	Caucasian	0
phchp040v2	SZA	50	M	Caucasian	0
phchp040v3	SZA	50	M	Caucasian	0
phchp045v1	BP	36	M	Caucasian	1
phchp045v3	BP	36	M	Caucasian	0
phchp046v1	SZA	45	M	Caucasian	0
phchp046v2	SZA	45	M	Caucasian	0
phchp046v3	SZA	45	M	Caucasian	0
phchp049v1	SZA	46	M	Caucasian	2
phchp049v2	SZA	47	M	Caucasian	1
phchp051v1	SZA	52	M	Caucasian	0
phchp052v1	SZ	60	M	Caucasian	2
phchp052v2	SZ	60	M	Caucasian	2
phchp052v3	SZ	60	M	Caucasian	2
phchp056v1	BP	36	M	Caucasian	0
phchp057v1	SZA	47	M	Caucasian	0
phchp061v1	SZ	49	M	Caucasian	0
phchp061v2	SZ	49	M	Caucasian	1
phchp061v3	SZ	50	M	Caucasian	1
phchp067v1	BP	39	M	Caucasian	0
phchp067v3	BP	40	M	Caucasian	1
phchp069v1	SZ	47	M	Caucasian	0
phchp069v2	SZ	47	M	Caucasian	0
phchp069v3	SZ	48	M	Caucasian	0
phchp070v1	SZ	52	M	African American	0
phchp070v2	SZ	52	M	African American	0
phchp070v3	SZ	52	M	African American	0
phchp073v1	SZA	50	M	Caucasian	0
phchp073v2	SZA	50	M	Caucasian	1
phchp073v3	SZA	50	M	Caucasian	0
phchp079v1	BP	44	M	Caucasian	1
phchp079v2	BP	44	M	Caucasian	0
phchp079v3	BP	45	M	Caucasian	0
phchp079v4	BP	49	M	Caucasian	0
phchp079v5	BP	50	M	Caucasian	0
phchp079v6	BP	50	M	Caucasian	0
phchp080v1	BP	44	M	Caucasian	0
phchp081v1	SZA	53	M	African American	3
phchp081v3	SZA	53	M	African American	3
phchp083v1	SZ	50	M	African American	0

phchp083v2	SZ	50	M	African American	0
phchp083v3	SZ	51	M	African American	0
phchp086v1	SZ	49	M	Caucasian	0
phchp086v2	SZ	49	M	Caucasian	0
phchp086v3	SZ	49	M	Caucasian	0
phchp092v1	BP	45	M	African American	0
phchp092v2	BP	46	M	African American	0
phchp092v3	BP	46	M	African American	0
phchp094v1	BP	41	M	African American	0
phchp099v1	SZ	49	M	Caucasian	1
phchp099v2	SZ	49	M	Caucasian	1
phchp099v3	SZ	49	M	Caucasian	0
phchp100v1	BP	28	M	Caucasian	0
phchp101v1	SZA	74	M	Caucasian	3
phchp102v1	SZA	56	M	Caucasian	2
phchp102v2	SZA	56	M	Caucasian	1
phchp102v3	SZA	56	M	Caucasian	2
phchp103v1	SZA	61	M	Caucasian	1
phchp108v1	SZ	42	M	Caucasian	0
phchp108v2	SZ	42	M	Caucasian	0
phchp108v3	SZ	43	M	Caucasian	0
phchp112v1	BP	46	M	Caucasian/Native Australian	0
phchp112v2	BP	46	M	Caucasian	0
phchp112v3	BP	47	M	Caucasian	0
phchp113v1	BP	37	M	Caucasian	1
phchp114v1	SZA	54	M	African American	0
phchp116v1	SZA	47	M	Caucasian	2
phchp117v1	BP	43	M	Caucasian	0
phchp117v2	BP	43	M	Caucasian	0
phchp117v3	BP	43	M	Caucasian	0
phchp118v1	SZA	46	M	African American	0
phchp118v2	SZA	47	M	African American	0
phchp118v4	SZA	50	M	African American	0
phchp120v1	SZ	51	M	Caucasian	0
phchp120v2	SZ	51	M	Caucasian	0
phchp120v3	SZ	51	M	Caucasian	0
phchp124v1	BP	53	M	Caucasian	0
phchp132v1	BP	51	M	Caucasian	0
phchp132v2	BP	51	M	Caucasian	0
phchp132v3	BP	52	M	Caucasian	0
phchp139v1	SZ	24	M	Caucasian	0
phchp147v1	BP	38	M	Caucasian	0
phchp147v2	BP	38	M	Caucasian	0

phchp147v3	BP	38	M	Caucasian	0
phchp148v1	SZ	25	M	Caucasian	0
phchp149v1	BP	45	M	Caucasian	0
phchp149v2	BP	45	M	Caucasian	0
phchp149v3	BP	46	M	Caucasian	0
phchp151v1	SZ	24	M	Caucasian	4
phchp151v2	SZ	24	M	Caucasian	2
phchp151v3	SZ	24	M	Caucasian	1
phchp152v1	BP	45	M	Caucasian	2
phchp154v1	SZA	51	M	African American	0
phchp154v2	SZA	51	M	African American	0
phchp154v3	SZA	52	M	African American	0
phchp158v1	BP	23	M	African American	4
phchp162v1	MDD	57	M	Caucasian	3
phchp162v2	MDD	57	M	Caucasian	2
phchp162v3	MDD	57	M	Caucasian	2
phchp167v1	MDD	49	M	Caucasian	0
phchp168v1	MDD	48	M	African American	0
phchp168v2	MDD	48	M	African American	0
phchp168v3	MDD	49	M	African American	0
phchp169v1	SZA	50	M	African American	0
phchp171v1	BP	36	M	Caucasian	0
phchp171v2	BP	36	M	Caucasian	0
phchp173v1	MDD	48	M	Caucasian	0
phchp173v2	MDD	49	M	Caucasian	0
phchp173v3	MDD	49	M	Caucasian	0
phchp174v1	MDD	54	M	Caucasian	3
phchp175v1	SZA	42	M	Caucasian	0
phchp176v1	SZ	23	M	African American	0
phchp176v2	SZ	24	M	African American	0
phchp178v1	BP	49	M	Caucasian	0
phchp185v1	SZA	51	M	African American	0
phchp185v2	SZA	51	M	African American	0
phchp185v3	SZA	52	M	African American	0
phchp186v1	BP	43	M	Caucasian	0
phchp186v2	BP	44	M	Caucasian	0
phchp186v3	BP	44	M	Caucasian	0
phchp186v4	BP	46	M	Caucasian	0
phchp187v1	SZ	49	M	African American	0
phchp187v2	SZ	49	M	African American	0
phchp188v1	SZ	54	M	African American	0
phchp189v1	SZ	25	M	Caucasian	1
phchp190v1	BP	49	M	Caucasian	1

phchp190v2	BP	49	M	Caucasian	0
phchp195v1	SZ	52	M	Caucasian	0
phchp195v2	SZ	53	M	Caucasian	0
phchp195v3	SZ	53	M	Caucasian	0
phchp196v1	MDD	56	M	African American	0
phchp196v2	MDD	56	M	African American	0
phchp196v3	MDD	57	M	African American	0
phchp199v1	SZ	49	M	African American	0
phchp199v2	SZ	49	M	African American	0
phchp199v3	SZ	50	M	African American	0
phchp200v1	MDD	56	M	Caucasian	0
phchp200v2	MDD	57	M	Caucasian	0
phchp200v3	MDD	57	M	Caucasian	0
phchp206v1	MDD	59	M	African American	0
phchp207v1	SZ	48	M	African American	1
phchp208v1	MDD	56	M	African American	0
phchp208v2	MDD	56	M	African American	0
phchp208v3	MDD	58	M	African American	0
phchp212v1	MDD	56	M	African American	0
phchp212v2	MDD	56	M	African American	0
phchp221v1	MDD	51	M	African American	0
phchp221v2	MDD	51	M	African American	0
phchp221v3	MDD	52	M	African American	0
phchp224v1	BP	59	M	Caucasian	4
phchp226v1	MDD	29	M	Caucasian	0
phchp226v2	MDD	29	M	Caucasian	0
phchp226v3	MDD	30	M	Caucasian	0
phchp227v1	MDD	55	M	Caucasian	0
phchp227v2	MDD	55	M	Caucasian	0
phchp227v3	MDD	55	M	Caucasian	0
phchp231v1	MDD	55	M	Caucasian	2
phchp234v1	BP	44	M	Caucasian	2
phchp234v2	BP	45	M	Caucasian	2
phchp234v3	BP	45	M	Caucasian	1
phchp235v1	MDD	54	M	African American	0
phchp235v2	MDD	55	M	African American	0
phchp235v3	MDD	55	M	African American	0
phchp238v1	MDD	62	M	Caucasian	0
phchp242v1	MDD	55	M	African American	0
phchp242v2	MDD	57	M	African American	0
phchp247v1	MDD	55	M	African American	0
phchp259v1	MDD	56	M	Caucasian	0
phchp259v2	MDD	57	M	Caucasian	0

phchp259v3	MDD	57	M	Caucasian	0
phchp273v1	BP	27	M	Caucasian	3
phchp273v2	BP	28	M	Caucasian	2
phchp274v1	BP	48	M	Caucasian	3
phchp274v2	BP	48	M	Caucasian	3
phchp274v3	BP	48	M	Caucasian	1
phchp283v1	SZ	51	M	Caucasian	0
phchp295v1	SZ	52	M	African American	0
phchp297v1	SZA	54	M	African American	0
phchp315v1	MDD	62	M	Caucasian	0
phchp322v1	BP	26	M	Caucasian	4
phchp324v1	MDD	33	M	African American	4
phchp327v1	MDD	42	M	Caucasian	3
phchp333v1	MDD	38	M	Caucasian	4
phchp335v1	MDD	25	M	Caucasian	3

Cohort 4: Testing cohort for future hospitalizations for suicidality (n=157) (373 chips)											
(SI- Suicidal Ideation, SA- Suicide Attempts)											
Subject ID visit	Diag nosi s	Age	Gend er	Ethnicity	Years Followed	Number Of First Year Hospitalizations Due To Suicidality		Number Of All Future Hospitalizations Due To Suicidality		Hospitalizations Frequency Due To Suicidality	
						SI	SA	SI	SA	SI	SA
phchp003 v1	SZ	50	M	African American	8.5	0	0	0	0	0	0
phchp003 v2	SZ	50	M	African American	8	0	0	0	0	0	0
phchp003 v3	SZ	50	M	African American	7.75	0	0	0	0	0	0
phchp004 v1	SZA	55	M	African American	8.416667	0	0	0	0	0	0
phchp004 v2	SZA	60	M	African American	2.083333	0	0	0	0	0	0
phchp004 v4	SZA	60	M	African American	1.75	0	0	0	0	0	0
phchp005 v1	SZA	45	M	Caucasian	8.083333	0	0	1	0	0.13	0
phchp005 v2	SZA	45	M	Caucasian	7.75	0	0	1	0	0.13	0
phchp005 v3	SZA	45	M	Caucasian	7.5	0	0	1	0	0.14	0
phchp006 v1	SZA	52	M	African American	5.666667	0	0	0	0	0	0
phchp006 v2	SZA	52	M	African American	5.5	0	0	0	0	0	0
phchp008 v1	SZ	47	M	African American	5.25	1	0	1	0	0.2	0
phchp009 v1	SZ	55	M	African American	6.5	0	0	0	0	0	0
phchp009 v3	SZ	56	M	African American	6	0	0	0	0	0	0
phchp010 v1	SZA	45	M	Caucasian	8	0	0	0	0	0	0
phchp010	SZA	45	M	Caucasian	7.75	0	0	0	0	0	0

v2									
phchp010 v3	SZA	45	M	Caucasian	7.5	0 0	0 0	0 0	
phchp012 v1	SZA	55	M	Caucasian	3.833333	0 0	1 0	0.27 0	
phchp012 v2	SZA	55	M	Caucasian	3.583333	0 0	1 0	0.28 0	
phchp012 v3	SZA	55	M	Caucasian	3.333333	0 0	1 0	0.3 0	
phchp013 v1	SZA	53	M	African American	8	0 0	0 0	0 0	
phchp013 v3	SZA	54	M	African American	7.5	0 0	0 0	0 0	
phchp014 v1	SZA	55	M	African American	8.25	0 0	1 0	0.13 0	
phchp015 v1	SZ	48	M	African American	8.25	0 0	1 1	0.13 0.13	
phchp015 v2	SZ	49	M	African American	7.916667	0 0	1 1	0.13 0.13	
phchp016 v1	SZ	54	M	African American	5.5	0 0	0 0	0 0	
phchp016 v2	SZ	54	M	African American	5.25	0 0	0 0	0 0	
phchp016 v3	SZ	54	M	African American	5	0 0	0 0	0 0	
phchp017 v2	SZA	53	M	African American	1.5	0 0	0 0	0 0	
phchp017 v3	SZA	54	M	African American	1	0 0	0 0	0 0	
phchp019 v1	SZ	50	M	African American	7.666667	0 0	1 0	0.14 0	
phchp019 v2	SZ	51	M	African American	7.333333	0 0	1 0	0.14 0	
phchp019 v3	SZ	51	M	African American	6.916667	0 0	1 0	0.15 0	
phchp020 v1	BP	62	M	Caucasian	7.083333	0 0	0 0	0 0	
phchp020	BP	62	M	Caucasian	6.833333	0 0	0 0	0 0	

v2									
phchp020 v3	BP	63	M	Caucasian	6.5	0 0	0 0	0 0	
phchp021 v1	SZA	48	M	Hispanic	7.083333	0 0	2 1	0.29 0.15	
phchp021 v2	SZA	49	M	Hispanic	6.833333	0 0	2 1	0.3 0.15	
phchp021 v3	SZA	49	M	Hispanic	6.5	0 0	2 1	0.31 0.16	
phchp022 v1	SZ	48	M	Caucasian	7.583333	0 0	0 0	0 0	
phchp022 v2	SZ	48	M	Caucasian	7.333333	0 0	0 0	0 0	
phchp024 v1	SZA	49	M	African American	7.75	1 0	2 0	0.26 0	
phchp025 v1	SZ	42	M	Caucasian	7.75	0 0	0 0	0 0	
phchp026 v1	SZA	49	M	African American	2.916667	0 0	0 0	0 0	
phchp026 v2	SZA	49	M	African American	2.666667	0 0	0 0	0 0	
phchp026 v3	SZA	49	M	African American	2.333333	0 0	0 0	0 0	
phchp027 v1	SZA	40	M	Caucasian	7.5	0 0	3 0	0.4 0	
phchp030 v1	BP	49	M	Caucasian	6.916667	1 0	4 0	0.58 0	
phchp030 v3	BP	49	M	Caucasian	6.25	0 0	3 0	0.48 0	
phchp031 v1	BP	51	M	Caucasian	4.666667	0 0	0 0	0 0	
phchp031 v2	BP	51	M	Caucasian	4.333333	0 0	0 0	0 0	
phchp031 v3	BP	52	M	Caucasian	4.083333	0 0	0 0	0 0	
phchp033 v1	SZA	48	M	Caucasian	2.5	0 0	1 0	0.4 0	
phchp038	SZA	58	M	African	7.25	0 0	0 0	0 0	

v1				American				
phchp038 v2	SZA	58	M	African American	7	0 0	0 0	0 0
phchp038 v3	SZA	59	M	African American	6.75	0 0	0 0	0 0
phchp039 v1	BP	52	M	Caucasian	6.75	0 0	0 0	0 0
phchp039 v3	BP	52	M	Caucasian	6.083333	0 0	0 0	0 0
phchp040 v1	SZA	50	M	Caucasian	5.833333	0 0	0 0	0 0
phchp040 v2	SZA	50	M	Caucasian	5.583333	0 0	0 0	0 0
phchp040 v3	SZA	50	M	Caucasian	5.333333	0 0	0 0	0 0
phchp041 v1	SZ	62	M	African American	7.333333	0 0	0 0	0 0
phchp042 v1	SZA	43	M	Caucasian	6	0 0	0 0	0 0
phchp042 v2	SZA	43	M	Caucasian	5.75	0 0	0 0	0 0
phchp042 v3	SZA	44	M	Caucasian	5.5	0 0	0 0	0 0
phchp045 v1	BP	36	M	Caucasian	7	0 0	0 0	0 0
phchp045 v3	BP	36	M	Caucasian	6.416667	0 0	0 0	0 0
phchp046 v1	SZA	45	M	Caucasian	7.083333	0 0	0 0	0 0
phchp046 v2	SZA	45	M	Caucasian	6.916667	0 0	0 0	0 0
phchp046 v3	SZA	45	M	Caucasian	6.666667	0 0	0 0	0 0
phchp047 v1	SZA	57	M	African American	6.333333	0 0	1 1	0.16 0.16
phchp047 v2	SZA	57	M	African American	6.083333	0 0	1 1	0.17 0.17
phchp047	SZA	58	M	African	5.833333	0 0	1 1	0.18 0.18

v3				American				
phchp048 v1	SZA	56	M	African American	5.25	0 0	0 0	0 0
phchp048 v2	SZA	57	M	African American	5.083333	0 0	0 0	0 0
phchp048 v3	SZA	57	M	African American	4.75	0 0	0 0	0 0
phchp049 v1	SZA	46	M	Caucasian	6.916667	0 0	0 0	0 0
phchp049 v2	SZA	47	M	Caucasian	6.666667	0 0	0 0	0 0
phchp051 v1	SZA	52	M	Caucasian	6.833333	0 0	0 0	0 0
phchp052 v1	SZ	60	M	Caucasian	1.166667	0 0	0 0	0 0
phchp053 v1	BP	58	M	Caucasian	6.333333	0 0	0 0	0 0
phchp053 v2	BP	58	M	Caucasian	6	0 0	0 0	0 0
phchp053 v3	BP	58	M	Caucasian	5.75	0 0	0 0	0 0
phchp057 v1	SZA	47	M	Caucasian	6.833333	0 0	0 0	0 0
phchp058 v1	SZ	56	M	African American	6.833333	0 0	0 0	0 0
phchp058 v2	SZ	56	M	African American	6.583333	0 0	0 0	0 0
phchp058 v3	SZ	56	M	African American	6.333333	0 0	0 0	0 0
phchp060 v1	SZ	62	M	Caucasian	3.5	0 0	0 0	0 0
phchp061 v1	SZ	49	M	Caucasian	7.083333	1 0	4 0	0.57 0
phchp061 v2	SZ	49	M	Caucasian	6.833333	1 0	4 0	0.59 0
phchp061 v3	SZ	50	M	Caucasian	6.166667	3 0	4 0	0.65 0
phchp062	SZ	56	M	Caucasian	6.75	0 0	0 0	0 0

v1									
phchp062 v2	SZ	56	M	Caucasian	6.5	0 0	0 0	0 0	
phchp062 v3	SZ	57	M	Caucasian	6.25	0 0	0 0	0 0	
phchp065 v1	SZA	62	M	Caucasian	6.583333	0 0	0 0	0 0	
phchp065 v2	SZA	62	M	Caucasian	6.333333	0 0	0 0	0 0	
phchp065 v3	SZA	62	M	Caucasian	6.083333	0 0	0 0	0 0	
phchp067 v1	BP	39	M	Caucasian	5.916667	0 0	0 0	0 0	
phchp067 v3	BP	40	M	Caucasian	5.333333	0 0	0 0	0 0	
phchp068 v1	SZA	57	M	African American	6.666667	0 0	0 0	0 0	
phchp068 v2	SZA	57	M	African American	6.333333	0 0	0 0	0 0	
phchp068 v3	SZA	57	M	African American	6	0 0	0 0	0 0	
phchp069 v1	SZ	47	M	Caucasian	6.583333	0 0	0 0	0 0	
phchp069 v2	SZ	47	M	Caucasian	6.333333	0 0	0 0	0 0	
phchp069 v3	SZ	48	M	Caucasian	6.083333	0 0	0 0	0 0	
phchp070 v1	SZ	52	M	African American	6.583333	0 0	0 0	0 0	
phchp070 v2	SZ	52	M	African American	6.25	0 0	0 0	0 0	
phchp070 v3	SZ	52	M	African American	6	0 0	0 0	0 0	
phchp070 v4	SZ	56	M	African American	2.083333	0 0	0 0	0 0	
phchp070 v5	SZ	56	M	African American	1.833333	0 0	0 0	0 0	
phchp070	SZ	57	M	African	1.583333	0 0	0 0	0 0	

v6	American							
phchp072 v1	SZA	60	M	Caucasian	6.5	0 0	1 0	0.16 0
phchp072 v2	SZA	60	M	Caucasian	6.25	0 0	1 0	0.16 0
phchp072 v3	SZA	60	M	Caucasian	5.916667	0 0	1 0	0.17 0
phchp073 v1	SZA	50	M	Caucasian	5.5	0 0	12 0	2.19 0
phchp073 v2	SZA	50	M	Caucasian	5.166667	0 0	12 0	2.33 0
phchp073 v3	SZA	50	M	Caucasian	4.916667	0 0	12 0	2.45 0
phchp075 v1	SZA	57	M	Caucasian	6.166667	0 0	3 0	0.49 0
phchp075 v2	SZA	58	M	Caucasian	5.916667	0 0	3 0	0.51 0
phchp075 v3	SZA	58	M	Caucasian	5.666667	0 0	3 0	0.53 0
phchp079 v1	BP	44	M	Caucasian	6.25	0 0	0 0	0 0
phchp079 v2	BP	44	M	Caucasian	6	0 0	0 0	0 0
phchp079 v3	BP	45	M	Caucasian	5.75	0 0	0 0	0 0
phchp079 v4	BP	49	M	Caucasian	1.083333	0 0	0 0	0 0
phchp080 v1	BP	44	M	Caucasian	5.416667	0 0	0 0	0 0
phchp081 v1	SZA	53	M	African American	1.166667	0 0	0 0	0 0
phchp083 v1	SZ	50	M	African American	6	0 0	0 0	0 0
phchp083 v2	SZ	50	M	African American	5.75	0 0	0 0	0 0
phchp083 v3	SZ	51	M	African American	5.5	0 0	0 0	0 0
phchp085	SZA	57	M	Caucasian	5.75	0 0	0 0	0 0

v1									
phchp085 v2	SZA	57	M	Caucasian	5.5	0 0	0 0	0 0	
phchp085 v3	SZA	57	M	Caucasian	5.25	0 0	0 0	0 0	
phchp086 v1	SZ	49	M	Caucasian	5.666667	0 0	0 0	0 0	
phchp086 v2	SZ	49	M	Caucasian	5.416667	0 0	0 0	0 0	
phchp086 v3	SZ	49	M	Caucasian	5.083333	0 0	0 0	0 0	
phchp087 v1	SZA	65	M	Caucasian	5.833333	0 0	0 0	0 0	
phchp087 v2	SZA	66	M	Caucasian	5.5	0 0	0 0	0 0	
phchp087 v3	SZA	66	M	Caucasian	5.25	0 0	0 0	0 0	
phchp088 v1	BP	44	M	Caucasian	5.916667	3 0	17 1	2.88 0.17	
phchp088 v2	BP	45	M	Caucasian	5.75	2 0	16 1	2.79 0.18	
phchp088 v3	BP	45	M	Caucasian	5.333333	1 0	15 1	2.82 0.19	
phchp088 v4	BP	49	M	Caucasian	1.333333	8 1	8 1	6.01 0.75	
phchp089 v1	SZA	33	M	Caucasian	5.75	0 0	1 0	0.18 0	
phchp089 v2	SZA	33	M	Caucasian	5.5	0 0	1 0	0.19 0	
phchp091 v1	SZA	55	M	Caucasian	5.333333	0 0	0 0	0 0	
phchp091 v2	SZA	55	M	Caucasian	5.083333	0 0	0 0	0 0	
phchp091 v3	SZA	55	M	Caucasian	4.833333	0 0	0 0	0 0	
phchp092 v1	BP	45	M	African American	5.75	0 0	0 0	0 0	
phchp092	BP	46	M	African	5.333333	0 0	0 0	0 0	

v2					American							
phchp092 v3	BP	46	M	African American	5.166667	0	0		0	0	0	0
phchp093 v1	BP	51	M	Caucasian	4.25	1	0		2	0	0.48	0
phchp093 v2	BP	51	M	Caucasian	4	1	0		2	0	0.5	0
phchp093 v3	BP	52	M	Caucasian	3.75	0	0		1	0	0.27	0
phchp094 v1	BP	41	M	African American	4.666667	0	0		0	0	0	0
phchp095 v1	BP	28	M	Caucasian	4.25	2	0		2	0	0.48	0
phchp095 v2	BP	29	M	Caucasian	4	2	0		2	0	0.5	0
phchp095 v3	BP	29	M	Caucasian	3.75	1	0		1	0	0.27	0
phchp096 v1	SZ	55	M	African American	4.833333	0	0		0	0	0	0
phchp096 v3	SZ	56	M	African American	4.333333	0	0		0	0	0	0
phchp096 v4	SZ	58	M	African American	2.416667	0	0		0	0	0	0
phchp098 v1	SZ	59	M	African American	4.75	0	0		0	0	0	0
phchp099 v1	SZ	49	M	Caucasian	4.583333	0	0		0	0	0	0
phchp099 v2	SZ	49	M	Caucasian	4.333333	0	0		0	0	0	0
phchp099 v3	SZ	49	M	Caucasian	4	0	0		0	0	0	0
phchp100 v1	BP	28	M	Caucasian	1.583333	0	0		0	0	0	0
phchp103 v1	SZA	61	M	Caucasian	2.583333	1	0		1	0	0.39	0
phchp105 v1	SZA	59	M	Caucasian	2.833333	0	0		0	0	0	0
phchp108	SZ	42	M	Caucasian	4.083333	0	0		0	0	0	0

v1								
phchp108 v2	SZ	42	M	Caucasian	3.833333	0 0	0 0	0 0
phchp108 v3	SZ	43	M	Caucasian	3.583333	0 0	0 0	0 0
phchp109 v1	BP	22	M	Caucasian	3.583333	0 0	3 0	0.84 0
phchp112 v1	BP	46	M	Caucasian/Native Australian	1.583333	0 0	0 0	0 0
phchp112 v2	BP	46	M	Caucasian	1.333333	0 0	0 0	0 0
phchp112 v3	BP	47	M	Caucasian	1	0 0	0 0	0 0
phchp113 v1	BP	37	M	Caucasian	3.333333	0 0	0 0	0 0
phchp114 v1	SZA	54	M	African American	3.75	0 0	0 0	0 0
phchp115 v1	BP	67	M	Caucasian	4.416667	0 0	0 0	0 0
phchp115 v2	BP	67	M	Caucasian	4.166667	0 0	0 0	0 0
phchp115 v3	BP	68	M	Caucasian	3.916667	0 0	0 0	0 0
phchp117 v1	BP	43	M	Caucasian	3.333333	0 0	0 0	0 0
phchp117 v2	BP	43	M	Caucasian	3.083333	0 0	0 0	0 0
phchp117 v3	BP	43	M	Caucasian	2.833333	0 0	0 0	0 0
phchp118 v1	SZA	46	M	African American	3.75	0 0	0 0	0 0
phchp118 v2	SZA	47	M	African American	3.166667	0 0	0 0	0 0
phchp119 v2	SZA	56	M	African American	3.583333	0 0	0 0	0 0
phchp119 v3	SZA	56	M	African American	3.333333	0 0	0 0	0 0
phchp120	SZ	51	M	Caucasian	4	0 0	0 0	0 0

v1									
phchp120 v2	SZ	51	M	Caucasian	3.75	0 0	0 0	0 0	
phchp120 v3	SZ	51	M	Caucasian	3.5	0 0	0 0	0 0	
phchp124 v1	BP	53	M	Caucasian	3.166667	1 0	4 0	1.27 0	
phchp124 v2	BP	54	M	Caucasian	2.833333	0 0	3 0	1.06 0	
phchp128 v1	BP	45	M	Caucasian	4.083333	0 0	0 0	0 0	
phchp128 v2	BP	45	M	Caucasian	3.75	0 0	0 0	0 0	
phchp129 v1	SZA	22	M	Caucasian	3.916667	0 0	1 0	0.26 0	
phchp132 v1	BP	51	M	Caucasian	3.916667	0 0	0 0	0 0	
phchp132 v2	BP	51	M	Caucasian	3.666667	0 0	0 0	0 0	
phchp132 v3	BP	52	M	Caucasian	3.416667	0 0	0 0	0 0	
phchp132 v4	BP	54	M	Caucasian	1.25	0 0	0 0	0 0	
phchp133 v1	SZ	55	M	Caucasian	4	0 0	4 0	1 0	
phchp134 v1	BP	59	M	Caucasian	4	0 0	0 0	0 0	
phchp134 v2	BP	59	M	Caucasian	3.75	0 0	0 0	0 0	
phchp134 v3	BP	59	M	Caucasian	3.5	0 0	0 0	0 0	
phchp134 v4	BP	61	M	Caucasian	1.333333	0 0	0 0	0 0	
phchp134 v5	BP	62	M	Caucasian	1.083333	0 0	0 0	0 0	
phchp136 v1	BP	41	M	Caucasian	3.166667	0 0	0 0	0 0	
phchp136	BP	41	M	Caucasian	2.916667	0 0	0 0	0 0	

v2								
phchp136 v3	BP	41	M	Caucasian	2.583333	0 0	0 0	0 0
phchp140 v1	BP	38	M	Caucasian	3.083333	0 0	0 0	0 0
phchp140 v2	BP	38	M	Caucasian	2.833333	0 0	0 0	0 0
phchp140 v3	BP	38	M	Caucasian	2.583333	0 0	0 0	0 0
phchp142 v1	BP	55	M	Caucasian	3.833333	0 0	0 0	0 0
phchp142 v2	BP	55	M	Caucasian	3.583333	0 0	0 0	0 0
phchp142 v3	BP	55	M	Caucasian	3.333333	0 0	0 0	0 0
phchp142 v4	BP	57	M	Caucasian	1.333333	0 0	0 0	0 0
phchp142 v5	BP	57	M	Caucasian	1.083333	0 0	0 0	0 0
phchp147 v1	BP	38	M	Caucasian	3.666667	0 0	0 0	0 0
phchp147 v2	BP	38	M	Caucasian	3.416667	0 0	0 0	0 0
phchp147 v3	BP	38	M	Caucasian	3.166667	0 0	0 0	0 0
phchp148 v1	SZ	25	M	Caucasian	3.416667	0 0	0 0	0 0
phchp149 v1	BP	45	M	Caucasian	3.333333	0 0	1 0	0.3 0
phchp149 v2	BP	45	M	Caucasian	3.083333	0 0	1 0	0.33 0
phchp149 v3	BP	46	M	Caucasian	2.75	0 0	1 0	0.37 0
phchp151 v1	SZ	24	M	Caucasian	3.833333	0 1	0 1	0 0.27
phchp151 v2	SZ	24	M	Caucasian	3.583333	0 0	0 0	0 0
phchp151	SZ	24	M	Caucasian	3.25	0 0	0 0	0 0

v3									
phchp152 v1	BP	45	M	Caucasian	3.5	0 0	0 0	0 0	
phchp153 v1	BP	55	M	Caucasian	3.333333	0 0	0 0	0 0	
phchp153 v2	BP	55	M	Caucasian	3	0 0	0 0	0 0	
phchp153 v3	BP	56	M	Caucasian	2.75	0 0	0 0	0 0	
phchp153 v4	BP	57	M	Caucasian	1	0 0	0 0	0 0	
phchp154 v1	SZA	51	M	African American	3.083333	1 0	1 0	0.33 0	
phchp154 v2	SZA	51	M	African American	2.833333	1 0	1 0	0.36 0	
phchp154 v3	SZA	52	M	African American	2.583333	0 0	0 0	0 0	
phchp155 v1	MD D	37	M	Caucasian	3.5	0 0	0 0	0 0	
phchp155 v2	MD D	37	M	Caucasian	3.25	0 0	0 0	0 0	
phchp158 v1	BP	23	M	African American	3.416667	0 0	0 0	0 0	
phchp161 v1	MD D	54	M	African American	3.166667	0 0	0 0	0 0	
phchp161 v2	MD D	54	M	African American	2.916667	0 0	0 0	0 0	
phchp161 v3	MD D	54	M	African American	2.75	0 0	0 0	0 0	
phchp162 v1	MD D	57	M	Caucasian	3.416667	1 0	1 0	0.3 0	
phchp162 v2	MD D	57	M	Caucasian	3	0 0	0 0	0 0	
phchp162 v3	MD D	57	M	Caucasian	2.75	0 0	0 0	0 0	
phchp165 v1	SZ	60	M	African American	3.333333	0 0	1 0	0.3 0	
phchp165	SZ	60	M	African	3.083333	1 0	1 0	0.33 0	

v2					American									
phchp165 v3	SZ	61	M	African American	2.916667	1	0		1	0		0.35	0	
phchp166 v1	BP	56	M	Caucasian	3	0	0		0	0		0	0	
phchp166 v2	BP	56	M	Caucasian	2.75	0	0		0	0		0	0	
phchp166 v3	BP	56	M	Caucasian	2.5	0	0		0	0		0	0	
phchp168 v1	MD D	48	M	African American	3.25	0	0		0	0		0	0	
phchp168 v2	MD D	48	M	African American	3	0	0		0	0		0	0	
phchp168 v3	MD D	49	M	African American	2.75	0	0		0	0		0	0	
phchp169 v1	SZA	50	M	African American	3.333333	0	0		0	0		0	0	
phchp171 v1	BP	36	M	Caucasian	3.083333	0	0		0	0		0	0	
phchp171 v2	BP	36	M	Caucasian	2.75	0	0		0	0		0	0	
phchp173 v1	MD D	48	M	Caucasian	2.833333	0	0		0	0		0	0	
phchp173 v2	MD D	49	M	Caucasian	2.583333	0	0		0	0		0	0	
phchp173 v3	MD D	49	M	Caucasian	2.333333	0	0		0	0		0	0	
phchp174 v1	MD D	54	M	Caucasian	2.333333	2	0		3	0		1.29	0	
phchp175 v1	SZA	42	M	Caucasian	2.5	0	0		0	0		0	0	
phchp176 v1	SZ	23	M	African American	2.25	0	0		0	0		0	0	
phchp176 v2	SZ	24	M	African American	1.916667	0	0		0	0		0	0	
phchp178 v1	BP	49	M	Caucasian	3.25	0	0		0	0		0	0	
phchp182	MD	39	M	Caucasian	3.166667	0	0		0	0		0	0	

v1	D								
phchp182 v2	MD D	39	M	Caucasian	2.916667	0 0	0 0	0 0	
phchp182 v3	MD D	40	M	Caucasian	2.666667	0 0	0 0	0 0	
phchp183 v1	BP	48	M	Caucasian	3.083333	0 0	0 0	0 0	
phchp183 v2	BP	48	M	Caucasian	2.833333	0 0	0 0	0 0	
phchp184 v1	BP	64	M	Caucasian	3.083333	0 0	0 0	0 0	
phchp184 v2	BP	64	M	Caucasian	2.833333	0 0	0 0	0 0	
phchp184 v3	BP	64	M	Caucasian	2.583333	0 0	0 0	0 0	
phchp185 v1	SZA	51	M	African American	3.083333	0 0	0 0	0 0	
phchp185 v2	SZA	51	M	African American	2.833333	0 0	0 0	0 0	
phchp185 v3	SZA	52	M	African American	2.416667	0 0	0 0	0 0	
phchp186 v1	BP	43	M	Caucasian	3.083333	0 0	0 0	0 0	
phchp186 v2	BP	44	M	Caucasian	2.833333	0 0	0 0	0 0	
phchp186 v3	BP	44	M	Caucasian	2.583333	0 0	0 0	0 0	
phchp187 v1	SZ	49	M	African American	3.166667	1 0	1 0	0.32 0	
phchp187 v2	SZ	49	M	African American	2.833333	0 0	0 0	0 0	
phchp188 v1	SZ	54	M	African American	3.166667	0 0	1 0	0.32 0	
phchp190 v1	BP	49	M	Caucasian	3.083333	0 0	0 0	0 0	
phchp190 v2	BP	49	M	Caucasian	2.75	0 0	0 0	0 0	
phchp190	BP	50	M	Caucasian	2.5	0 0	0 0	0 0	

v3									
phchp192 v1	SZA	55	M	African American	3	0 0		0 0	0 0
phchp192 v2	SZA	56	M	African American	2.75	0 0		0 0	0 0
phchp192 v3	SZA	56	M	African American	2.5	0 0		0 0	0 0
phchp193 v1	BP	39	M	Hispanic	2.916667	0 0		0 0	0 0
phchp193 v3	BP	39	M	Hispanic	2.333333	0 0		0 0	0 0
phchp193 v4	BP	40	M	Hispanic	2.083333	0 0		0 0	0 0
phchp194 v1	MD D	47	M	Caucasian	3.083333	0 0		0 0	0 0
phchp194 v2	MD D	47	M	Caucasian	2.833333	0 0		0 0	0 0
phchp194 v3	MD D	47	M	Caucasian	2.583333	0 0		0 0	0 0
phchp195 v1	SZ	52	M	Caucasian	2.833333	0 0		0 0	0 0
phchp195 v2	SZ	53	M	Caucasian	2.583333	0 0		0 0	0 0
phchp195 v3	SZ	53	M	Caucasian	2.333333	0 0		0 0	0 0
phchp196 v1	MD D	56	M	African American	2.833333	0 0		0 0	0 0
phchp196 v2	MD D	56	M	African American	2.583333	0 0		0 0	0 0
phchp196 v3	MD D	57	M	African American	2.333333	0 0		0 0	0 0
phchp197 v1	SZ	56	M	Caucasian	2.416667	0 0		0 0	0 0
phchp197 v2	SZ	57	M	Caucasian	1.416667	0 0		0 0	0 0
phchp197 v3	SZ	57	M	Caucasian	1.166667	0 0		0 0	0 0
phchp198	MD	61	M	Caucasian	2.833333	0 1		0 1	0 0.36

v1	D								
phchp198 v2	MD D	61	M	Caucasian	2.583333	0 1	0 1	0 0.39	
phchp198 v4	MD D	62	M	Caucasian	2.083333	0 1	0 1	0 0.48	
phchp199 v1	SZ	49	M	African American	2.916667	0 0	0 0	0 0	
phchp199 v2	SZ	49	M	African American	2.666667	0 0	0 0	0 0	
phchp199 v3	SZ	50	M	African American	2.333333	0 0	0 0	0 0	
phchp200 v1	MD D	56	M	Caucasian	2.833333	0 0	0 0	0 0	
phchp200 v2	MD D	57	M	Caucasian	2.583333	0 0	0 0	0 0	
phchp200 v3	MD D	57	M	Caucasian	2.333333	0 0	0 0	0 0	
phchp206 v1	MD D	59	M	African American	2.833333	0 0	0 0	0 0	
phchp207 v1	SZ	48	M	African American	1.5	0 0	0 0	0 0	
phchp208 v1	MD D	56	M	African American	2.75	0 0	0 0	0 0	
phchp208 v2	MD D	56	M	African American	2.5	0 0	0 0	0 0	
phchp208 v3	MD D	58	M	African American	1	0 0	0 0	0 0	
phchp210 v1	BP	43	M	Caucasian	1.666667	0 0	0 0	0 0	
phchp210 v2	BP	43	M	Caucasian	1.416667	0 0	0 0	0 0	
phchp211 v1	SZ	62	M	Caucasian	1.75	0 0	0 0	0 0	
phchp211 v2	SZ	62	M	Caucasian	1.166667	0 0	0 0	0 0	
phchp212 v1	MD D	56	M	African American	2.666667	0 0	0 0	0 0	
phchp212	MD	56	M	African	2.416667	0 0	0 0	0 0	

v2	D			American				
phchp219 v1	BP	61	M	Caucasian	2.25	0 0	0 0	0 0
phchp219 v2	BP	61	M	Caucasian	1.916667	0 0	0 0	0 0
phchp219 v3	BP	62	M	Caucasian	1.416667	0 0	0 0	0 0
phchp221 v1	MD D	51	M	African American	2.25	0 0	0 0	0 0
phchp221 v2	MD D	51	M	African American	2	0 0	0 0	0 0
phchp221 v3	MD D	52	M	African American	1.666667	0 0	0 0	0 0
phchp222 v2	SZ	60	M	Caucasian	1.416667	0 0	0 0	0 0
phchp222 v3	SZ	61	M	Caucasian	1.166667	0 0	0 0	0 0
phchp224 v1	BP	59	M	Caucasian	1.083333	1 0	1 0	0.93 0
phchp226 v1	MD D	29	M	Caucasian	1.833333	0 0	0 0	0 0
phchp226 v2	MD D	29	M	Caucasian	1.583333	0 0	0 0	0 0
phchp227 v1	MD D	55	M	Caucasian	2.083333	0 0	0 0	0 0
phchp227 v2	MD D	55	M	Caucasian	1.833333	0 0	0 0	0 0
phchp227 v3	MD D	55	M	Caucasian	1.583333	0 0	0 0	0 0
phchp234 v1	BP	44	M	Caucasian	2.166667	0 0	0 0	0 0
phchp234 v2	BP	45	M	Caucasian	1.583333	0 0	0 0	0 0
phchp234 v3	BP	45	M	Caucasian	1.333333	0 0	0 0	0 0
phchp235 v1	MD D	54	M	African American	1.833333	0 0	0 0	0 0
phchp235	MD	55	M	African	1.583333	0 0	0 0	0 0

v2	D			American				
phchp235 v3	MD D	55	M	African American	1.25	0 0	0 0	0 0
phchp236 v1	MD D	51	M	Caucasian	2.166667	0 0	0 0	0 0
phchp236 v2	MD D	51	M	Caucasian	1.916667	0 0	0 0	0 0
phchp238 v1	MD D	62	M	Caucasian	2.166667	0 0	0 0	0 0
phchp238 v2	MD D	63	M	Caucasian	1.916667	0 0	0 0	0 0
phchp238 v3	MD D	63	M	Caucasian	1.583333	0 0	0 0	0 0
phchp242 v1	MD D	55	M	African American	2.083333	0 0	0 0	0 0
phchp247 v1	MD D	55	M	African American	2.083333	0 0	0 0	0 0
phchp248 v1	SZ	52	M	African American	2	0 0	0 0	0 0
phchp248 v2	SZ	52	M	African American	1.666667	0 0	0 0	0 0
phchp248 v3	SZ	53	M	African American	1.416667	0 0	0 0	0 0
phchp253 v1	BP	25	M	Caucasian	1.916667	0 0	0 0	0 0
phchp253 v2	BP	26	M	Caucasian	1.083333	0 0	0 0	0 0
phchp259 v1	MD D	56	M	Caucasian	1.75	0 0	0 0	0 0
phchp259 v2	MD D	57	M	Caucasian	1.416667	0 0	0 0	0 0
phchp259 v3	MD D	57	M	Caucasian	1	0 0	0 0	0 0
phchp270 v1	BP	41	M	Caucasian	1.75	0 0	0 0	0 0
phchp270 v2	BP	41	M	Caucasian	1.5	0 0	0 0	0 0
phchp273	BP	27	M	Caucasian	1.666667	0 0	0 0	0 0

v1								
phchp273 v2	BP	28	M	Caucasian	1.416667	0 0	0 0	0 0
phchp274 v1	BP	48	M	Caucasian	1.666667	1 0	1 0	0.6 0
phchp274 v2	BP	48	M	Caucasian	1.416667	0 0	0 0	0 0
phchp274 v3	BP	48	M	Caucasian	1.166667	0 0	0 0	0 0
phchp275 v1	SZ	63	M	Caucasian	1	0 0	0 0	0 0
phchp276 v1	SZ	59	M	African American	1.083333	0 0	0 0	0 0
phchp277 v1	SZ	49	M	Caucasian	1.583333	0 0	0 0	0 0
phchp277 v2	SZ	50	M	Caucasian	1.333333	0 0	0 0	0 0
phchp277 v3	SZ	50	M	Caucasian	1.083333	0 0	0 0	0 0
phchp287 v1	SZA	59	M	Caucasian	1	0 0	0 0	0 0
phchp292 v1	BP	42	M	Caucasian	1.333333	0 0	0 0	0 0
phchp292 v2	BP	42	M	Caucasian	1.083333	0 0	0 0	0 0
phchp293 v1	BP	43	M	Caucasian	1.166667	0 0	0 0	0 0
phchp295 v1	SZ	52	M	African American	1.083333	0 0	0 0	0 0
phchp296 v1	BP	48	M	Caucasian	1.083333	0 0	0 0	0 0

Table S2. Top candidate biomarker genes -evidence for involvement in suicidality.

The top genes from discovery (internal score of 4), prioritization (genes with CFG score of 8 and above), and validation (nominally significant). Underlined gene symbol means reproduces suicide biomarkers findings from our earlier smaller study in bipolar participants¹. **Bold p-value is Bonferroni significant after validation in suicide completers.**

Gene symbol/ Gene Name	Probesets	Discovery (Change) Method/ Score	Prior human genetic evidence	Prior human brain expression evidence	Prior human peripheral expression evidence	Prioritization on Total CFG Score For Suicide	Validation ANOVA p-value
SKA2 spindle and kinetochore associated complex subunit 2	225686_at	(D) DE/1 AP/1	Suicide ²	(D) PFC ²	(D) Methylation in blood ²	9	0.006 0.027
CCDC136 coiled-coil domain containing 136	226972_s_ at	(D) AP4		(D) HIP ³		8	NC
CD44 CD44 molecule (Indian blood group)	209835_x_ at	(D) DE2	Suicide ⁴	(D) BA9 and BA24 ⁴		8	NC
FADS1 fatty acid desaturase 1	208962_s_ at 208964_s_ at	(D) DE4 (I) DE1		(D) PFC ⁵		8	NC 2.08E-06
FKBP5 FK506 binding protein 5	204560_at	(D) DE2	Suicide ^{6 7 8 9 10}	(D) AMY ¹¹		8	NC
FOXN3 forkhead box N3	205021_s_ at	(D) AP2	Suicide ¹²	(D) BA24 ¹² (I) BA9 ¹²	(I) Blood¹	8	4.99E-04
HADHA hydroxyacyl-CoA dehydrogenase/3- ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), alpha subunit	208631_s_ at	(D) DE4		(D) HIP ³		8	NC
IL6 interleukin 6 (interferon, beta 2)	205207_at	(I) AP2		(I) PFC (BA-10) ¹³ HIP ¹⁴	(I) CSF ^{15 16} (D) Blood ¹⁷	8	1.44E-08
SAT1 spermidine/spermi ne N1- acetyltransferase 1	213988_s_ at 210592_s_ at 230333_at	(I) DE2 DE1	Suicide ¹⁸ ¹⁹	(I) PFC BA46 ²⁰	(I) Blood¹	8	1.08E-44 1.24E-40 6.93E-12 3.09E-38

	203455_s_at						
SLC4A4 solute carrier family 4 (sodium bicarbonate cotransporter), member 4	211494_s_at 210739_x_at	(I) AP2 DE1	Suicide ²¹	(D) PFC (BA 46/10) in SZ ²²		8	5.84E-05 0.002
MAOB monoamine oxidase B	204041_at	(I) DE1		(I) PFC ²³	(D) Blood ²⁴	7	8.11E-08
AHCYL1 adenosylhomocysteinase-like 1	207464_at	(D) DE2 AP1		(D) PFC ²²		6	2.22E-06 0.0238
AKT1S1 AKT1 substrate 1 (proline-rich)	224982_at	(D) DE2 AP2		(D) HIP ³		6	1.97E-07 3.54E-07
ALDH3A2 aldehyde dehydrogenase 3 family, member A2	210544_s_at; 210544_s_at	(D) DE2 AP1		(I) BA4, BA44 and Lateral thalamus ²⁵		6	3.73E-05 0.0348
ARHGAP26 Rho GTPase activating protein 26	205068_s_at	(I) DE1	Linkage D5S1480 ²⁶	(D) DLFPC ²⁷		6	9.91E-08
BCL2 B-cell CLL/lymphoma 2	207005_s_at 207004_at	(D) DE1 (I) AP1		(D) PFC ²⁸		6	0.0003 0.02
C20orf27	218081_at; 50314_i_at	(D) DE2		(I) ACC ²⁷		6	2.80E-13 2.47E-05
CAPNS1 calpain, small subunit 1	200001_at	(D) DE2		(D) PFC ²⁹ (I) BA4 ³⁰		6	0.0002
CDC42EP4 CDC42 effector protein (Rho GTPase binding) 4	218062_x_at	(D) AP2		(D) BA11 ³⁰		6	1.16E-06
CDH4 cadherin 4, type 1, R-cadherin (retinal)	220227_at	(I) DE2		(D) DLFPC ²⁷		6	0.00908
CXCL11 chemokine (C-X-C motif) ligand 11	210163_at	(I) AP2		(D) NAC ²⁷		6	0.0293
EHBP1 EH domain binding protein 1	212650_at	(D) DE 4	Suicide ³¹			6	NC
EIF5A eukaryotic translation initiation factor 5A	201123_s_at	(D) DE2		(D) PFC ³²		6	0.0006
EMID1 EMI domain containing 1	1564251_at	(I) DE2		(D) BA4 ³⁰		6	0.0346
FAM49B family with sequence similarity	217535_at	(I) AP2		(D) HIP ³		6	0.0188

49, member B							
FH fumarate hydratase	203032_s_ at	(D) DE2		(I) PFC (I) ²⁹		6	5.10E-11
GCOM1 GRINL1A complex locus 1	228568_at	(I) DE2		(D) BA44 ²⁰	(I) Blood ¹	6	2.13E-09
GPM6B glycoprotein M6B	236116_at; 209170_s_ at	(D) AP1 DE1	Linkage DXS1224 DXS8019 ³³	(D) BA 8/9,BA 46,BA 44 ³³ (I) BA46 ²⁰		6	2.32E-07 0.0119
HOMER homeobox and leucine zipper encoding	231868_at	(D) DE2 AP1		(D) HIP ³		6	1.38E-12 8.27E-05
HPCAL1 hippocalcin-like 1	1560154_a_ at	(I) DE2		(I) BA4 ³⁰		6	7.50E-05
IKBKB inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta	211027_s_ at	(D) DE2		(I) ACC ²⁷		6	1.24E-06
ITGB4 integrin, beta 4	211905_s_ at	(D) DE2		(D) PFC ³²		6	0.0290
LDLRAP1 low density lipoprotein receptor adaptor protein 1	221790_s_ at	(D) DE2		(I) ACC ²⁷		6	2.24E-16
LOC728543 uncharacterized LOC728543	234133_s_ at	(D) DE2		(D) ACC ²⁷		6	1.97E-05
MAP2K5 mitogen-activated protein kinase kinase 5	211370_s_ at	(D) DE2		(D) HIP ³⁴		6	0.00612
MAPK9 mitogen-activated protein kinase 9	225781_at	(I) DE2		(I) PFC ³⁵		6	0.0132
NEAT1 nuclear paraspeckle assembly transcript 1 (non- protein coding)	224565_at	(I) DE2		(I) NAC ²⁷		6	2.33E-24
NMB neuromedin B	205204_at	(D) DE2		(D) Dorsovagal complex ³⁶		6	0.0149
PAFAH1B2 platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (30kDa)	210160_at	(D) DE2		(I) NAC ²⁷		6	3.66E-08
PCBD2	231085_s_ at	(D)		(D)		6	0.0345

pterin-4 alpha-carbinolamine dehydratase/dimerization cofactor of hepatocyte nuclear factor 1 alpha (TCF1) 2	at	DE2		HIP ³			
PIK3C2A phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha	1553694_a_at	(D) DE2		(D) PFC ³⁷ BA8/9 ³⁰		6	3.75E-09
PKP4 plakophilin 4	201927_s_at	(D) AP1		(I) NAC ²⁷		6	0.0486
PTK2 protein tyrosine kinase 2	241453_at	(I) DE2		(D) Frontopolar cortex ³⁸		6	1.11E-33
RASL11B RAS-like, family 11, member B	219142_at	(I) AP2		(D) DLFPC ²⁷		6	0.0124
SLC5A3 solute carrier family 5 (sodium/myo-inositol cotransporter), member 3	213167_s_at	(D) DE2		(D) NAC ²⁷		6	1.06E-11
SNORA68 small nucleolar RNA, H/ACA box 68	1566402_at t1566403_at	(I) DE2 AP1		(D) HIP ³		6	0.00310 0.00813
SOD2 superoxide dismutase 2, mitochondrial	216841_s_at	(I) DE1		(I) PFC ³⁹		6	0.00042
SYNE2 spectrin repeat containing, nuclear envelope 2	242774_at; 1558392_at	(D) DE2 DE1		(D) HIP ³		6	6.83E-08 0.0183
TCF7L2 transcription factor 7-like 2 (T-cell specific, HMG-box)	212762_s_at	(I) DE1		(D) HIP ³		6	0.0280
TGOLN2 trans-golgi network protein 2	203834_s_at	(D) AP1	Linkage D2S428 D2S1790 ^{40,41}	(I) BA4 ³⁰		6	1.10E-07
TRAK2 trafficking protein, kinesin binding 2	202124_s_at	(D) DE2		(I) NAC ²⁷		6	0.006
ADRBK1 adrenergic, beta, receptor kinase 1	201401_s_at	(D) DE1		(I) PFC (Brodmann area 9) ⁴²		5	2.22E-05
AHCYL2 adenosylhomocysteinase-like 2	212814_at	(D) AP1		(I) NAC ²⁷		5	0.00103

AIMP1 aminoacyl tRNA synthetase complex- interacting multifunctional protein 1	227605_at; 202542_s_ at; 235594_at	(D) AP1 DE2		(I) NAC ²⁷		5	8.37E-05; 0.0138; 0.0301
ATP6V0E1 ATPase, H+ transporting, lysosomal 9kDa, V0 subunit e1	236527_at	(D) AP1		(D) BA11 ³⁰	(I) Blood ¹	5	3.80E-07
BRAF v-raf murine sarcoma viral oncogene homolog B	236402_at	(I) DE1		(D) HIP ⁴³		5	6.07E-29
BRCC3 BRCA1/BRCA2- containing complex, subunit 3	216521_s_ at	(D) DE1		(I) PFC ²⁹		5	5.79E-08
C1orf61	205103_at	(I) DE1		(I) NAC ²⁷		5	2.95E-13
CALR calreticulin	212953_x_ at	(I) DE1		(D) Frontopolar cortex ³⁸		5	6.20E-06
CAMK2B calcium/calmoduli n-dependent protein kinase II beta	209956_s_ at	(I) DE1		(I) PFC ³⁵		5	0.00025
CAV1 caveolin 1, caveolae protein, 22kDa	212097_at	(I) DE1		(I) ACC ²⁷		5	7.31E-07
CHD2 chromodomain helicase DNA binding protein 2	1554014_a t	(I) DE1		(I) NAC ²⁷		5	2.40E-24
CLTA clathrin, light chain A	1560434_x_ at	(I) DE1		(I) Frontopolar cortex ³⁸		5	0.00064
CNP 2',3'-cyclic nucleotide 3' phosphodiesterase	1557943_a t	(D) AP1		(D) HIP ³		5	0.0315
COL9A2 collagen, type IX, alpha 2	232542_at	(D) DE1		(I) NAC ²⁷		5	0.00044
CPSF2 cleavage and polyadenylation specific factor 2, 100kDa	233208_x_ at	(D) AP1		(I) ACC ²⁷		5	0.00171
CREM cAMP responsive element modulator	241740_at	(I) AP1		(D) Frontopolar cortex ³⁸		5	1.08E-06

CTTN cortactin	214782_at 201059_at	(I) DE1		(D) Frontopolar cortex ³⁸		5	3.46E-18 0.0363
CUL4B cullin 4B	210257_x_ at	(D) DE1		(I) ACC ²⁷		5	0.00776
DAAM2 dishevelled associated activator of morphogenesis 2	212793_at	(I) DE1		(I) NAC ²⁷		5	0.00856
DAB2 Dab, mitogen- responsive phosphoprotein, homolog 2 (Drosophila)	201279_s_ at	(I) DE1		(I) NAC ²⁷		5	0.00098
DLL1 delta-like 1 (Drosophila)	227938_s_ at	(D) DE1		(D) AMY ⁴⁴ (I) DLPFC ⁴⁴		5	0.00016
DNAH2 dynein, axonemal, heavy chain 2	215840_at	(D) DE1		(I) ACC ²⁷		5	0.00637
DPP4 dipeptidyl- peptidase 4	211478_s_ at	(D) DE4	Linkage D2S1353 ⁴⁵			5	1.43E-07
G2E3 G2/M-phase specific E3 ubiquitin protein ligase	223254_s_ at	(D) AP1		(I) ACC ²⁷		5	0.0214
GABARAPL1 GABA(A) receptor- associated protein like 1	208869_s_ at	(I) DE1		(D) BA20,BA10,BA4 6 ⁴⁶		5	3.48E-28
GLUL glutamate- ammonia ligase	215001_s_ at	(I) DE1		(D) BA44 ²⁰ AMY,BA46,BA44 ,BA45 ⁴⁶ frontopolar cortex ³⁸		5	3.96E-15
GUK1 guanylate kinase 1	200075_s_ at	(D) DE1		(D) HIP ³ PFC ²⁹		5	0.0362
HELZ helicase with zinc finger	240486_at	(I) DE1		(I) BA4 ³⁰		5	3.56E-06
IGHG1 immunoglobulin heavy constant gamma 1 (G1m marker)	241074_at	(I) DE1		(D) ACC ²⁷		5	0.0342
IL1B interleukin 1, beta	205067_at 39402_at	(I) DE1		(I) PFC (BA-10) ¹³	(I) Blood ¹	5	0.0338; 0.0380
JAK3 Janus kinase 3	211108_s_ at	(D) DE1		(D) DLFPC ²⁷		5	5.42E-11

JUN jun proto-oncogene	201464_x_at 213281_at 201466_s_at	(I) DE1 AP1		(D) HIP ³		5	2.63E-51 1.02E-41 2.21E-08
JUNB jun B proto-oncogene	201473_at	(I) DE1		(D) HIP ³		5	1.09E-18
LAPTM4B lysosomal protein transmembrane 4 beta	1554679_a_at	(D) AP1		(I) BA8/9 ³⁰		5	0.0113
LHFP lipoma HMGIC fusion partner	218656_s_at	(I) DE1		(I) NAC ²⁷	(I) Blood ¹	5	1.27E-06
LPAR1 lysophosphatidic acid receptor 1	204036_at	(D) AP1		(I) NAC ²⁷		5	7.67E-06
MAGI3 membrane associated guanylate kinase, WW and PDZ domain containing 3	226770_at	(D) AP1		(D) DLFPC ²⁷		5	0.0292
MARCKS myristoylated alanine-rich protein kinase C substrate	213002_at 201670_s_at	(I) DE1		(I) HIP, PFC ⁴⁷ PFC{Punzi, 2014 #36847}	(I) Blood ¹	5	1.51E-06; 0.0004
MBP myelin basic protein	225408_at	(D) AP1		(I) NAC ²⁷		5	6.74E-10
MCRS1 microspherule protein 1	202556_s_at	(D) DE1		(D) HIP ³		5	3.29E-05
MEF2C myocyte enhancer factor 2C	207968_s_at	(D) DE1		(D) HIP ³⁴		5	3.47E-09
MT1E metallothionein 1E	212859_x_at	(I) DE1		(D) ACC ²⁷ PFC (BA 46/10) ₃₂		5	0.00020
MT1H metallothionein 1H	206461_x_at	(I) DE1		(D) ACC, NAC ²⁷ PFC (BA 46/10) ²²		5	5.62E-05
MT2A metallothionein 2A	212185_x_at	(I) DE1		(D) ACC ²⁷		5	0.00218
NDRG1 N-myc downstream regulated 1	200632_s_at	(I) DE1		(I) NAC ²⁷		5	3.21E-22
NUCB2 nucleobindin 2	229838_at	(I) DE1		(I) Edinger-Westphal nucleus (midbrain) ⁴⁸		5	0.0124

OGFR opioid growth factor receptor	211513_s_at	(D) DE1		(D) HIP ³		5	0.00053
PCDH9 protocadherin 9	238919_at	(D) AP1		(D) BA45; BA46 ²⁰		5	0.0215
PHF20L1 PHD finger protein 20-like 1	219606_at	(I) DE1		(I) ACC ²⁷		5	7.97E-05
PLEKHB1 pleckstrin homology domain containing, family B (evectins) member 1	209504_s_at	(D) DE1		(I) NAC ²⁷		5	6.07E-07
POLR2D polymerase (RNA) II (DNA directed) polypeptide D	214144_at	(D) AP1		(I) ACC ²⁷		5	1.02E-09
PRKACA protein kinase, cAMP-dependent, catalytic, alpha	202801_at	(D) AP1		(D) PFC, NAC ⁴⁹		5	0.0324
PRKCB protein kinase C, beta	227824_at; 230437_s_at	(D) DE1 AP1		(D) PFC, HIP ⁵⁰		5	3.15E-09 1.34E-04 0.003
PSMB4 proteasome (prosome, macropain) subunit, beta type, 4	202243_s_at	(D) DE1		(D) PFC ²⁹		5	9.98E-07
PTEN phosphatase and tensin homolog	204053_x_at 222176_at	(I) DE1		(I) PFC, HIP ⁵¹	(I) Blood ¹	5	7.66E-17 0.0003
RAB35 RAB35, member RAS oncogene family	205461_at	(D) DE2		(I) ACC ²⁷		5	0.00034
RBMX RNA binding motif protein, X-linked	1556336_at 213762_x_at	(D) DE1		(D) HIP (D) ³ BA 8/9, BA 11 (D) (Suicide) ³³ (I) ACC ²⁷		5	1.40E-13 0.0232
RECK reversion-inducing-cysteine-rich protein with kazal motifs	216153_x_at	(I) DE1		(I) ACC ²⁷	(I) Blood ¹	5	0.00093
RNASEL ribonuclease L (2',5'-oligoadenylate synthetase-dependent)	221287_at	(D) AP1		(D) HIP ³		5	6.05E-06

SELENBP1 selenium binding protein 1	214433_s_ at	(D) DE1		(I) PFC ²⁹		5	0.00019
SHISA2 shisa family member 2	230493_at	(I) DE1		(I) NAC ²⁷		5	0.00107
SLC35E1 solute carrier family 35, member E1	222263_at	(D) AP1		(D) BA4 ³⁰		5	0.00651
SNAP23 synaptosomal- associated protein, 23kDa	209131_s_ at	(D) AP1		(D) BA44 ²⁰ BA24 ⁵²		5	0.00039
TM4SF1 transmembrane 4 L six family member 1	209386_at	(I) DE1		(D) PFC (BA 46/10) ²²		5	6.12E-11
TMEM254 transmembrane protein 254	218174_s_ at	(D) DE1		(D) HIP ³		5	1.35E-08
TMEM259 transmembrane protein 259	212574_x_ at; 212575_at; 213986_s_ at	(D) DE1		(I) ACC ²⁷		5	0.0007; 0.003; 0.004
TNS1 tensin 1	218863_s_ at	(D) DE1 AP2		(I) NAC ²⁷		5	6.29E-05; 0.0123
TPBG trophoblast glycoprotein	203476_at	(I) DE1		(I) ACC ²⁷		5	6.66E-06
TPD52L1 tumor protein D52-like 1	203786_s_ at	(I) DE1		(D) PFC (BA 46/10) ²²		5	1.52E-16
TRIM23 tripartite motif containing 23	210995_s_ at	(D) DE1		(I) PFC (BA 46/10) ²²		5	3.28E-14
TSC22D3 TSC22 domain family, member 3	208763_s_ at	(I) DE1		(D) PFC, AMY ⁵³		5	2.01E-05
TSPAN33 tetraspanin 33	225775_at	(D) AP1		(D) HIP ³		5	0.00302
VMP1 vacuole membrane protein 1	1569003_a t	(I) DE1		(D) NAC ²⁷		5	0.00291
VPREB3 pre-B lymphocyte 3	220068_at	(D) DE1		(D) HIP ³		5	0.00104
ZFP36 ZFP36 ring finger protein	201531_at	(I) DE1		(D) Orbitofrontal cortex ⁵⁴		5	8.72E-27
ZFYVE21 zinc finger, FYVE domain containing 21	219929_s_ at	(D) AP1		(D) HIP ³		5	1.69E-04
ZHX2 zinc fingers and	203556_at	(I) DE1		(D) PFC		5	0.00198

homeoboxes 2				BA46/10 ³²			
ZNF519 zinc finger protein 519	1568873_a t	(D) AP1		(I) ACC ²⁷		5	0.01164
B4GALT1 UDP- Gal:betaGlcNAc beta 1,4- galactosyltransfera se, polypeptide 1	228498_at	(I) DE 4				4	NC
BTBD3 BTB (POZ) domain containing 3	243461_at	(I) DE 4				4	NC
CADM1 cell adhesion molecule 1	237259_at	(I) DE4				4	NC
CATSPER3 cation channel, sperm associated 3	230981_at	(D) AP4				4	NC
CCL28 chemokine (C-C motif) ligand 28	224240_s_ at	(D) AP4				4	NC
CLIP4 CAP-GLY domain containing linker protein family, member 4	219944_at	(D) DE4				4	NC
CTBS chitinase, di-N- acetyl-	218924_s_ at	(I) DE 4				4	NC
CYorf17 chromosome Y open reading frame 17	234274_at	(D) DE 4				4	NC
DCAF15 DDB1 and CUL4 associated factor 15	221851_at	(D) DE4				4	0.0302
DEPDC5 DEP domain containing 5	234548_at	(I) AP4				4	NC
DTNA dystrobrevin, alpha	211493_x_ at	(I) AP4				4	NC
EMR2 egf-like module containing, mucin- like, hormone receptor-like 2	232009_at	(I) DE 4				4	NC
EPHA10 EPH receptor A10	243717_at	(D) DE4				4	0.00801
ERG v-ets avian erythroblastosis virus E26 oncogene homolog	213541_s_ at	(D) DE 4				4	NC
ERV3-2	222139_at	(I)				4	NC

endogenous retrovirus group 3, member 2		DE 4					
FAM183CP family with sequence similarity 183, member C, pseudogene	1569887_a_at	(I) AP4				4	NC
HIST1H2BO histone cluster 1, H2bo	214540_at	(I) DE4				4	4.77E-10
HS3ST3B1 heparan sulfate (glucosamine) 3-O-sulfotransferase 3B1	1561908_a_at	(D) AP4				4	NC
IQCH IQ motif containing H	224165_s_at	(D) DE4				4	0.00324
KCTD21 potassium channel tetramerization domain containing 21	229873_at	(I) DE 4				4	NC
KERA keratocan	220504_at	(I) DE4				4	0.00021
KIF2C kinesin family member 2C	211519_s_at	(D) AP4				4	0.00056
KLHDC3 kelch domain containing 3	214383_x_at	(D) DE4			(D) Blood ¹	4	1.57E-17
LAMB1 laminin, beta 1	238608_at	(I) AP4				4	NC
LOC100129917 uncharacterized LOC100129917	236411_at	(D) DE4				4	0.00225
LOC100289061 uncharacterized LOC100289061	1563071_a_t	(I) AP4				4	NC
LOC100996345 uncharacterized LOC100996345	240697_at	(D) DE4				4	7.20E-05
LOC285500 uncharacterized LOC285500	1558451_a_t	(I) DE 4				4	NC
MED21 mediator complex subunit 21	209363_s_at	(D) AP4				4	0.07426
PCIF1 PDX1 C-terminal inhibiting factor 1	222045_s_at	(D) AP4				4	NC
PLEC plectin	216971_s_at	(D) DE 4				4	NC
RAB36 RAB36, member RAS oncogene family	211471_s_at	(I) AP4				4	NC

RAD23A RAD23 homolog A (S. cerevisiae)	201039_s_ at	(D) DE 4				4	NC
RHAG Rh-associated glycoprotein	206145_at	(D) AP4				4	NC
ROBO4 roundabout, axon guidance receptor, homolog 4 (Drosophila)	220758_s_ at	(D) AP4				4	NC
RP11-669N7.2 uncharacterized LO C283352	1561757_a_ at	(I) AP4				4	NC
RPL6P17 ribosomal protein L6 pseudogene 17	216816_at	(D) AP4				4	NC
SETD8 SET domain containing (lysine methyltransferase) 8	220200_s_ at	(D) DE 4				4	NC
SH3GLB2 SH3-domain GRB2- like endophilin B2	218813_s_ at	(D) DE4				4	0.00017
ST6GALNAC4 ST6 (alpha-N- acetyl-neuraminyl- 2,3-beta- galactosyl-1,3)-N- acetylgalactosamin ide alpha-2,6- sialyltransferase 4	221551_x_ at	(D) DE4				4	3.22E-05
TEX10 testis expressed 10	1558702_a_ t	(D) AP4				4	0.00281
TEX261 testis expressed 261	1559675_a_ t	(D) AP4				4	0.00427
TFDP1 transcription factor Dp-1	242538_at	(I) AP4				4	0.00238
TMLHE-AS1 TMLHE antisense RNA 1	1560797_s_ at	(I) DE 4				4	NC
TMSB15B thymosin beta 15B	1556964_s_ at	(D) DE4				4	0.007
TUBGCP3 tubulin, gamma complex associated protein 3	215739_s_ at	(D) DE2	Suicide ¹²			4	2.05E-16
TXNRD2 thioredoxin reductase 2	210803_at	(D) AP4				4	0.0425
USP12 ubiquitin specific peptidase 12	229987_at	(D) AP4				4	0.2723

VEGFB vascular endothelial growth factor B	203683_s_ at	(D) AP4				4	5.13E-07
ZBTB7A zinc finger and BTB domain containing 7A	213299_at	(D) DE4				4	2.05E-06

Table S3. Top candidate biomarker genes - mechanistic understanding. The top genes from discovery (internal score of 4), prioritization (genes with CFG score of 8 and above), and validation (nominally significant). Underlined gene symbol means overlaps with findings from our previous mood and psychosis biomarker studies. DLPFC- Dorsolateral Prefrontal Cortex ; APC- Anterior Prefrontal Cortex; ACC- Anterior Cingulate Cortex; AMY-Amygdala; VT- Ventral Tegmentum; HIP- Hippocampus; NAC-Nucleus Accumbens. Alc-alcoholism.

Gene symbol/ Gene Name	Probesets	Discovery (Change) Method/ Score	Prioritization Total CFG Score For Suicide	Validation ANOVA p-value		Psychiatric disorders genetic evidence	Psychiatric disorders brain expression evidence	Psychiatric disorders peripheral expression evidence	Psychiatric Co-morbidity CFG Score For Other Disorders	Evidence for involvement in apoptosis
SKA2 spindle and kinetochore associated complex subunit 2	225686_at	(D) DE1 AP1	9	0.006 0.027					0	—
CCDC136 coiled-coil domain containing 136	226972_s_at	(D) AP4	8	NC				(I) Hallucinations blood ⁵⁵	2	—
CD44 CD44 molecule (Indian blood group)	209835_x_at	(D) DE2	8	NC			(D) Alc Frontal Cortex ⁵⁶	(D) Autistic Spectrum Disorder Lymphoblastoid ⁵⁷ MDD CSF ⁵⁸ (I) BP lymphocyte	6	—

							te ⁵⁹		
FADS1 fatty acid desaturase 1	208962_s_at 208964_s_at	(D) DE4 (I) DE1	8	NC 2.08E- 06			(I) SZ lymphobl astoid ⁶⁰	2	—
FKBP5 FK506 binding protein 5	204560_at	(D) DE2	8	NC	PTSD ⁶¹ 62 63 64 BP ⁷ MDD ^{65 66} 67 SZ ⁶⁸	(I) BP PFC DLPFC ⁶⁹ 70 Alc hippoca mpus ⁷¹	(D) PTSD Blood ⁷² Social Isolation Blood ⁷³ Alc Blood ⁷⁴ (I) MDD Blood ^{75 76}	8	—
FOXN3 forkhead box N3	205021_s_at	(D) AP2	8	4.99E- 04	SZ ⁷⁷ BP ^{78 79 80} Alc ⁸¹	(I) MDD AMY and cingulat e cortex ⁸² SZ cerebell ar cortex ⁸³	(I) SZ IPSC ⁸⁴	8	—
HADHA hydroxyacyl-CoA dehydrogenase/ 3-ketoacyl-CoA thiolase/enoyl- CoA hydratase (trifunctional protein), alpha subunit	208631_s_at	(D) DE4	8	NC				0	—
IL6 interleukin 6 (interferon, beta 2)	205207_at	(I) AP2	8	1.44E- 08	SZ ^{85 86 87 88} Stress ^{89 90} MDD ⁹¹	(I) SZ DLPFC BA46 ⁹²	(I) BP blood ^{93 94} 95 96 97 98 MDD blood ⁹⁹ 100 101 102 103 104 105 106 107 108 109 saliva ¹¹⁰ Antidepr essants Plasma ¹¹¹ SZ	8	—

							Blood¹¹² 113 114 115 116 117 118 119 120 88 Psychosis Blood¹²¹ 109 Antipsych otics serum¹²² Mild Cognitive Impairme nt Plasma¹²³ Stress blood¹²⁴ 125 110 Circadian Abnormal ities Serum¹⁰² Borderlin e Personali ty Disorder blood¹²⁴ PTSD blood¹²⁶ 127 CSF¹²⁸ Panic Disorder serum¹²⁹ Pain oral mucosa¹³⁰ Conduct Disorder Saliva¹¹⁰ Anxiety plasma¹⁰⁷ (D) Mood		
--	--	--	--	--	--	--	--	--	--

							blood ¹³¹		
SAT1 spermidine/spermine N1-acetyltransferase 1	213988_s_at 210592_s_at 230333_at 203455_s_at	(I) DE2 DE1	8	1.08E-44 1.24E-40 6.93E-12 3.09E-38		Anxiety ¹³²	(I) MDD AMY and cingulate cortex ⁸²	(I) MDD blood ¹³³	8 Yes ¹³⁴
SLC4A4 solute carrier family 4 (sodium bicarbonate cotransporter), member 4	211494_s_at 210739_x_at	(I) AP2 DE1	8	5.84E-05 0.002				(D) SZ IPSC ⁸⁴	2 —
MAOB monoamine oxidase B	204041_at	(I) DE1	7	8.11E-08		Alc ¹³⁵ SZ ¹³⁶	(I) BP ACC, DLPFC cortex ¹³⁷ PFC ¹³⁸ MDD AMY and cingulate cortex ⁸² Alc prefrontal cortex ¹³⁹	(I) Alc human glioblastoma and neuroblastoma cell lines ¹³⁹	8 Yes ¹⁴⁰
AHCYL1 adenosylhomocysteinase-like 1	207464_at	(D) DE2 AP1	6	2.22E-06 0.0238					0 —
AKT1S1 AKT1 substrate 1 (proline-rich)	224982_at	(D) DE2 AP2	6	1.97E-07 3.54E-07				(I) Circadian abnormalities Blood ¹⁴¹	2 —
ALDH3A2 aldehyde dehydrogenase 3 family, member A2	210544_s_at 210544_s_at	(D) DE2 AP1	6	3.73E-05 0.0348			(D) BP Brain ⁷⁰		4 —
ARHGAP26 Rho GTPase activating protein 26	205068_s_at	(I) DE1	6	9.91E-08		SZ ⁷⁷ ¹⁴² Autistic Spectrum Disorder ¹⁴³	(D) BP Brain ⁷⁰	(I) BP Blood ¹⁴⁴ Panic Disorder Lymphocyte ¹⁴⁵	8 —

								(D) MDD Fibroblast ¹⁴⁶		
BCL2 B-cell CLL/lymphoma 2	207005_s_at 207004_at	(D) DE1 (I) AP1	6	0.000 3 0.02		BP ^{147 148} ¹⁴⁹ Anxiety SZ ¹⁵⁰ ¹⁴⁸	(D) BP Frontal Cortex ¹⁵¹ PTSD DLPFC BA46 ¹⁵²	(D) Mood stabilizer s Blood ¹⁵³ BP Lymphobl ast ¹⁴⁷ (I) Alc Blood ¹⁵⁴ Pain Vertebral disc ¹⁵⁵	8	—
C20orf27	218081_at 50314_i_at	(D) DE2	6	2.80E- 13 2.47E- 05			(D) BP Brain ⁷⁰	(I) MDD Fibroblast ¹⁴⁶	6	—
CAPNS1 calpain, small subunit 1	200001_at	(D) DE2	6	0.000 2			(D) SZ ¹⁵⁶ PFC DLPFC ¹⁵⁷ BP Brain ⁷⁰ (I) Alc frontal ⁵⁶	(I) SZ Fibroblast s ¹⁵⁸	6	—
CDC42EP4 CDC42 effector protein (Rho GTPase binding) 4	218062_x_at	(D) AP2	6	1.16E- 06			(D) MDD AMY and cingulat e cortex ⁸²	(D) Alc Blood ¹⁵⁴	6	—
CDH4 cadherin 4, type 1, R-cadherin (retinal)	220227_at	(I) DE2	6	0.009 08		MDD ¹⁵⁹ ADHD ¹⁶⁰ SZ ¹⁶¹ BP ¹⁶¹	(D) MDD DLPFC ¹⁶²		6	—
CXCL11	210163_at	(I)	6	0.029					0	—

chemokine (C-X-C motif) ligand 11		AP2		3						
EHBP1 EH domain binding protein 1	212650_at	(D) DE 4	6.00	NC		MDD ¹⁵⁹ Addictions ₃₁	(D) ASD Autistic Spectrum Disorder cerebral cortex ₁₆₃	(D) SZ lymphobl astoid ⁶⁰ (D) Sleep Circadian abnormalities blood ¹⁴¹	8.00	-
EIF5A eukaryotic translation initiation factor 5A	201123_s_at	(D) DE2	6	0.0006			(D) Addictions, Stimulants NAC ¹⁶⁴	(I) BP Blood ¹⁴⁴	6	—
EMID1 EMI domain containing 1	1564251_at	(I) DE2	6	0.0346				(D) BP Blood ¹⁶⁵	2	
FAM49B family with sequence similarity 49, member B	217535_at	(I) AP2	6	0.0188			(D) BP Brain ⁷⁰		4	
FH fumarate hydratase	203032_s_at	(D) DE2	6	5.10E-11			(D) MDD AMY and cingulate cortex ₈₂ BP Brain ⁷⁰ BP Hippocampus ¹⁶⁶	(D) Stress Blood ¹⁶⁷ MDD MNC ¹⁶⁸ (I) BP Whole blood ¹⁴⁴	6	—
GCOM1 GRINL1A complex locus 1	228568_at	(I) DE2	6	2.13E-09				(D) PTSD Blood ¹⁶⁹	2	—
GPM6B glycoprotein M6B	236116_at 209170_s_at	(D) AP1 DE1	6	2.32E-07 0.0119			(D) Alc Frontal cortex ⁵⁶ MDD DLPFC ₁₆₂ Tourette Syndrome	(D) Delusions Blood ⁵⁵ SZ lymphocyte ⁵⁹	6	—

						Putamen ¹⁷⁰ (I) Alc Frontal, motor cortex ¹⁷¹ SZ Cerebellum ¹⁷²			
HOMEZ homeobox and leucine zipper encoding	231868_at	(D) DE2 AP1	6	1.38E-12 8.27E-05				0	—
HPCAL1 hippocalcin-like 1	1560154_a_at	(I) DE2	6	7.50E-05	MDD ¹⁷³	(D) BP Brain ⁷⁰	(I) Migraine Lymphocyte ¹⁷⁴	8	—
IKBKB inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta	211027_s_at	(D) DE2	6	1.24E-06			(D) Relaxation Response Blood ¹⁷⁵	2	—
ITGB4 integrin, beta 4	211905_s_at	(D) DE2	6	0.0290		(I) Alc Hippocampus ⁷¹	(D) SZ IPSC ⁸⁴	6	—
LDLRAP1 low density lipoprotein receptor adaptor protein 1	221790_s_at	(D) DE2	6	2.24E-16				0	—
LOC728543 uncharacterized LOC728543	234133_s_at	(D) DE2	6	1.97E-05				0	—
MAP2K5 mitogen-activated protein kinase kinase 5	211370_s_at	(D) DE2	6	0.00612	Addictions, Stimulants ¹⁷⁶ Addictions, Nicotine ¹⁷⁷ MDD ¹⁷⁸ Agoraphobia ¹⁷⁸	(D) MDD AMY and cingulate cortex ⁸² BP brain ⁷⁰		6	—
MAPK9 mitogen-activated protein kinase 9	225781_at	(I) DE2	6	0.0132		(D) BP Brain ⁷⁰		4	—

NEAT1 nuclear paraspeckle assembly transcript 1 (non-protein coding)	224565_at	(I) DE2	6	2.33E- 24				0	—
NMB neuromedin B	205204_at	(D) DE2	6	0.014 9	SZ ^{179, 180}	(I) MDD AMY and cingulat e cortex ⁸²		6	—
PAFAH1B2 platelet- activating factor acetylhydrolase 1b, catalytic subunit 2 (30kDa)	210160_at	(D) DE2	6	3.66E- 08				0	—
PCBD2 pterin-4 alpha- carbinolamine dehydratase/dim erization cofactor of hepatocyte nuclear factor 1 alpha (TCF1) 2	231085_s_at	(D) DE2	6	0.034 5			(D) Hallucina tions Blood ⁵⁵ (I) Alcohol Blood ¹⁵⁴	2	—
PIK3C2A phosphatidylinos itol-4-phosphate 3-kinase, catalytic subunit type 2 alpha	1553694_a_at	(D) DE2	6	3.75E- 09	BP ¹⁸¹ SZ ^{181 180}	(D) MDD ACC ¹⁸² (I) BP ACC ¹⁸²	(D) Delusions Blood ⁵⁵ Hallucina tions Blood ⁵⁵	8	Yes ^{183 184, 185}
PKP4 plakophilin 4	201927_s_at	(D) AP1	6	0.048 6		(D) BP brain ⁷⁰ (I) MDD AMY cingulat e cortex ⁸² Alc PFC ¹⁸⁶ SZ PFC ¹⁸⁷	(I) Delusions blood ⁵⁵ MDD Fibroblast ¹⁴⁶	6	—
PTK2 protein tyrosine kinase 2	241453_at	(I) DE2	6	1.11E- 33	SZ ¹⁸⁸	(I) BP Brain ⁷⁰ Alc	(I) Pain Vertebral disc ¹⁵⁵	8	—

						Superior frontal cortex ¹⁸⁹	(D) Hallucinations Blood ⁵⁵ Delusions Blood ⁵⁵ Autistic Spectrum Disorder lymphocyte ⁵⁷ Relaxation Response Blood mononuclear cells ¹⁷⁵		
RASL11B RAS-like, family 11, member B	219142_at	(I) AP2	6	0.0124				0	—
SLC5A3 solute carrier family 5 (sodium/myo-inositol cotransporter), member 3	213167_s_at	(D) DE2	6	1.06E-11			(D) Stress Blood ¹⁶⁷	2	Yes ^{190, 191}
SNORA68 small nucleolar RNA, H/ACA box 68	1566402_at1566403_at	(I) DE2 AP1	6	0.00310 0.00813				0	—
SOD2 superoxide dismutase 2, mitochondrial	216841_s_at	(I) DE1	6	0.00042		Addictions, Stimulants ¹⁹²	(D) MDD AMY and cingulate cortex ⁸² SZ Hippocampus ¹⁹³	6	—
SYNE2 spectrin repeat containing, nuclear envelope 2	242774_at1558392_at	(D) DE2 DE1	6	6.83E-08 0.0183		SZ ^{194 195 196}	(D) Circadian abnormalities Whole blood ¹⁴¹ (I) BP Lymphocyte ¹⁹⁷	2	Yes ¹⁹⁸
TCF7L2	212762_s_at	(I)	6	0.028		SZ ^{199 200}	(I) (D)	8	Yes ^{205,}

transcription factor 7-like 2 (T-cell specific, HMG-box)		DE1		0		BP ²⁰¹ Autistic Spectrum Disorder ²⁰²	SZ PFC ²⁰³ hippocampus Alc HIP ⁷¹	BP Blood ²⁰⁴		^{206, 207, 208, 209, 210}
TGOLN2 trans-golgi network protein 2	203834_s_at	(D) AP1	6	1.10E-07			(D) BP brain ⁷⁰ (I) MDD AMY and cingulate cortex ⁸² SZ PFC (left dorsolateral) ²¹¹	(D) Stress Blood ¹⁶⁷ SZ Blood ²¹² (I) Relaxation Response Blood ¹⁷⁵	6	—
TRAK2 trafficking protein, kinesin binding 2	202124_s_at	(D) DE2	6	0.006			(I) BP APC ²¹³		4	—
ADRBK1 adrenergic, beta, receptor kinase 1	201401_s_at	(D) DE1	5	2.22E-05			(D) SZ DLPFC (Brodmann area 9/46) supragenual (BA24) anterior cingulate cortex ^{214 215}	(D) MDD Blood ²¹⁶ Pain vertebral disc ¹⁵⁵	6	—
AHCYL2 adenosylhomocysteinase-like 2	212814_at	(D) AP1	5	0.00103		Autistic Spectrum Disorder ²¹⁷			2	—
AIMP1 aminoacyl tRNA synthetase complex-interacting multifunctional protein 1	227605_at 202542_s_at 235594_at	(D) AP1 DE2	5	8.37E-05 0.0138 0.0301					0	
ATP6V0E1 ATPase, H ⁺ transporting, lysosomal 9kDa, V0 subunit e1	236527_at	(D) AP1	5	3.80E-07		BP ²¹⁸	(D) MDD ACC, DLPFC ²¹⁹ (I)	(D) Alcohol Blood ¹⁵⁴ Stress Blood ¹⁶⁷	6	—

							BP ACC, DLPFC ²¹⁹			
BRAF v-raf murine sarcoma viral oncogene homolog B	236402_at	(I) DE1	5	6.07E- 29			(D) SZ, BP Frontal cortex ²²⁰		4	—
BRCC3 BRCA1/BRCA2- containing complex, subunit 3	216521_s_at	(D) DE1	5	5.79E- 08			(D) BP Brain ⁷⁰	(D) Circadian abnormal ities Blood ¹⁴¹	6	—
C1orf61	205103_at	(I) DE1	5	2.95E- 13				(D) SZ IPSC ⁸⁴	2	—
CALR calreticulin	212953_x_at	(I) DE1	5	6.20E- 06		SZA ²²¹	(D) MDD DLPFC ²²²	(I) Pain Vertebral disc ¹⁵⁵ (D) Relaxatio n Response Blood ¹⁷⁵	8	—
CAMK2B calcium/calmodu lin-dependent protein kinase II beta	209956_s_at	(I) DE1	5	0.000 25			(I) BP Frontal DLPFC Broadm ann Area 9 ^{223 224} SZ Frontal cortex ²²³ (D) BP Brain ⁷⁰ Cocaine, Cannabi s, PCP abuse Anterior PFC ²²⁵ SZ Suprage nual ACC ²¹⁵		4	—
CAV1 caveolin 1, caveolae protein,	212097_at	(I) DE1	5	7.31E- 07		SZ ¹⁸⁸	DLPFC (BA46)		6	Yes ²²⁸

22kDa						Alzheimer's Disease ²²⁶	(D) ²²⁷ (BP)			
CHD2 chromodomain helicase DNA binding protein 2	1554014_at	(I) DE1	5	2.40E- 24		Autistic Spectrum Disorder 202	(I) BP Brain ⁷⁰	(D) Mood Blood ¹⁶⁵ SZ Blood 229 MDD Fibroblast 146	8	—
CLTA clathrin, light chain A	1560434_x_at	(I) DE1	5	0.000 64			(D) BP Brain ⁷⁰	(D) Alzheimer's Disease Blood 230	6	—
CNP 2',3'-cyclic nucleotide 3' phosphodiesterase	1557943_at	(D) AP1	5	0.031 5		SZ ²³¹	(D) SZ PFC ²³² 231 233 Addictions, Alcohol Frontal cortex ⁵⁶ 189 Occipital cortex 234 MDD Middle temporal gyrus corresponding to Brodmann's area 21 (BA21) 235 AMY ²³⁶	(D) Circadian abnormalities Blood ¹⁴¹	8	—
COL9A2 collagen, type IX, alpha 2	232542_at	(D) DE1	5	0.000 44					0	Yes ²³⁷
CPSF2 cleavage and polyadenylation specific factor 2, 100kDa	233208_x_at	(D) AP1	5	0.001 71					0	—
CREM cAMP	241740_at	(I)	5	1.08E-		Panic	(I)		6	—

responsive element modulator		AP1		06		Disorder 238 239	MDD AMY and cingulate cortex ⁸² (D) Addictions, Alcohol Frontal, motor cortex ¹⁷¹		
CTTN cortactin	214782_at 201059_at	(I) DE1	5	3.46E-18 0.0363			(D) MDD AMY and cingulate cortex ⁸² (I) Mood Stabilizers NT2.D1 cells ²⁴⁰ (D) Stress, Social Isolation Blood ⁷³	6	—
CUL4B cullin 4B	210257_x_at	(D) DE1	5	0.00776				0	—
DAAM2 dishevelled associated activator of morphogenesis 2	212793_at	(I) DE1	5	0.00856		SZ 241	(I) SZ Superior temporal gyrus ²⁴² Addictions, Alcohol PFC I ¹⁸⁶ MDD AMY ²⁴³	(I) SZ Blood ²⁴⁴ 229 (D) PTSD Blood ²⁴⁵	8 —
DAB2 Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila)	201279_s_at	(I) DE1	5	0.00098				(I) Delusions Blood ⁵⁵	2 —
DLL1 delta-like 1 (Drosophila)	227938_s_at	(D) DE1	5	0.00016			(I) BP Brain ⁷⁰	(D) SZ iPSC ⁸⁴ PTSD PBMC ²⁴⁶	6 Yes ²⁴⁷
DNAH2 dynein,	215840_at	(D) DE1	5	0.00637				(D) Autistic	2 —

axonemal, heavy chain 2							Spectrum Disorder Blood ²⁴⁸		
DPP4 dipeptidyl-peptidase 4	211478_s_at	(D) DE4	5	1.43E-07		SZ 249	(D) PTSD Blood ¹⁶⁹ (I) SZ Blood ²⁰⁴	4	—
G2E3 G2/M-phase specific E3 ubiquitin protein ligase	223254_s_at	(D) AP1	5	0.0214				0	
GABARAPL1 GABA(A) receptor-associated protein like 1	208869_s_at	(I) DE1	5	3.48E-28		(D) BP Brain ⁷⁰	(D) Panic Disorder Lymphocyte ¹⁴⁵	6	Yes ²⁵⁰
GLUL glutamate-ammonia ligase	215001_s_at	(I) DE1	5	3.96E-15		(I) SZ Thalamus ²⁵¹ BP Anterior cingulate cortex, DLPFC ²¹⁹ SZ DLPFC (BA 46) ²⁵² BP DLPFC (BA 46) ²⁵² (D) MDD DLPFC ²⁵³ Locus coeruleus (LC) forebrain ²⁵⁴ DLPFC ¹⁶²	(I) Circadian abnormalities Blood ¹⁴¹ Mood stabilizers Blood ²⁵⁷ BP Blood ¹⁴⁴	6	—

						Anterior cingulate cortex, DLPFC ²¹⁹ SZ DLPFC ²⁵⁵ PFC gray matter ²⁵⁶			
GUK1 guanylate kinase 1	200075_s_at	(D) DE1	5	0.036 2			(I) MDD Plasma ²⁵⁸ SZ Blood ²¹²	2	—
HELZ helicase with zinc finger	240486_at	(I) DE1	5	3.56E- 06				0	—
IGHG1 immunoglobulin heavy constant gamma 1 (G1m marker)	241074_at	(I) DE1	5	0.034 2		(I) SZ APC ²¹³ BP APC ²¹³ (D) SZA APC ²¹³	(I) Hallucinations Blood ⁵⁵ (D) Mood Blood ¹⁶⁵ Autistic Spectrum Disorder Lymphocyte ⁵⁷ Stress, Social Isolation Blood ⁷³	6	—
IL1B interleukin 1, beta	205067_at 39402_at	(I) DE1	5	0.033 8 0.038 0	BP 259 260 SZ 261 Addictions, Alcohol 262 MDD ²⁶³ 264 Anxiety 263	(I) Alzheimer's Disease Hippocampal cornu ammonis 1 (CA1) 265 BP Frontal cortex 266 SZ	(I) BP Blood ^{93 94} SZ Plasma ²⁶⁸ Serum ¹¹³ 115 Blood ²⁶⁹ 270 CSF ²⁷¹ MDD Blood	8	—

						Stress ⁸⁹ 90	DLPFC (BA46) ⁹² Tourette e Syndrome Putamen ¹⁷⁰ (D) MDD DLPFC ²⁶⁷	²⁷² Plasma ¹⁰⁷ Serum ²⁷³ PTSD Serum ²⁷⁴ PBMC ¹²⁷ Autistic Spectrum Disorder Blood ²⁷⁵ Stress, Social Isolation Leukocytes ⁷³ Psychosis Serum ¹²¹ Antipsych otics Serum ¹²² Anxiety Plasma ¹⁰⁷ (D) Borderlin e Personali ty Disorder Blood ¹²⁴ Stress Blood ¹²⁴		
JAK3 Janus kinase 3	211108_s_at	(D) DE1	5	5.42E- 11					0	—
JUN jun proto- oncogene	201464_x_at 213281_at 201466_s_at	(I) DE1 AP1	5	2.63E- 51 1.02E- 41 2.21E- 08			(I) SZ cerebell ar vermis ²⁷⁶ middle tempora l gyrus ²⁷⁷ thalamu s ²³⁶ MDD middle tempora l gyrus	(I) Pain Vertebral disc ¹⁵⁵ SZ Fibroblast s ²⁷⁸ (D) SZ blood ²⁷⁸	6	—

							235 AMY ²³⁶			
JUNB jun B proto-oncogene	201473_at	(I) DE1	5	1.09E- 18			(I) MDD PFC ²⁷⁹ Addiction ns, Alcohol PFC ¹⁸⁶	(I) SZ Blood ²⁴⁴ Pain Blood ²⁸⁰	6	—
LAPTM4B lysosomal protein transmembrane 4 beta	1554679_a_at	(D) AP1	5	0.011 3			(D) BP Brain ⁷⁰	(D) Mood Blood ¹⁶⁵ PTSD Blood ¹⁶⁹	6	—
LHFP lipoma HMGIC fusion partner	218656_s_at	(I) DE1	5	1.27E- 06		SZ 281			2	—
LPAR1 lysophosphatidic acid receptor 1	204036_at	(D) AP1	5	7.67E- 06		BP 148 SZ 148	(I) BP Parietal cortex ²⁸² Anterior cingulate cortex ¹⁸² (D) MDD Middle temporal gyrus corresponding to Brodmann's area 21 (BA21) ²³⁵ AMY ²³⁶ Anterior cingulate cortex ¹⁸²	(I) Mood Blood ¹⁶⁵ (D) SZ Lymphocytes ²⁸³	8	—
MAGI3 membrane associated guanylate kinase,	226770_at	(D) AP1	5	0.029 2					0	—

WW and PDZ domain containing 3									
MARCKS myristoylated alanine-rich protein kinase C substrate	213002_at 201670_s_at	(I) DE1	5	1.51E- 06 0.000 4		(I) MDD PFC ²⁸⁴ SZ DLPFC (left hemisph ere, Broadm an area 46) ²⁸⁵ SZ DLPFC Broadm ann Area 9 ²²⁴ (D) BP Brain ⁷⁰ SZ DLPFC (Brodma nn areas 9/46) ²⁸⁶	(D) MDD Blood ²⁸⁷	6	—
MBP myelin basic protein	225408_at	(D) AP1	5	6.74E- 10		SZ ^{288 148} BP ⁷⁹ ₁₄₈ (D) BP Hippoca mpus ²⁸⁹ APC ²¹³ SZ Hippoca mpal formatio n ²⁸⁹ PFC (BA- 9) (D) ²⁹⁰ Primary Visual Cortex ²⁹¹ Alzheim er's Disease Frontal	(D) SZ blood ²¹² (I) Mood Blood ¹⁶⁵ Pain Vertebral disc ¹⁵⁵	8	

						white matter ²⁹² MDD AMY ²³⁶ DLPFC BA9 ²²⁴			
MCRS1 microspherule protein 1	202556_s_at	(D) DE1	5	3.29E-05		(I) MDD Pituitary ²⁹³		4	Yes ²⁹⁴
MEF2C myocyte enhancer factor 2C	207968_s_at	(D) DE1	5	3.47E-09	SZ ²⁴⁹ BP ⁸⁰	(D) BP Brain ⁷⁰ (I) PTSD Blood ¹⁶⁹	(D) Chronic Stress Blood ¹⁶⁷	8	—
MT1E metallothionein 1E	212859_x_at	(I) DE1	5	0.00020		(I) BP Brain ⁷⁰ SZ DLPFC ²⁹⁵ (D) SZ Frontal cortex ²⁹⁶		4	Yes ²⁹⁷
MT1H metallothionein 1H	206461_x_at	(I) DE1	5	5.62E-05		(I) BP Brain ⁷⁰ SZ DLPFC ²⁹⁵ (D) MDD AMY and cingulate cortex ⁸²	(I) Mood Stabilizers NT2.D1 cells ²⁴⁰	5	—
MT2A metallothionein 2A	212185_x_at	(I) DE1	5	0.00218		(I) BP Brain ⁷⁰ SZ Middle		4	Yes ^{300, 301, 302}

						temporal gyrus ²⁷⁷ DLPFC ^{298 295} Thalamus ²⁹⁹ Addictions, Alcohol Hippocampus ⁷¹ (D) MDD AMY and cingulate cortex ⁸²			
NDRG1 N-myc downstream regulated 1	200632_s_at	(I) DE1	5	3.21E-22		(I) SZ APC ²¹³		4	—
NUCB2 nucleobindin 2	229838_at	(I) DE1	5	0.0124				0	Yes ³⁰³
OGFR opioid growth factor receptor	211513_s_at	(D) DE1	5	0.00053				0	Yes ^{304, 305}
PCDH9 protocadherin 9	238919_at	(D) AP1	5	0.0215			(D) Hallucinations Blood ⁵⁵	2	—
PHF20L1 PHD finger protein 20-like 1	219606_at	(I) DE1	5	7.97E-05		(I) SZ PFC ²⁰³ (D) BP Brain ⁷⁰		4	Yes ³⁰⁶
PLEKHB1 pleckstrin homology domain containing, family B (evectins) member 1	209504_s_at	(D) DE1	5	6.07E-07			(D) Alcohol Blood ¹⁵⁴ SZ IPSC ⁸⁴	2	—
POLR2D polymerase (RNA) II (DNA directed) polypeptide D	214144_at	(D) AP1	5	1.02E-09		(D) BP Brain ⁷⁰		4	—
PRKACA protein kinase, cAMP-	202801_at	(D) AP1	5	0.0324		(D) SZ DLPFC	(D) MDD CSF ⁵⁸	6	—

dependent, catalytic, alpha							157 BP Brain ⁷⁰			
PRKCB protein kinase C, beta	227824_at 230437_s_at	(D) DE1 AP1	5	3.15E- 09 1.34E- 04 0.003		MDD 307 Autistic Spectrum Disorder 308 309	(D) BP Anterior cingulat e cortex ¹⁸² Autistic Spectru m Disorder Tempor al neocort ex ³⁰⁸ (I) MDD Anterior cingulat e cortex ¹⁸² SZ DLPFC (left hemisph ere, Broadm an area 46) ²⁸⁵ (D) Chronic Stress Blood ¹⁶⁷ BP Blood ³¹⁰ PTSD Blood ³¹¹ (I) SZ Blood ³¹²	8	Yes ³¹³	
PSMB4 proteasome (prosome, macropain) subunit, beta type, 4	202243_s_at	(D) DE1	5	9.98E- 07		MDD 314 315	(D) SZ DLPFC ³¹⁶ (D) SZA DLPFC ³¹⁶ (D) BP Brain ⁷⁰ (I) MDD AMY and cingulat e cortex ⁸²	6	—	
PTEN phosphatase and	204053_x_at 222176_at	(I) DE1	5	7.66E- 17			(I) SZ	(D) PTSD	6	—

tensin homolog				0.0003			PFC ²⁰³	Blood ¹⁶⁹		
RAB35 RAB35, member RAS oncogene family	205461_at	(D) DE2	5	0.00034			(D) BP Brain ⁷⁰		4	—
RBMX RNA binding motif protein, X-linked	1556336_at 213762_x_at	(D) DE1	5	1.40E-13 0.0232					0	—
RECK reversion-inducing-cysteine-rich protein with kazal motifs	216153_x_at	(I) DE1	5	0.00093				(I) PTSD Blood ¹⁶⁹	2	Yes ^{317, 318, 319}
RNASEL ribonuclease L (2',5'-oligoadenylate synthetase-dependent)	221287_at	(D) AP1	5	6.05E-06			(D) BP Brain ⁷⁰	(I) SZ IPSC ⁸⁴	6	—
SELENBP1 selenium binding protein 1	214433_s_at	(D) DE1	5	0.00019		Autistic Spectrum Disorder ³²⁰ SZ ³²¹	(I) SZ Hippocampus ³²¹ DLPFC ³²²	(D) SZ Blood ²⁴⁴ (I) Circadian abnormalities Blood ¹⁴¹	8	Yes ³²³
SHISA2 shisa family member 2	230493_at	(I) DE1	5	0.00107					0	—
SLC35E1 solute carrier family 35, member E1	222263_at	(D) AP1	5	0.00651			(I) MDD AMY and cingulate cortex ⁸²		4	—
SNAP23 synaptosomal-associated protein, 23kDa	209131_s_at	(D) AP1	5	0.00039				(D) BP Blood ¹⁴⁴ Stress, Social Isolation Leukocytes ⁷³	2	Yes ³²⁴
TM4SF1 transmembrane 4 L six family member 1	209386_at	(I) DE1	5	6.12E-11				(D) SZ lymphocyte ⁵⁹	2	—
TMEM254 transmembrane protein 254	218174_s_at	(D) DE1	5	1.35E-08					0	—

TMEM259 transmembrane protein 259	212574_x_at 212575_at 213986_s_at	(D) DE1	5	0.000 7 0.003 0.004			(D) SZ Blood 325 PTSD Blood 169 (I) MDD Leukocyte s 326	2	—
TNS1 tensin 1	218863_s_at	(D) DE1 AP2	5	6.29E- 05 0.012 3		(D) MDD AMY and cingulat e cortex 82	(D) SZ Blood ²⁴⁴ (I) Circadian abnormal ities Blood ¹⁴¹	6	Yes ³²⁷ , 328
TPBG trophoblast glycoprotein	203476_at	(I) DE1	5	6.66E- 06		(D) BP Brain ⁷⁰ SZ PFC ¹⁸⁷	(I) Mood stabilizer s neuroblas toma VPA 282	4	—
TPD52L1 tumor protein D52-like 1	203786_s_at	(I) DE1	5	1.52E- 16			(I) Mood Stabilizer s NT2.D1 cells 240	1	—
TRIM23 tripartite motif containing 23	210995_s_at	(D) DE1	5	3.28E- 14		(D) BP Brain ⁷⁰ BP Orbitofr ontal Cortex 329 SZ DLPFC 298		4	Yes ³³⁰
TSC22D3 TSC22 domain family, member 3	208763_s_at	(I) DE1	5	2.01E- 05		(I) Addictio ns, Alcohol HIP ⁷¹	(D) Delusions Blood ⁵⁵ MDD Blood 106	6	Yes ³³¹
TSPAN33	225775_at	(D)	5	0.003				0	—

tetraspanin 33		AP1		02					
VMP1 vacuole membrane protein 1	1569003_at	(I) DE1	5	0.002 91				0	Yes ³³²
VPREB3 pre-B lymphocyte 3	220068_at	(D) DE1	5	0.001 04				0	—
ZFP36 ZFP36 ring finger protein	201531_at	(I) DE1	5	8.72E- 27		(I) MDD DLPFC ¹⁶²	(I) Pain Blood ²⁸⁰	6	—
ZFYVE21 zinc finger, FYVE domain containing 21	219929_s_at	(D) AP1	5	1.69E- 04	SZ ²⁴⁹			2	—
ZHX2 zinc fingers and homeoboxes 2	203556_at	(I) DE1	5	0.001 98			(I) BP lymphocy te ⁵⁹	2	³³³
ZNF519 zinc finger protein 519	1568873_at	(D) AP1	5	0.011 64			(I) Autistic Spectrum Disorder Blood ²⁴⁸	2	Yes ³³⁴
B4GALT1 UDP- Gal:betaGlcNAc beta 1,4- galactosyltransfe rase, polypeptide 1	228498_at	(I) DE 4	4	NC		(D) Addictio ns ³³⁵ NAC	(I) Mood Stabilizer s NT2.D1 cells ²⁴⁰	3	-
BTBD3 BTB (POZ) domain containing 3	243461_at	(I) DE 4	4	NC	OCD ³³⁶			2	Yes ³³⁷
CADM1 cell adhesion molecule 1	237259_at	(I) DE4	4	NC	Autistic Spectrum Disorder ³³⁸	(I) BP brain ⁷⁰ (D) BP APC ²¹³	(D) Mood Blood ¹⁶⁵ MDD blood ²⁸⁷	8	—
CATSPER3 cation channel, sperm associated 3	230981_at	(D) AP4	4	NC				0	-
CCL28 chemokine (C-C motif) ligand 28	224240_s_at	(D) AP4	4	NC			(D) BP blood ¹⁶⁵ Sleep Circadian abnormal ities blood ¹⁴¹ (I)	2	Yes ^{340 341}

							Anxiety SSRI lymphobl astoid ³³⁹		
CLIP4 CAP-GLY domain containing linker protein family, member 4	219944_at	(D) DE4	4	NC				0	—
CTBS chitobiase, di-N- acetyl-	218924_s_at	(I) DE 4	4	NC		(I) MDD PFC ¹⁶²		4	-
CYorf17 chromosome Y open reading frame 17	234274_at	(D) DE 4	4	NC				0	-
DCAF15 DDB1 and CUL4 associated factor 15	221851_at	(D) DE4	4	0.030 2		(I) Addictio ns, Alcohol HIP ⁷¹		4	—
DEPDC5 DEP domain containing 5	234548_at	(I) AP4	4	NC		(D) BP PFC ⁷⁰ (I) BP PFC ³⁴²		4	-
DTNA dystrobrevin, alpha	211493_x_at	(I) AP4	4	NC	BP ⁸⁰	(I) BP PFC ³⁴² (D) MDD AMY and cingulat e cortex ⁸² Tourett e Syndro me putame n ¹⁷⁰		6	—
EMR2 egf-like module containing, mucin-like, hormone receptor-like 2	232009_at	(I) DE 4	4	NC			(D) Chronic stress blood ¹⁶⁷	2	Yes ³⁴³
EPHA10 EPH receptor	243717_at	(D) DE4	4	0.008 01				0	—

A10										
ERG v-ets avian erythroblastosis virus E26 oncogene homolog	213541_s_at	(D) DE 4	4	NC		Addictions 344			1	-
ERV3-2 endogenous retrovirus group 3, member 2	222139_at	(I) DE 4	4	NC				(I) SZ blood ²²⁹	2	-
FAM183CP family with sequence similarity 183, member C, pseudogene	1569887_a_at	(I) AP4	4	NC					0	-
HIST1H2BO histone cluster 1, H2bo	214540_at	(I) DE4	4	4.77E- 10				(I) Relaxatio n Response Blood ¹⁷⁵	2	—
HS3ST3B1 heparan sulfate (glucosamine) 3- O- sulfotransferase 3B1	1561908_a_at	(D) AP4	4	NC		Aging Longevity 345		(I) SZ fibroblast s ⁸⁴	4	-
IQCH IQ motif containing H	224165_s_at	(D) DE4	4	0.003 24				(D) Delusions Blood ⁵⁵	2	—
KCTD21 potassium channel tetramerization domain containing 21	229873_at	(I) DE 4	4	NC					0	-
KERA keratocan	220504_at	(I) DE4	4	0.000 21					0	—
KIF2C kinesin family member 2C	211519_s_at	(D) AP4	4	0.000 56					0	—
KLHDC3 kelch domain containing 3	214383_x_at	(D) DE4	4	1.57E- 17			(D) BP brain ⁷⁰	(D) BP Lymphocy te ¹⁹⁷	6	—
LAMB1 laminin, beta 1	238608_at	(I) AP4	4	NC		Personality Conscienti ousness ³⁴⁶	(D) Aging PFC ³⁴⁷ BP PFC ⁷⁰ (I) Addictio ns FC ¹⁸⁹	(I) Hallucina tions blood ⁵⁵	6.00	-
LOC100129917	236411_at	(D)	4	0.002					0	Yes

uncharacterized LOC100129917		DE4		25					348
LOC100289061 uncharacterized LOC100289061	1563071_at	(I) AP4	4	NC				0	-
LOC100996345 uncharacterized LOC100996345	240697_at	(D) DE4	4	7.20E-05				0	-
LOC285500 uncharacterized LOC285500	1558451_at	(I) DE 4	4	NC				0	-
MED21 mediator complex subunit 21	209363_s_at	(D) AP4	4	0.074 26		(D) BP ⁷⁰		4	-
PCIF1 PDX1 C-terminal inhibiting factor 1	222045_s_at	(D) AP4	4	NC			(D) MDD Fibroblast ¹⁴⁶	2	Yes 349
PLEC plectin	216971_s_at	(D) DE 4	4	NC			(D) BP blood ¹⁴⁴	2	Yes 350
RAB36 RAB36, member RAS oncogene family	211471_s_at	(I) AP4	4	NC				0	-
RAD23A RAD23 homolog A (S. cerevisiae)	201039_s_at	(D) DE 4	4	NC		(I) MDD AMY and cingulat e cortex ⁸²		4	Yes 351
RHAG Rh-associated glycoprotein	206145_at	(D) AP4	4	NC			(I) Delusions blood ⁵⁵	2	-
ROBO4 roundabout, axon guidance receptor, homolog 4 (Drosophila)	220758_s_at	(D) AP4	4	NC				0	-
RP11-669N7.2 uncharacterized LOC283352	1561757_a_at	(I) AP4	4	NC				0	-
RPL6P17 ribosomal protein L6 pseudogene 17	216816_at	(D) AP4	4	NC				0	-
SETD8 SET domain containing (lysine methyltransferase) 8	220200_s_at	(D) DE 4	4	NC	SZ ²⁴⁹		(D) Mood blood ¹⁶⁵	4	Yes 352 353
SH3GLB2 SH3-domain GRB2-like	218813_s_at	(D) DE4	4	0.000 17		(D) BP Brain ⁷⁰	(D) BP Blood	6	-

endophilin B2							144		
ST6GALNAC4 ST6 (alpha-N-acetylneuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 4	221551_x_at	(D) DE4	4	3.22E-05				0	—
TEX10 testis expressed 10	1558702_at	(D) AP4	4	0.00281				0	—
TEX261 testis expressed 261	1559675_at	(D) AP4	4	0.00427			(I) Mood Blood ¹⁶⁵ (D) Hallucinations Blood ⁵⁵	2	—
TFDP1 transcription factor Dp-1	242538_at	(I) AP4	4	0.00238				0	—
TMLHE-AS1 TMLHE antisense RNA 1	1560797_s_at	(I) DE 4	4	NC				0	-
TMSB15B thymosin beta 15B	1556964_s_at	(D) DE4	4	0.007			(I) MDD Fibroblast ¹⁴⁶	2	—
TUBGCP3 tubulin, gamma complex associated protein 3	215739_s_at	(D) DE2	4	2.05E-16			(D) BP Blood ¹⁴⁴	2	—
TXNRD2 thioredoxin reductase 2	210803_at	(D) AP4	4	0.0425				0	Yes ³⁵⁴
USP12 ubiquitin specific peptidase 12	229987_at	(D) AP4	4	0.2723			(I) Sleep Circadian abnormalities blood ¹⁴¹	2	Yes ³⁵⁵
VEGFB vascular endothelial growth factor B	203683_s_at	(D) AP4	4	5.13E-07				0	—
ZBTB7A zinc finger and BTB domain containing 7A	213299_at	(D) DE4	4	2.05E-06			(I) MDD AMY and cingulate cortex ⁸²	4	—

Table S4. Top candidate biomarker genes - drugs that modulate these markers in the opposite direction.

Gene symbol/ Gene Name	Discovery (Change) Method/ Score	Prioritization Total CFG Score For Suicide	Validation ANOVA p-value	Modulated by Omega-3	Modulated by Lithium	Modulated by Clozapine	Other Drugs
CCDC136 coiled-coil domain containing 136	(D) AP4	8	NC			(I) Mouse VT ³⁵⁶	
CD44 CD44 molecule (Indian blood group)	(D) DE2	8	NC			(I) Mouse Blood ³⁵⁶	
IL6 interleukin 6 (interferon, beta 2)	(I) AP2	8	1.44E-08	(D) Human Blood ³⁵⁷			tocilizuma b siltuxima b
SAT1 spermidine/sper mine N1- acetyltransferas e 1	(I) DE2 DE1	8	1.08E-44	(D) Mouse Blood ³⁵⁸			
MAOB monoamine oxidase B	(I) DE1	7	8.11E-08				selegiline
ARHGAP26 Rho GTPase activating protein 26	(I) DE1	6	9.91E-08			(D) Mouse VT ³⁵⁶	
BCL2 B-cell CLL/lymphoma 2	(D) DE1	6	0.0003		(I) Human Blood ¹⁵³	(I) Rat Dentate gyrus Hippocampus ³⁵⁹	
EHBP1 EH domain binding protein 1	(D) DE 4	6	NC			(I) VT ³⁵⁶	
FAM49B family with sequence similarity 49, member B	(I) AP2	6	0.0188	(D) Mouse Blood ³⁵⁸			
HPCAL1 hippocalcin-like 1	(I) DE2	6	7.50E-05			(D) Mouse VT ³⁵⁶	
MAPK9 mitogen- activated protein kinase 9	(I) DE2	6	0.0132			(D) Mouse VT ³⁵⁶	
NEAT1 nuclear	(I) DE2	6	2.33E-24			(D) Mouse	

paraspeckle assembly transcript 1 (non-protein coding)						VT ³⁵⁶	
RASL11B RAS-like, family 11, member B	(I) AP2	6	0.0124			(D) Mouse Caudate putamen ³⁵⁶	
TRAK2 trafficking protein, kinesin binding 2	(D) DE2	6	0.006	(I) Mouse Blood ³⁵⁸	(I) Mouse PFC ³⁶⁰		
ADRBK1 adrenergic, beta, receptor kinase 1	(D) DE1	5	2.22E-05			(I) Mouse PFC ³⁶¹	
BRAF v-raf murine sarcoma viral oncogene homolog B	(I) DE1	5	6.07E-29				Vemurafenib Dabrafenib
CAMK2B calcium/calmodulin-dependent protein kinase II beta	(I) DE1	5	0.00025			(D) Mouse striatum ³⁶²	
CNP 2',3'-cyclic nucleotide 3' phosphodiesterase	(D) AP1	5	0.0315	(I) Mouse Hippocampus ³⁵⁸		(I) Mouse AMY ³⁵⁶	
CTTN cortactin	(I) DE1	5	3.46E-18	(D) Mouse Blood ³⁵⁸		(D) Mouse VT ³⁵⁶	
G2E3 G2/M-phase specific E3 ubiquitin protein ligase	(D) AP1	5	0.0214	(I) Mouse Hippocampus ³⁵⁸			
GABARAPL1 GABA(A) receptor-associated protein like 1	(I) DE1	5	3.48E-28	(D) Mouse Blood ³⁵⁸			
HELZ helicase with zinc finger	(I) DE1	5	3.56E-06	(D) Mouse Blood ³⁵⁸			
IL1B interleukin 1, beta	(I) DE1	5	0.0338	(D) Mouse Blood ³⁵⁸			canakinumab gevokizumab gallium nitrate
LHFP lipoma HMGIC fusion partner	(I) DE1	5	1.27E-06	(D) Mouse Blood ³⁵⁸			

LPAR1 lysophosphatidic acid receptor 1	(D) AP1	5	7.67E-06	(I) Mouse Hippocampus, Blood ³⁵⁸		(I) Mouse AMY ³⁵⁶	
MBP myelin basic protein	(D) AP1	5	6.74E-10	(I) Mouse Blood ³⁵⁸	(I) Oligodendrocytes ³⁶³ Mouse Brain ³⁶⁰	(I) Mouse AMY and Blood ³⁵⁶	
MEF2C myocyte enhancer factor 2C	(D) DE1	5	3.47E-09			(I) Mouse Hippocampus and VT ³⁵⁶	
NDRG1 N-myc downstream regulated 1	(I) DE1	5	3.21E-22	(D) Mouse Blood ³⁵⁸			
OGFR opioid growth factor receptor	(D) DE1	5	0.00053				enkephalin methionine
PCDH9 protocadherin 9	(D) AP1	5	0.0215			(I) Mouse VT ³⁵⁶	
PHF20L1 PHD finger protein 20-like 1	(I) DE1	5	7.97E-05	(D) Mouse Blood ³⁵⁸		(D) Mouse Hippocampus ³⁵⁶	
PRKCB protein kinase C, beta	(D) DE1 AP1	5	3.15E-09		(I) Mouse PFC ³⁶⁰ AMY ³⁶⁴		
RBMX RNA binding motif protein, X-linked	(D) DE1	5	1.40E-13	(I) Mouse NAC, Blood ³⁵⁸			
RNASEL ribonuclease L (2',5'- oligoadenylate synthetase- dependent)	(D) AP1	5	6.05E-06	(I) Mouse Blood ³⁵⁸			
SNAP23 synaptosomal- associated protein, 23kDa	(D) AP1	5	0.00039			(I) Mouse Blood ³⁵⁶	
TM4SF1 transmembrane 4 L six family member 1	(I) DE1	5	6.12E-11	(D) Mouse Blood ³⁵⁸			
TSPAN33 tetraspanin 33	(D) AP1	5	0.00302	(I) Mouse Blood ³⁵⁸		(I) Mouse VT ³⁵⁶	
VMP1 vacuole membrane protein 1	(I) DE1	5	0.00291	(D) Mouse Blood ³⁵⁸			

ZFP36 ZFP36 ring finger protein	(I) DE1	5	8.72E-27	(D) Mouse Blood ³⁵⁸	(D) Rat Brain ³⁶⁵		
BTBD3 BTB (POZ) domain containing 3	(I) DE 4	4	NC	(D) Mouse AMY ³⁵⁸			
CADM1 cell adhesion molecule 1	(I) DE4	4	NC			(D) Mouse VT ³⁵⁶	
CTBS chitinase, di-N-acetyl-	(I) DE 4	4	NC			(D) VT ³⁵⁶	
LAMB1 laminin, beta 1	(I) AP4	4	NC	(D) Mouse HIP ³⁵⁸			
PLEC plectin	(D) DE 4	4	NC			(I) Mouse VT ³⁵⁶	
RAD23A RAD23 homolog A (<i>S. cerevisiae</i>)	(D) DE 4	4	NC	(I) Mouse Blood ³⁵⁸			
SETD8 SET domain containing (lysine methyltransferase) 8	(D) DE 4	4	NC	(I) Mouse Blood ³⁵⁸			
TXNRD2 thioredoxin reductase 2	(D) AP4	4	0.0425			(I) Mouse Blood ³⁵⁶	

Table S5 Biomarker discovery within each diagnostic group. Within-participant design. N=37 for all, N= 15 for BP, N=7 for MDD, N= 6 for SZA, and N=4 for SZ

	Top Biomarkers Discovered, Prioritized and Validated by Diagnosis				
Gene Symbol/ Affymetrix Probeset ID	Top Biomarkers All diagnoses	Top Biomarkers Bipolar disorder (BP)	Top Biomarkers Depression (MDD)	Top Biomarkers Schizoaffective disorder (SZA)	Top Biomarkers Schizophrenia (SZ)
Top Discovery AP Increased	DTNA 211493_x_at	DTNA 211493_x_at	PHF20 210500_at	USP48 232621_at	RP11-389C8.2 1556314_a_at
Top Discovery AP Decreased	KIF2C 211519_s_at	HS3ST3B1 1561908_a_at	EIF1B-AS1 1557212_at	NPRL3 210672_s_at	CYB561 210816_s_at
Top Discovery DE Increased	CADM1 237259_at	CADM1 237259_at	TLN1 232763_at	TSPYL1, 1560648_s_at	LOC100128288 1559045_at
Top Discovery DE Decreased	CLIP4 219944_at	Unknown 231262_at	NUCKS1 222027_at	TMSB15B, 1556964_s_at MCM8, 231827_at	CCDC163P 1559003_a_at
Top Prioritization AP Increased	SLC4A4 210739_x_at	KSR1 213769_at	DLK1 209560_s_at	IL6 205207_at	C1orf61 205103_at
Top Prioritization AP Decreased	SKA2 225686_at	CD44 216056_at	BBIP1 232910_at	TNS1 218863_s_at	SKA2 225686_at
Top Prioritization DE Increased	SAT1 210592_s_at	DAPP1 219290_x_at	BDNF 239367_at	TNF 207113_s_at	BDNF 206382_s_at
Top Prioritization DE Decreased	SKA2 225686_at	OPRM1 207989_at	SKA2 225686_at	S100B 1561521_at	HTR2A 211616_s_at
Top Validation AP Increased	IL6 205207_at	SPTBN1 215918_s_at	IL10 207433_at	JUN 201466_s_at	SLC5A3 1553313_s_at
Top Validation AP Decreased	MBP 225408_at	AKT1S1 224982_at	EIF1B-AS1 1557212_at	BATF2 228439_at	ATP6V0E1 236527_at
Top Validation DE Increased	JUN 201464_x_at	SAT1 213988_s_at	GATM 1566861_at	JUN 201464_x_at	JUN 201464_x_at
Top Validation DE Decreased	KLHDC3 214383_x_at	C20orf27 218081_at	PRPF40A 226687_at	ANXA11 228727_at	LOC100131662 236973_at

Table S6 Biological Pathways and Diseases. Suicidal ideation markers non-validated for behavior in completers (n=208) vs. suicidal ideation markers that were validated for behavior in completers (n=204).

A.	Ingenuity Pathways				KEGG Pathways			GeneGO Pathways		
		Top Canonical Pathways	P-Value	Ratio	Pathway Name	Enrichment Score	Enrichment p-value	Process Networks	Ratio	p-value
Non-Validated in Completers Stepwise (n=208 genes)	1	G-Protein Coupled Receptor Signaling	2.28E-08	5.7% 15/264	Pathogenic Escherichia coli infection	7.19808	0.000748	Cytoskeleton_ Regulation of cytoskeleton rearrangement	16/183	5.75E-07
	2	cAMP-mediated signaling	1.51E-07	5.8% 13/223	Amoebiasis	5.51218	0.004037	Development_ Neurogenesis_Axonal guidance	17/230	2.65E-06
	3	CREB Signaling in Neurons	6.20E-06	5.6% 10/179	Dorso-ventral axis formation	4.7856	0.008349	Development_ Hedgehog signaling	17/254	1.01E-05
	4	Cardiac Hypertrophy Signaling	1.02E-05	4.7% 11/232	Melanogenesis	4.31121	0.013417	Reproduction_ Progesterone signaling	14/214	8.25E-05
	5	Synaptic Long Term Potentiation	2.26E-05	6.3% 8/127	Influenza A	4.23564	0.014471	Cardiac development_ Wnt_beta-catenin, Notch, VEGF, IP3 and integrin signaling	11/150	0.0001819
Validated in Completers Stepwise (n=204 genes)	1	B Cell Receptor Signaling	1.01E-08	7.2 % 13/181	Focal adhesion	10.5307	2.67E-05	Signal transduction_ WNT signaling	19/177	8.10E-10
	2	Ovarian Cancer Signaling	3.31E-08	8.3 % 11/133	Colorectal cancer	10.3054	3.35E-05	Cell cycle_ G1-S Growth factor regulation	18/195	2.62E-08
	3	Glucocorticoid Receptor Signaling	3.97E-08	5.3 % 15/281	GABAergic synapse	8.60276	0.000184	Reproduction_ Gonadotropin regulation	18/199	3.60E-08
	4	Colorectal Cancer Metastasis Signaling	4.00E-08	5.8 % 14/241	mTOR signaling pathway	8.47678	0.000208	Reproduction_ GnRH signaling pathway	16/166	9.05E-08
	5	G12/13 Signaling	1.12E-08	8.5 % 10/118	Chagas disease (American trypanosomiasis)	7.66796	0.000468	Neurophysiological process_ Transmission of nerve impulse	18/212	9.58E-08

			E-07							
--	--	--	------	--	--	--	--	--	--	--

B.	Ingenuity				GeneGO		
		Diseases and Disorders	P-Value	# Molecules	Diseases	pValue	Ratio
Non- Validated in Completers Stepwise (n=208 genes)	1	Neurological disease	5.43E-04 - 8.63E-13	78	Psychiatry and Psychology	1.6E-30	85/1919
	2	Psychological Disorders	1.77E-04 - 2.04E-12	62	Mental Disorders	2.82E-30	78/1614
	3	Skeletal and Muscular Disorders	1.98E-04 - 5.33E-10	60	Schizophrenia	3.6E-22	51/914
	4	Organismal Injury and Abnormalities	6.69E-04 - 1.81E-09	184	Schizophrenia and Disorders with Psychotic Features	4.37E-22	51/918
	5	Cancer	6.32E-04 - 2.59E-09	182	Central Nervous System Diseases	5.41E-22	94/3069
		Diseases and Disorders	P-Value	# Molecules	Diseases	pValue	Ratio
Validated in Completers Stepwise (n=204 genes)	1	Organismal Injury and Abnormalities	5.21E-04 - 1.23E-13	178	Psychiatry and Psychology	1.77E-23	76/1919
	2	Cancer	2.20E-04 - 5.41E-13	176	Mental Disorders	1.23E-21	67/1614
	3	Neurological Disease	1.31E-04 - 1.07E-12	81	Mood Disorders	4.02E-21	47/797
	4	Psychological Disorders	1.31E-04 - 1.07E-12	63	Depressive Disorder, Major	1.06E-18	37/546
	5	Tumor Morphology	1.87E-04 - 1.83E-12	38	Depressive Disorder	2.44E-18	37/560

Literature Cited

1. Le-Niculescu H, Levey DF, Ayalew M, Palmer L, Gavrin LM, Jain N *et al.* Discovery and validation of blood biomarkers for suicidality. *Mol Psychiatry* 2013; **18**(12): 1249-1264.
2. Guintivano J, Brown T, Newcomer A, Jones M, Cox O, Maher BS *et al.* Identification and replication of a combined epigenetic and genetic biomarker predicting suicide and suicidal behaviors. *Am J Psychiatry* 2014; **171**(12): 1287-1296.
3. Labonte B, Suderman M, Maussion G, Lopez JP, Navarro-Sanchez L, Yerko V *et al.* Genome-wide methylation changes in the brains of suicide completers. *Am J Psychiatry* 2013; **170**(5): 511-520.
4. Galfalvy H, Zalsman G, Huang YY, Murphy L, Rosoklija G, Dwork AJ *et al.* A pilot genome wide association and gene expression array study of suicide with and without major depression. *World J Biol Psychiatry* 2013; **14**(8): 574-582.
5. Mann JJ, Gibbons RD. Guns and suicide. *Am J Psychiatry* 2013; **170**(9): 939-941.
6. Perroud N, Bondolfi G, Uher R, Gex-Fabry M, Aubry JM, Bertschy G *et al.* Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. *Pharmacogenomics* 2011; **12**(3): 365-377.
7. Willour VL, Chen H, Toolan J, Belmonte P, Cutler DJ, Goes FS *et al.* Family-based association of FKBP5 in bipolar disorder. *Mol Psychiatry* 2009; **14**(3): 261-268.
8. Roy A, Hodgkinson CA, Deluca V, Goldman D, Enoch MA. Two HPA axis genes, CRHBP and FKBP5, interact with childhood trauma to increase the risk for suicidal behavior. *J Psychiatr Res* 2012; **46**(1): 72-79.
9. Roy A, Gorodetsky E, Yuan Q, Goldman D, Enoch MA. Interaction of FKBP5, a stress-related gene, with childhood trauma increases the risk for attempting suicide. *Neuropsychopharmacology* 2010; **35**(8): 1674-1683.
10. Supriyanto I, Sasada T, Fukutake M, Asano M, Ueno Y, Nagasaki Y *et al.* Association of FKBP5 gene haplotypes with completed suicide in the Japanese population. *Prog Neuropsychopharmacol Biol Psychiatry* 2011; **35**(1): 252-256.

11. Perez-Ortiz JM, Garcia-Gutierrez MS, Navarrete F, Giner S, Manzanares J. Gene and protein alterations of FKBP5 and glucocorticoid receptor in the amygdala of suicide victims. *Psychoneuroendocrinology* 2013; **38**(8): 1251-1258.
12. Galfalvy H, Zalsman G, Huang YY, Murphy L, Rosoklija G, Dwork AJ *et al.* A pilot genome wide association and gene expression array study of suicide with and without major depression. *World J Biol Psychiatry* 2013; **14**(8): 574-582.
13. Pandey GN, Rizavi HS, Ren X, Fareed J, Hoppensteadt DA, Roberts RC *et al.* Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims. *J Psychiatr Res* 2012; **46**(1): 57-63.
14. Hoyo-Becerra C, Huebener A, Trippler M, Lutterbeck M, Liu ZJ, Truebner K *et al.* Concomitant interferon alpha stimulation and TLR3 activation induces neuronal expression of depression-related genes that are elevated in the brain of suicidal persons. *PLoS One* 2013; **8**(12): e83149.
15. Lindqvist D, Janelidze S, Erhardt S, Traskman-Bendz L, Engstrom G, Brundin L. CSF biomarkers in suicide attempters--a principal component analysis. *Acta Psychiatr Scand* 2011; **124**(1): 52-61.
16. Bay-Richter C, Linderholm KR, Lim CK, Samuelsson M, Traskman-Bendz L, Guillemin GJ *et al.* A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality. *Brain Behav Immun* 2015; **43**: 110-117.
17. Kim YK, Lee SW, Kim SH, Shim SH, Han SW, Choi SH *et al.* Differences in cytokines between non-suicidal patients and suicidal patients in major depression. *Prog Neuropsychopharmacol Biol Psychiatry* 2008; **32**(2): 356-361.
18. Fiori LM, Wanner B, Jomphe V, Croteau J, Vitaro F, Tremblay RE *et al.* Association of polyaminergic loci with anxiety, mood disorders, and attempted suicide. *PLoS One* 2010; **5**(11): e15146.
19. Sokolowski M, Ben-Efraim YJ, Wasserman J, Wasserman D. Glutamatergic GRIN2B and polyaminergic ODC1 genes in suicide attempts: associations and gene-environment interactions with childhood/adolescent physical assault. *Mol Psychiatry* 2013; **18**(9): 985-992.
20. Klempan TA, Sequeira A, Canetti L, Lalovic A, Ernst C, French-Mullen J *et al.* Altered expression of genes involved in ATP biosynthesis and GABAergic neurotransmission in the ventral prefrontal cortex of suicides with and without major depression. *Mol Psychiatry* 2009; **14**(2): 175-189.
21. Perlis RH, Huang J, Purcell S, Fava M, Rush AJ, Sullivan PF *et al.* Genome-wide association study of suicide attempts in mood disorder patients. *Am J Psychiatry* 2010; **167**(12): 1499-1507.

22. Kim S, Choi KH, Baykiz AF, Gershenfeld HK. Suicide candidate genes associated with bipolar disorder and schizophrenia: An exploratory gene expression profiling analysis of post-mortem prefrontal cortex. *BMC genomics* 2007; **8**(1): 413.
23. Ballesteros J, Maeztu AI, Callado LF, Meana JJ, Gutierrez M. Specific binding of [3H]Ro 19-6327 (lazabemide) to monoamine oxidase B is increased in frontal cortex of suicide victims after controlling for age at death. *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology* 2008; **18**(1): 55-61.
24. Roggenbach J, Muller-Oerlinghausen B, Franke L, Uebelhack R, Blank S, Ahrens B. Peripheral serotonergic markers in acutely suicidal patients. 1. Comparison of serotonergic platelet measures between suicidal individuals, nonsuicidal patients with major depression and healthy subjects. *J Neural Transm* 2007; **114**(4): 479-487.
25. Fiori LM, Bureau A, Labbe A, Croteau J, Noel S, Merette C *et al.* Global gene expression profiling of the polyamine system in suicide completers. *Int J Neuropsychopharmacol* 2011; **14**(5): 595-605.
26. Zubenko GS, Maher BS, Hughes HB, 3rd, Zubenko WN, Scott Stiffler J, Marazita ML. Genome-wide linkage survey for genetic loci that affect the risk of suicide attempts in families with recurrent, early-onset, major depression. *Am J Med Genet B Neuropsychiatr Genet* 2004; **129B**(1): 47-54.
27. Sequeira A, Morgan L, Walsh DM, Cartagena PM, Choudary P, Li J *et al.* Gene expression changes in the prefrontal cortex, anterior cingulate cortex and nucleus accumbens of mood disorders subjects that committed suicide. *PLoS One* 2012; **7**(4): e35367.
28. Smalheiser NR, Lugli G, Rizavi HS, Torvik VI, Turecki G, Dwivedi Y. MicroRNA expression is down-regulated and reorganized in prefrontal cortex of depressed suicide subjects. *PLoS One* 2012; **7**(3): e33201.
29. Kekesi KA, Juhasz G, Simor A, Gulyassy P, Szego EM, Hunyadi-Gulyas E *et al.* Altered functional protein networks in the prefrontal cortex and amygdala of victims of suicide. *PLoS One* 2012; **7**(12): e50532.
30. Sequeira A, Gwadry FG, Ffrench-Mullen JM, Canetti L, Gingras Y, Casero RA, Jr. *et al.* Implication of SSAT by gene expression and genetic variation in suicide and major depression. *Arch Gen Psychiatry* 2006; **63**(1): 35-48.

31. Dick DM, Meyers J, Aliev F, Nurnberger J, Jr., Kramer J, Kuperman S *et al.* Evidence for genes on chromosome 2 contributing to alcohol dependence with conduct disorder and suicide attempts. *Am J Med Genet B Neuropsychiatr Genet* 2010; **153B**(6): 1179-1188.
32. Kim S, Choi KH, Baykiz AF, Gershenfeld HK. Suicide candidate genes associated with bipolar disorder and schizophrenia: an exploratory gene expression profiling analysis of post-mortem prefrontal cortex. *BMC genomics* 2007; **8**: 413.
33. Fiori LM, Zouk H, Himmelman C, Turecki G. X chromosome and suicide. *Mol Psychiatry* 2011; **16**(2): 216-226.
34. Dwivedi Y, Rizavi HS, Teppen T, Sasaki N, Chen H, Zhang H *et al.* Aberrant extracellular signal-regulated kinase (ERK) 5 signaling in hippocampus of suicide subjects. *Neuropsychopharmacology* 2007; **32**(11): 2338-2350.
35. Choi K, Le T, Xing G, Johnson LR, Ursano RJ. Analysis of kinase gene expression in the frontal cortex of suicide victims: implications of fear and stress. *Front Behav Neurosci* 2011; **5**: 46.
36. Merali Z, Kent P, Du L, Hrdina P, Palkovits M, Faludi G *et al.* Corticotropin-releasing hormone, arginine vasopressin, gastrin-releasing peptide, and neuromedin B alterations in stress-relevant brain regions of suicides and control subjects. *Biol Psychiatry* 2006; **59**(7): 594-602.
37. Lalovic A, Klempan T, Sequeira A, Luheshi G, Turecki G. Altered expression of lipid metabolism and immune response genes in the frontal cortex of suicide completers. *J Affect Disord* 2010; **120**(1-3): 24-31.
38. Zhurov V, Stead JD, Merali Z, Palkovits M, Faludi G, Schild-Poulter C *et al.* Molecular pathway reconstruction and analysis of disturbed gene expression in depressed individuals who died by suicide. *PLoS One* 2012; **7**(10): e47581.
39. Schlicht K, Buttner A, Siedler F, Scheffer B, Zill P, Eisenmenger W *et al.* Comparative proteomic analysis with postmortem prefrontal cortex tissues of suicide victims versus controls. *J Psychiatr Res* 2007; **41**(6): 493-501.
40. Butler AW, Breen G, Tozzi F, Craddock N, Gill M, Korszun A *et al.* A genomewide linkage study on suicidality in major depressive disorder confirms evidence for linkage to 2p12. *Am J Med Genet B Neuropsychiatr Genet* 2010; **153B**(8): 1465-1473.
41. Willour VL, Zandi PP, Badner JA, Steele J, Miao K, Lopez V *et al.* Attempted suicide in bipolar disorder pedigrees: evidence for linkage to 2p12. *Biol Psychiatry* 2007; **61**(5): 725-727.

42. Garcia-Sevilla JA, Escriba PV, Ozaita A, La Harpe R, Walzer C, Eytan A *et al.* Up-regulation of immunolabeled alpha2A-adrenoceptors, Gi coupling proteins, and regulatory receptor kinases in the prefrontal cortex of depressed suicides. *Journal of neurochemistry* 1999; **72**(1): 282-291.
43. Dwivedi Y, Rizavi HS, Conley RR, Pandey GN. ERK MAP kinase signaling in post-mortem brain of suicide subjects: differential regulation of upstream Raf kinases Raf-1 and B-Raf. *Mol Psychiatry* 2006; **11**(1): 86-98.
44. Monsalve EM, Garcia-Gutierrez MS, Navarrete F, Giner S, Laborda J, Manzanares J. Abnormal expression pattern of Notch receptors, ligands, and downstream effectors in the dorsolateral prefrontal cortex and amygdala of suicidal victims. *Molecular neurobiology* 2014; **49**(2): 957-965.
45. Cheng R, Juo SH, Loth JE, Nee J, Iossifov I, Blumenthal R *et al.* Genome-wide linkage scan in a large bipolar disorder sample from the National Institute of Mental Health genetics initiative suggests putative loci for bipolar disorder, psychosis, suicide, and panic disorder. *Mol Psychiatry* 2006; **11**(3): 252-260.
46. Sequeira A, Mamdani F, Ernst C, Vawter MP, Bunney WE, Lebel V *et al.* Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. *PLoS One* 2009; **4**(8): e6585.
47. Pandey GN, Dwivedi Y, Ren X, Rizavi HS, Roberts RC, Conley RR *et al.* Altered expression and phosphorylation of myristoylated alanine-rich C kinase substrate (MARCKS) in postmortem brain of suicide victims with or without depression. *J Psychiatr Res* 2003; **37**(5): 421-432.
48. Bloem B, Xu L, Morava E, Faludi G, Palkovits M, Roubos EW *et al.* Sex-specific differences in the dynamics of cocaine- and amphetamine-regulated transcript and nesfatin-1 expressions in the midbrain of depressed suicide victims vs. controls. *Neuropharmacology* 2012; **62**(1): 297-303.
49. Pandey GN, Dwivedi Y, Ren X, Rizavi HS, Mondal AC, Shukla PK *et al.* Brain region specific alterations in the protein and mRNA levels of protein kinase A subunits in the post-mortem brain of teenage suicide victims. *Neuropsychopharmacology* 2005; **30**(8): 1548-1556.
50. Pandey GN, Dwivedi Y, Rizavi HS, Ren X, Conley RR. Decreased catalytic activity and expression of protein kinase C isozymes in teenage suicide victims: a postmortem brain study. *Arch Gen Psychiatry* 2004; **61**(7): 685-693.
51. Dwivedi Y, Rizavi HS, Zhang H, Roberts RC, Conley RR, Pandey GN. Modulation in activation and expression of phosphatase and tensin homolog on chromosome ten, Akt1, and 3-

- phosphoinositide-dependent kinase 1: further evidence demonstrating altered phosphoinositide 3-kinase signaling in postmortem brain of suicide subjects. *Biol Psychiatry* 2010; **67**(11): 1017-1025.
52. Sequeira A, Klempan T, Canetti L, French-Mullen J, Benkelfat C, Rouleau GA *et al.* Patterns of gene expression in the limbic system of suicides with and without major depression. *Mol Psychiatry* 2007; **12**(7): 640-655.
 53. Pandey GN, Rizavi HS, Ren X, Dwivedi Y, Palkovits M. Region-specific alterations in glucocorticoid receptor expression in the postmortem brain of teenage suicide victims. *Psychoneuroendocrinology* 2013; **38**(11): 2628-2639.
 54. Thalmeier A, Dickmann M, Giegling I, Schneider B, A MH, Maurer K *et al.* Gene expression profiling of post-mortem orbitofrontal cortex in violent suicide victims. *Int J Neuropsychopharmacol* 2008; **11**(2): 217-228.
 55. Kurian SM, Le-Niculescu H, Patel SD, Bertram D, Davis J, Dike C *et al.* Identification of blood biomarkers for psychosis using convergent functional genomics. *Mol Psychiatry* 2011; **16**(1): 37-58.
 56. Lewohl JM, Wang L, Miles MF, Zhang L, Dodd PR, Harris RA. Gene expression in human alcoholism: microarray analysis of frontal cortex. *Alcohol Clin Exp Res* 2000; **24**(12): 1873-1882.
 57. Hu VW, Frank BC, Heine S, Lee NH, Quackenbush J. Gene expression profiling of lymphoblastoid cell lines from monozygotic twins discordant in severity of autism reveals differential regulation of neurologically relevant genes. *BMC genomics* 2006; **7**: 118.
 58. Ditzen C, Tang N, Jastorff AM, Teplytska L, Yassouridis A, Maccarrone G *et al.* Cerebrospinal fluid biomarkers for major depression confirm relevance of associated pathophysiology. *Neuropsychopharmacology* 2012; **37**(4): 1013-1025.
 59. Middleton FA, Pato CN, Gentile KL, McGann L, Brown AM, Trauzzi M *et al.* Gene expression analysis of peripheral blood leukocytes from discordant sib-pairs with schizophrenia and bipolar disorder reveals points of convergence between genetic and functional genomic approaches. *Am J Med Genet B Neuropsychiatr Genet* 2005; **136**(1): 12-25.
 60. Sanders AR, Goring HH, Duan J, Drigalenko EI, Moy W, Freda J *et al.* Transcriptome study of differential expression in schizophrenia. *Human molecular genetics* 2013; **22**(24): 5001-5014.

61. Mehta D, Gonik M, Klengel T, Rex-Haffner M, Menke A, Rubel J *et al.* Using polymorphisms in FKBP5 to define biologically distinct subtypes of posttraumatic stress disorder: evidence from endocrine and gene expression studies. *Arch Gen Psychiatry* 2011; **68**(9): 901-910.
62. Klengel T, Mehta D, Anacker C, Rex-Haffner M, Pruessner JC, Pariante CM *et al.* Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. *Nature neuroscience* 2013; **16**(1): 33-41.
63. Binder EB, Bradley RG, Liu W, Epstein MP, Deveau TC, Mercer KB *et al.* Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. *JAMA : the journal of the American Medical Association* 2008; **299**(11): 1291-1305.
64. Xie P, Kranzler HR, Poling J, Stein MB, Anton RF, Farrer LA *et al.* Interaction of FKBP5 with childhood adversity on risk for post-traumatic stress disorder. *Neuropsychopharmacology* 2010; **35**(8): 1684-1692.
65. Szczepankiewicz A, Leszczynska-Rodziewicz A, Pawlak J, Narozna B, Rajewska-Rager A, Wilkosc M *et al.* FKBP5 polymorphism is associated with major depression but not with bipolar disorder. *J Affect Disord* 2014; **164**: 33-37.
66. Lavebratt C, Aberg E, Sjöholm LK, Forsell Y. Variations in FKBP5 and BDNF genes are suggestively associated with depression in a Swedish population-based cohort. *J Affect Disord* 2010; **125**(1-3): 249-255.
67. Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Putz B *et al.* Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. *Nat Genet* 2004; **36**(12): 1319-1325.
68. Simons CJ, van Winkel R, Group. Intermediate phenotype analysis of patients, unaffected siblings, and healthy controls identifies VMAT2 as a candidate gene for psychotic disorder and neurocognition. *Schizophr Bull* 2013; **39**(4): 848-856.
69. Sinclair D, Fillman SG, Webster MJ, Weickert CS. Dysregulation of glucocorticoid receptor co-factors FKBP5, BAG1 and PTGES3 in prefrontal cortex in psychotic illness. *Scientific reports* 2013; **3**: 3539.
70. Chen H, Wang N, Zhao X, Ross CA, O'Shea KS, McInnis MG. Gene expression alterations in bipolar disorder postmortem brains. *Bipolar Disord* 2013; **15**(2): 177-187.

71. McClintick JN, Xuei X, Tischfield JA, Goate A, Foroud T, Wetherill L *et al.* Stress-response pathways are altered in the hippocampus of chronic alcoholics. *Alcohol* 2013; **47**(7): 505-515.
72. Yehuda R, Cai G, Golier JA, Sarapas C, Galea S, Ising M *et al.* Gene expression patterns associated with posttraumatic stress disorder following exposure to the World Trade Center attacks. *Biol Psychiatry* 2009; **66**(7): 708-711.
73. Cole SW, Hawkey LC, Arevalo JM, Sung CY, Rose RM, Cacioppo JT. Social regulation of gene expression in human leukocytes. *Genome Biol* 2007; **8**(9): R189.
74. Kupfer DM, White VL, Strayer DL, Crouch DJ, Burian D. Microarray characterization of gene expression changes in blood during acute ethanol exposure. *BMC medical genomics* 2013; **6**: 26.
75. Menke A, Arloth J, Putz B, Weber P, Klengel T, Mehta D *et al.* Dexamethasone stimulated gene expression in peripheral blood is a sensitive marker for glucocorticoid receptor resistance in depressed patients. *Neuropsychopharmacology* 2012; **37**(6): 1455-1464.
76. Katz ER, Stowe ZN, Newport DJ, Kelley ME, Pace TW, Cubells JF *et al.* Regulation of mRNA expression encoding chaperone and co-chaperone proteins of the glucocorticoid receptor in peripheral blood: association with depressive symptoms during pregnancy. *Psychol Med* 2012; **42**(5): 943-956.
77. Aberg KA, McClay JL, Nerella S, Clark S, Kumar G, Chen W *et al.* Methylome-wide association study of schizophrenia: identifying blood biomarker signatures of environmental insults. *JAMA Psychiatry* 2014; **71**(3): 255-264.
78. Baum AE, Akula N, Cabanero M, Cardona I, Corona W, Klemens B *et al.* A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. *Mol Psychiatry* 2008; **13**(2): 197-207.
79. Johnson C, Drgon T, McMahon FJ, Uhl GR. Convergent genome wide association results for bipolar disorder and substance dependence. *Am J Med Genet B Neuropsychiatr Genet* 2009; **150B**(2): 182-190.
80. Nurnberger JI, Jr., Koller DL, Jung J, Edenberg HJ, Foroud T, Guella I *et al.* Identification of pathways for bipolar disorder: a meta-analysis. *JAMA Psychiatry* 2014; **71**(6): 657-664.
81. Ye Y, Zhong X, Zhang H. A genome-wide tree- and forest-based association analysis of comorbidity of alcoholism and smoking. *BMC genetics* 2005; **6 Suppl 1**: S135.

82. Gaiteri C, Guilloux JP, Lewis DA, Sibille E. Altered gene synchrony suggests a combined hormone-mediated dysregulated state in major depression. *PLoS One* 2010; **5**(4): e9970.
83. Mudge J, Miller NA, Khrebtukova I, Lindquist IE, May GD, Huntley JJ *et al.* Genomic convergence analysis of schizophrenia: mRNA sequencing reveals altered synaptic vesicular transport in post-mortem cerebellum. *PLoS One* 2008; **3**(11): e3625.
84. Brennand KJ, Simone A, Jou J, Gelboin-Burkhart C, Tran N, Sangar S *et al.* Modelling schizophrenia using human induced pluripotent stem cells. *Nature* 2011; **473**(7346): 221-225.
85. Paul-Samojedny M, Kowalczyk M, Suchanek R, Owczarek A, Fila-Danilow A, Szczygiel A *et al.* Functional polymorphism in the interleukin-6 and interleukin-10 genes in patients with paranoid schizophrenia--a case-control study. *Journal of molecular neuroscience : MN* 2010; **42**(1): 112-119.
86. Paul-Samojedny M, Owczarek A, Kowalczyk M, Suchanek R, Palacz M, Kucia K *et al.* Association of interleukin 2 (IL-2), interleukin 6 (IL-6), and TNF-alpha (TNFalpha) gene polymorphisms with paranoid schizophrenia in a Polish population. *The Journal of neuropsychiatry and clinical neurosciences* 2013; **25**(1): 72-82.
87. Frydecka D, Misiak B, Pawlak-Adamska E, Karabon L, Tomkiewicz A, Sedlaczek P *et al.* Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation. *European archives of psychiatry and clinical neuroscience* 2014.
88. Zakharyan R, Petrek M, Arakelyan A, Mrazek F, Atshemyan S, Boyajyan A. Interleukin-6 promoter polymorphism and plasma levels in patients with schizophrenia. *Tissue antigens* 2012; **80**(2): 136-142.
89. Hartwell KJ, Moran-Santa Maria MM, Twal WO, Shaftman S, DeSantis SM, McRae-Clark AL *et al.* Association of elevated cytokines with childhood adversity in a sample of healthy adults. *J Psychiatr Res* 2013; **47**(5): 604-610.
90. Tartter M, Hammen C, Bower JE, Brennan PA, Cole S. Effects of chronic interpersonal stress exposure on depressive symptoms are moderated by genetic variation at IL6 and IL1beta in youth. *Brain Behav Immun* 2015.
91. Su S, Miller AH, Snieder H, Bremner JD, Ritchie J, Maisano C *et al.* Common genetic contributions to depressive symptoms and inflammatory markers in middle-aged men: the Twins Heart Study. *Psychosom Med* 2009; **71**(2): 152-158.

92. Fillman SG, Cloonan N, Catts VS, Miller LC, Wong J, McCrossin T *et al.* Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. *Mol Psychiatry* 2013; **18**(2): 206-214.
93. Padmos RC, Hillegers MH, Knijff EM, Vonk R, Bouvy A, Staal FJ *et al.* A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. *Arch Gen Psychiatry* 2008; **65**(4): 395-407.
94. Padmos RC, Van Baal GC, Vonk R, Wijkhuijs AJ, Kahn RS, Nolen WA *et al.* Genetic and environmental influences on pro-inflammatory monocytes in bipolar disorder: a twin study. *Arch Gen Psychiatry* 2009; **66**(9): 957-965.
95. Brambilla P, Bellani M, Isola M, Bergami A, Marinelli V, Dusi N *et al.* Increased M1/decreased M2 signature and signs of Th1/Th2 shift in chronic patients with bipolar disorder, but not in those with schizophrenia. *Transl Psychiatry* 2014; **4**: e406.
96. Munkholm K, Weikop P, Kessing LV, Vinberg M. Elevated levels of IL-6 and IL-18 in manic and hypomanic states in rapid cycling bipolar disorder patients. *Brain Behav Immun* 2015; **43**: 205-213.
97. Brietzke E, Stertz L, Fernandes BS, Kauer-Sant'anna M, Mascarenhas M, Escosteguy Vargas A *et al.* Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. *J Affect Disord* 2009; **116**(3): 214-217.
98. Goldstein BI, Collinger KA, Lotrich F, Marsland AL, Gill MK, Axelson DA *et al.* Preliminary findings regarding proinflammatory markers and brain-derived neurotrophic factor among adolescents with bipolar spectrum disorders. *Journal of child and adolescent psychopharmacology* 2011; **21**(5): 479-484.
99. Carvalho LA, Bergink V, Sumaski L, Wijkhuijs J, Hoogendijk WJ, Birkenhager TK *et al.* Inflammatory activation is associated with a reduced glucocorticoid receptor alpha/beta expression ratio in monocytes of inpatients with melancholic major depressive disorder. *Transl Psychiatry* 2014; **4**: e344.
100. Lehto SM, Niskanen L, Miettola J, Tolmunen T, Viinamaki H, Mantyselka P. Serum anti-inflammatory markers in general population subjects with elevated depressive symptoms. *Neurosci Lett* 2010; **484**(3): 201-205.

101. Spanemberg L, Caldieraro MA, Vares EA, Wollenhaupt-Aguiar B, Kauer-Sant'Anna M, Kawamoto SY *et al.* Biological differences between melancholic and nonmelancholic depression subtyped by the CORE measure. *Neuropsychiatric disease and treatment* 2014; **10**: 1523-1531.
102. Song C, Lin A, Bonaccorso S, Heide C, Verkerk R, Kenis G *et al.* The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. *J Affect Disord* 1998; **49**(3): 211-219.
103. Miller GE, Cole SW. Clustering of depression and inflammation in adolescents previously exposed to childhood adversity. *Biol Psychiatry* 2012; **72**(1): 34-40.
104. Iacob E, Light KC, Tadler SC, Weeks HR, White AT, Huguen RW *et al.* Dysregulation of leukocyte gene expression in women with medication-refractory depression versus healthy non-depressed controls. *BMC Psychiatry* 2013; **13**: 273.
105. Simon NM, McNamara K, Chow CW, Maser RS, Papakostas GI, Pollack MH *et al.* A detailed examination of cytokine abnormalities in Major Depressive Disorder. *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology* 2008; **18**(3): 230-233.
106. Frodl T, Carballido A, Hughes MM, Saleh K, Fagan A, Skokauskas N *et al.* Reduced expression of glucocorticoid-inducible genes GILZ and SGK-1: high IL-6 levels are associated with reduced hippocampal volumes in major depressive disorder. *Transl Psychiatry* 2012; **2**: e88.
107. Henje Blom E, Lekander M, Ingvar M, Asberg M, Mobarrez F, Serlachius E. Pro-inflammatory cytokines are elevated in adolescent females with emotional disorders not treated with SSRIs. *J Affect Disord* 2012; **136**(3): 716-723.
108. Rohleder N, Miller GE. Acute deviations from long-term trait depressive symptoms predict systemic inflammatory activity. *Brain Behav Immun* 2008; **22**(5): 709-716.
109. Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. *JAMA Psychiatry* 2014; **71**(10): 1121-1128.
110. Keller PS, El-Sheikh M, Vaughn B, Granger DA. Relations between mucosal immunity and children's mental health: the role of child sex. *Physiol Behav* 2010; **101**(5): 705-712.

111. O'Brien SM, Scully P, Fitzgerald P, Scott LV, Dinan TG. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. *J Psychiatr Res* 2007; **41**(3-4): 326-331.
112. Mondelli V, Cattaneo A, Belvederi Murri M, Di Forti M, Handley R, Hepgul N *et al.* Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. *J Clin Psychiatry* 2011; **72**(12): 1677-1684.
113. Drexhage RC, Padmos RC, de Wit H, Versnel MA, Hooijkaas H, van der Lely AJ *et al.* Patients with schizophrenia show raised serum levels of the pro-inflammatory chemokine CCL2: association with the metabolic syndrome in patients? *Schizophr Res* 2008; **102**(1-3): 352-355.
114. Zhang XY, Zhou DF, Zhang PY, Wu GY, Cao LY, Shen YC. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. *Schizophr Res* 2002; **57**(2-3): 247-258.
115. Beumer W, Drexhage RC, De Wit H, Versnel MA, Drexhage HA, Cohen D. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. *Psychoneuroendocrinology* 2012; **37**(12): 1901-1911.
116. Dennison U, McKernan D, Cryan J, Dinan T. Schizophrenia patients with a history of childhood trauma have a pro-inflammatory phenotype. *Psychol Med* 2012; **42**(9): 1865-1871.
117. Kaminska T, Wysocka A, Marmurowska-Michalowska H, Dubas-Slomp H, Kandefer-Szerszen M. Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizophrenic patients. *Archivum immunologiae et therapiae experimentalis* 2001; **49**(6): 439-445.
118. Pedrini M, Massuda R, Fries GR, de Bittencourt Pasquali MA, Schnorr CE, Moreira JC *et al.* Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. *J Psychiatr Res* 2012; **46**(6): 819-824.
119. Stojanovic A, Martorell L, Montalvo I, Ortega L, Monseny R, Vilella E *et al.* Increased serum interleukin-6 levels in early stages of psychosis: associations with at-risk mental states and the severity of psychotic symptoms. *Psychoneuroendocrinology* 2014; **41**: 23-32.
120. Falcone T, Carlton E, Lee C, Janigro M, Fazio V, Forcen FE *et al.* Does systemic inflammation play a role in pediatric psychosis? *Clinical schizophrenia & related psychoses* 2013: 1-43.

121. Di Nicola M, Cattaneo A, Hepgul N, Di Forti M, Aitchison KJ, Janiri L *et al.* Serum and gene expression profile of cytokines in first-episode psychosis. *Brain Behav Immun* 2013; **31**: 90-95.
122. O'Connell KE, Thakore J, Dev KK. Pro-inflammatory cytokine levels are raised in female schizophrenia patients treated with clozapine. *Schizophr Res* 2014; **156**(1): 1-8.
123. Magaki S, Mueller C, Dickson C, Kirsch W. Increased production of inflammatory cytokines in mild cognitive impairment. *Experimental gerontology* 2007; **42**(3): 233-240.
124. Schmahl C, Arvastson L, Tamm JA, Bohus M, Abdourahman A, Antonijevic I. Gene expression profiles in relation to tension and dissociation in borderline personality disorder. *PLoS One* 2013; **8**(8): e70787.
125. Miller GE, Rohleder N, Cole SW. Chronic interpersonal stress predicts activation of pro- and anti-inflammatory signaling pathways 6 months later. *Psychosom Med* 2009; **71**(1): 57-62.
126. Maes M, Lin AH, Delmeire L, Van Gastel A, Kenis G, De Jongh R *et al.* Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in posttraumatic stress disorder following accidental man-made traumatic events. *Biol Psychiatry* 1999; **45**(7): 833-839.
127. Gola H, Engler H, Sommershof A, Adenauer H, Kolassa S, Schedlowski M *et al.* Posttraumatic stress disorder is associated with an enhanced spontaneous production of pro-inflammatory cytokines by peripheral blood mononuclear cells. *BMC Psychiatry* 2013; **13**: 40.
128. Baker DG, Ekhtator NN, Kasckow JW, Hill KK, Zoumakis E, Dashevsky BA *et al.* Plasma and cerebrospinal fluid interleukin-6 concentrations in posttraumatic stress disorder. *Neuroimmunomodulation* 2001; **9**(4): 209-217.
129. de la Fontaine L, Schwarz MJ, Eser D, Muller N, Rupprecht R, Zwanzger P. Effects of experimentally induced panic attacks on neuroimmunological markers. *J Neural Transm* 2009; **116**(6): 699-702.
130. Wang XM, Hamza M, Wu TX, Dionne RA. Upregulation of IL-6, IL-8 and CCL2 gene expression after acute inflammation: Correlation to clinical pain. *Pain* 2009; **142**(3): 275-283.
131. Rief W, Mills PJ, Ancoli-Israel S, Ziegler MG, Pung MA, Dimsdale JE. Overnight changes of immune parameters and catecholamines are associated with mood and stress. *Psychosom Med* 2010; **72**(8): 755-762.

132. Vaquero-Lorenzo C, Rianza Bermudo-Soriano C, Perez-Rodriguez MM, Diaz-Hernandez M, Lopez-Castroman J, Fernandez-Piqueras J *et al.* Positive association between SAT-1 -1415T/C polymorphism and anxiety. *Am J Med Genet B Neuropsychiatr Genet* 2009; **150B**(4): 515-519.
133. Belzeaux R, Formisano-Treziny C, Loundou A, Boyer L, Gabert J, Samuelian JC *et al.* Clinical variations modulate patterns of gene expression and define blood biomarkers in major depression. *J Psychiatr Res* 2010; **44**(16): 1205-1213.
134. Grunebaum MF, Ellis SP, Li S, Oquendo MA, Mann JJ. Antidepressants and suicide risk in the United States, 1985-1999. *J Clin Psychiatry* 2004; **65**(11): 1456-1462.
135. Ducci F, Enoch MA, Hodgkinson C, Xu K, Catena M, Robin RW *et al.* Interaction between a functional MAOA locus and childhood sexual abuse predicts alcoholism and antisocial personality disorder in adult women. *Mol Psychiatry* 2008; **13**(3): 334-347.
136. Piton A, Gauthier J, Hamdan FF, Lafreniere RG, Yang Y, Henrion E *et al.* Systematic resequencing of X-chromosome synaptic genes in autism spectrum disorder and schizophrenia. *Mol Psychiatry* 2011; **16**(8): 867-880.
137. Deo AJ, Huang YY, Hodgkinson CA, Xin Y, Oquendo MA, Dwork AJ *et al.* A large-scale candidate gene analysis of mood disorders: evidence of neurotrophic tyrosine kinase receptor and opioid receptor signaling dysfunction. *Psychiatr Genet* 2013; **23**(2): 47-55.
138. Iwamoto K, Bundo M, Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. *Human molecular genetics* 2005; **14**(2): 241-253.
139. Ou XM, Stockmeier CA, Meltzer HY, Overholser JC, Jurjus GJ, Dieter L *et al.* A novel role for glyceraldehyde-3-phosphate dehydrogenase and monoamine oxidase B cascade in ethanol-induced cellular damage. *Biol Psychiatry* 2010; **67**(9): 855-863.
140. Teles LM, Aquino EN, Neves AC, Garcia CH, Roepstorff P, Fontes B *et al.* Comparison of the neutrophil proteome in trauma patients and normal controls. *Protein and peptide letters* 2012; **19**(6): 663-672.
141. Moller-Levet CS, Archer SN, Bucca G, Laing EE, Slak A, Kabiljo R *et al.* Effects of insufficient sleep on circadian rhythmicity and expression amplitude of the human blood transcriptome. *Proc Natl Acad Sci U S A* 2013; **110**(12): E1132-1141.

142. International Schizophrenia C, Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC *et al.* Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature* 2009; **460**(7256): 748-752.
143. Bremer A, Giacobini M, Eriksson M, Gustavsson P, Nordin V, Fernell E *et al.* Copy number variation characteristics in subpopulations of patients with autism spectrum disorders. *Am J Med Genet B Neuropsychiatr Genet* 2011; **156**(2): 115-124.
144. Beech RD, Lowthert L, Leffert JJ, Mason PN, Taylor MM, Umlauf S *et al.* Increased peripheral blood expression of electron transport chain genes in bipolar depression. *Bipolar Disord* 2010; **12**(8): 813-824.
145. Philibert RA, Crowe R, Ryu GY, Yoon JG, Secrest D, Sandhu H *et al.* Transcriptional profiling of lymphoblast lines from subjects with panic disorder. *Am J Med Genet B Neuropsychiatr Genet* 2007; **144B**(5): 674-682.
146. Garbett KA, Vereczkei A, Kalman S, Wang L, Korade Z, Shelton RC *et al.* Fibroblasts from patients with major depressive disorder show distinct transcriptional response to metabolic stressors. *Transl Psychiatry* 2015; **5**: e523.
147. Machado-Vieira R, Pivovarova NB, Stanika RI, Yuan P, Wang Y, Zhou R *et al.* The Bcl-2 gene polymorphism rs956572AA increases inositol 1,4,5-trisphosphate receptor-mediated endoplasmic reticulum calcium release in subjects with bipolar disorder. *Biol Psychiatry* 2011; **69**(4): 344-352.
148. Yu H, Bi W, Liu C, Zhao Y, Zhang D, Yue W. A hypothesis-driven pathway analysis reveals myelin-related pathways that contribute to the risk of schizophrenia and bipolar disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 2014; **51**: 140-145.
149. Soeiro-de-Souza MG, Salvatore G, Moreno RA, Otaduy MC, Chaim KT, Gattaz WF *et al.* Bcl-2 rs956572 polymorphism is associated with increased anterior cingulate cortical glutamate in euthymic bipolar I disorder. *Neuropsychopharmacology* 2013; **38**(3): 468-475.
150. Sipila T, Kananen L, Greco D, Donner J, Silander K, Terwilliger JD *et al.* An association analysis of circadian genes in anxiety disorders. *Biol Psychiatry* 2010; **67**(12): 1163-1170.
151. Kim HW, Rapoport SI, Rao JS. Altered expression of apoptotic factors and synaptic markers in postmortem brain from bipolar disorder patients. *Neurobiology of disease* 2010; **37**(3): 596-603.

152. Su YA, Wu J, Zhang L, Zhang Q, Su DM, He P *et al.* Dysregulated mitochondrial genes and networks with drug targets in postmortem brain of patients with posttraumatic stress disorder (PTSD) revealed by human mitochondria-focused cDNA microarrays. *International journal of biological sciences* 2008; **4**(4): 223-235.
153. Lowthert L, Leffert J, Lin A, Umlauf S, Maloney K, Muralidharan A *et al.* Increased ratio of anti-apoptotic to pro-apoptotic Bcl2 gene-family members in lithium-responders one month after treatment initiation. *Biology of mood & anxiety disorders* 2012; **2**(1): 15.
154. Beech RD, Qu J, Leffert JJ, Lin A, Hong KA, Hansen J *et al.* Altered expression of cytokine signaling pathway genes in peripheral blood cells of alcohol dependent subjects: preliminary findings. *Alcohol Clin Exp Res* 2012; **36**(9): 1487-1496.
155. Gruber HE, Hoelscher GL, Ingram JA, Hanley EN, Jr. Genome-wide analysis of pain-, nerve- and neurotrophin -related gene expression in the degenerating human annulus. *Molecular pain* 2012; **8**: 63.
156. Maycox PR, Kelly F, Taylor A, Bates S, Reid J, Logendra R *et al.* Analysis of gene expression in two large schizophrenia cohorts identifies multiple changes associated with nerve terminal function. *Mol Psychiatry* 2009; **14**(12): 1083-1094.
157. Glatt SJ, Everall IP, Kremen WS, Corbeil J, Sasik R, Khanlou N *et al.* Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia. *Proc Natl Acad Sci U S A* 2005; **102**(43): 15533-15538.
158. Wang L, Lockstone HE, Guest PC, Levin Y, Palotas A, Pietsch S *et al.* Expression profiling of fibroblasts identifies cell cycle abnormalities in schizophrenia. *Journal of proteome research* 2010; **9**(1): 521-527.
159. Chang LC, Jamain S, Lin CW, Rujescu D, Tseng GC, Sibille E. A conserved BDNF, glutamate- and GABA-enriched gene module related to human depression identified by coexpression meta-analysis and DNA variant genome-wide association studies. *PLoS One* 2014; **9**(3): e90980.
160. Elia J, Gai X, Xie HM, Perin JC, Geiger E, Glessner JT *et al.* Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes. *Mol Psychiatry* 2010; **15**(6): 637-646.
161. O'Dushlaine C, Kenny E, Heron E, Donohoe G, Gill M, Morris D *et al.* Molecular pathways involved in neuronal cell adhesion and membrane scaffolding contribute to schizophrenia and bipolar disorder susceptibility. *Mol Psychiatry* 2011; **16**(3): 286-292.

162. Kang HJ, Adams DH, Simen A, Simen BB, Rajkowska G, Stockmeier CA *et al.* Gene expression profiling in postmortem prefrontal cortex of major depressive disorder. *J Neurosci* 2007; **27**(48): 13329-13340.
163. Voineagu I, Wang X, Johnston P, Lowe JK, Tian Y, Horvath S *et al.* Transcriptomic analysis of autistic brain reveals convergent molecular pathology. *Nature* 2011; **474**(7351): 380-384.
164. Albertson DN, Schmidt CJ, Kapatos G, Bannon MJ. Distinctive profiles of gene expression in the human nucleus accumbens associated with cocaine and heroin abuse. *Neuropsychopharmacology* 2006; **31**(10): 2304-2312.
165. Le-Niculescu H, Kurian SM, Yehyaw N, Dike C, Patel SD, Edenberg HJ *et al.* Identifying blood biomarkers for mood disorders using convergent functional genomics. *Mol Psychiatry* 2009; **14**(2): 156-174.
166. Konradi C, Eaton M, MacDonald ML, Walsh J, Benes FM, Heckers S. Molecular evidence for mitochondrial dysfunction in bipolar disorder. *Arch Gen Psychiatry* 2004; **61**(3): 300-308.
167. Miller GE, Chen E, Sze J, Marin T, Arevalo JM, Doll R *et al.* A functional genomic fingerprint of chronic stress in humans: blunted glucocorticoid and increased NF-kappaB signaling. *Biol Psychiatry* 2008; **64**(4): 266-272.
168. Martins-de-Souza D, Maccarrone G, Ising M, Kloiber S, Lucae S, Holsboer F *et al.* Blood mononuclear cell proteome suggests integrin and Ras signaling as critical pathways for antidepressant treatment response. *Biol Psychiatry* 2014; **76**(7): e15-17.
169. Mehta D, Klengel T, Conneely KN, Smith AK, Altmann A, Pace TW *et al.* Childhood maltreatment is associated with distinct genomic and epigenetic profiles in posttraumatic stress disorder. *Proc Natl Acad Sci U S A* 2013; **110**(20): 8302-8307.
170. Hong JJ, Loiselle CR, Yoon DY, Lee O, Becker KG, Singer HS. Microarray analysis in Tourette syndrome postmortem putamen. *Journal of the neurological sciences* 2004; **225**(1-2): 57-64.
171. Mayfield RD, Lewohl JM, Dodd PR, Herlihy A, Liu J, Harris RA. Patterns of gene expression are altered in the frontal and motor cortices of human alcoholics. *Journal of neurochemistry* 2002; **81**(4): 802-813.

172. Vawter MP, Barrett T, Cheadle C, Sokolov BP, Wood WH, 3rd, Donovan DM *et al.* Application of cDNA microarrays to examine gene expression differences in schizophrenia. *Brain research bulletin* 2001; **55**(5): 641-650.
173. Shyn SI, Shi J, Kraft JB, Potash JB, Knowles JA, Weissman MM *et al.* Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies. *Mol Psychiatry* 2011; **16**(2): 202-215.
174. Nagata E, Hattori H, Kato M, Ogasawara S, Suzuki S, Shibata M *et al.* Identification of biomarkers associated with migraine with aura. *Neuroscience research* 2009; **64**(1): 104-110.
175. Bhasin MK, Dusek JA, Chang BH, Joseph MG, Denninger JW, Fricchione GL *et al.* Relaxation response induces temporal transcriptome changes in energy metabolism, insulin secretion and inflammatory pathways. *PLoS One* 2013; **8**(5): e62817.
176. Uhl GR, Drgon T, Liu QR, Johnson C, Walther D, Komiyama T *et al.* Genome-wide association for methamphetamine dependence: convergent results from 2 samples. *Arch Gen Psychiatry* 2008; **65**(3): 345-355.
177. Thorgeirsson TE, Gudbjartsson DF, Sulem P, Besenbacher S, Styrkarsdottir U, Thorleifsson G *et al.* A common biological basis of obesity and nicotine addiction. *Transl Psychiatry* 2013; **3**: e308.
178. Jensen KP, Kranzler HR, Stein MB, Gelernter J. The effects of a MAP2K5 microRNA target site SNP on risk for anxiety and depressive disorders. *Am J Med Genet B Neuropsychiatr Genet* 2014; **165B**(2): 175-183.
179. Dow DJ, Huxley-Jones J, Hall JM, Francks C, Maycox PR, Kew JN *et al.* ADAMTSL3 as a candidate gene for schizophrenia: gene sequencing and ultra-high density association analysis by imputation. *Schizophr Res* 2011; **127**(1-3): 28-34.
180. Andreassen OA, Thompson WK, Schork AJ, Ripke S, Mattingsdal M, Kelsoe JR *et al.* Improved detection of common variants associated with schizophrenia and bipolar disorder using pleiotropy-informed conditional false discovery rate. *PLoS Genet* 2013; **9**(4): e1003455.
181. Ruderfer DM, Fanous AH, Ripke S, McQuillin A, Amdur RL, Schizophrenia Working Group of Psychiatric Genomics C *et al.* Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia. *Mol Psychiatry* 2014; **19**(9): 1017-1024.
182. Tomita H, Ziegler ME, Kim HB, Evans SJ, Choudary PV, Li JZ *et al.* G protein-linked signaling pathways in bipolar and major depressive disorders. *Frontiers in genetics* 2013; **4**: 297.

183. Taylor CA, Sun Z, Cliche DO, Ming H, Eshaque B, Jin S *et al.* Eukaryotic translation initiation factor 5A induces apoptosis in colon cancer cells and associates with the nucleus in response to tumour necrosis factor alpha signalling. *Experimental cell research* 2007; **313**(3): 437-449.
184. Li AL, Li HY, Jin BF, Ye QN, Zhou T, Yu XD *et al.* A novel eIF5A complex functions as a regulator of p53 and p53-dependent apoptosis. *J Biol Chem* 2004; **279**(47): 49251-49258.
185. Sun Z, Cheng Z, Taylor CA, McConkey BJ, Thompson JE. Apoptosis induction by eIF5A1 involves activation of the intrinsic mitochondrial pathway. *J Cell Physiol* 2010; **223**(3): 798-809.
186. Iwamoto K, Bundo M, Yamamoto M, Ozawa H, Saito T, Kato T. Decreased expression of NEFH and PCP4/PEP19 in the prefrontal cortex of alcoholics. *Neuroscience research* 2004; **49**(4): 379-385.
187. Mistry M, Gillis J, Pavlidis P. Genome-wide expression profiling of schizophrenia using a large combined cohort. *Mol Psychiatry* 2013; **18**(2): 215-225.
188. Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM *et al.* Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. *Science* 2008; **320**(5875): 539-543.
189. Liu J, Lewohl JM, Harris RA, Iyer VR, Dodd PR, Randall PK *et al.* Patterns of gene expression in the frontal cortex discriminate alcoholic from nonalcoholic individuals. *Neuropsychopharmacology* 2006; **31**(7): 1574-1582.
190. Thedieck K, Polak P, Kim ML, Molle KD, Cohen A, Jeno P *et al.* PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. *PLoS One* 2007; **2**(11): e1217.
191. Madhunapantula SV, Sharma A, Robertson GP. PRAS40 deregulates apoptosis in malignant melanoma. *Cancer research* 2007; **67**(8): 3626-3636.
192. Nakamura K, Chen CK, Sekine Y, Iwata Y, Anitha A, Loh el W *et al.* Association analysis of SOD2 variants with methamphetamine psychosis in Japanese and Taiwanese populations. *Hum Genet* 2006; **120**(2): 243-252.
193. Edgar PF, Douglas JE, Cooper GJ, Dean B, Kydd R, Faull RL. Comparative proteome analysis of the hippocampus implicates chromosome 6q in schizophrenia. *Mol Psychiatry* 2000; **5**(1): 85-90.

194. Kirov G, Grozeva D, Norton N, Ivanov D, Mantripragada KK, Holmans P *et al.* Support for the involvement of large copy number variants in the pathogenesis of schizophrenia. *Human molecular genetics* 2009; **18**(8): 1497-1503.
195. International Schizophrenia C. Rare chromosomal deletions and duplications increase risk of schizophrenia. *Nature* 2008; **455**(7210): 237-241.
196. Levinson DF, Duan J, Oh S, Wang K, Sanders AR, Shi J *et al.* Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. *Am J Psychiatry* 2011; **168**(3): 302-316.
197. Matigian N, Windus L, Smith H, Filippich C, Pantelis C, McGrath J *et al.* Expression profiling in monozygotic twins discordant for bipolar disorder reveals dysregulation of the WNT signalling pathway. *Mol Psychiatry* 2007; **12**(9): 815-825.
198. Bilecova-Rabajdova M, Urban P, Gregova K, Varga J, Fialkovicova V, Kruzliak P *et al.* Breast carcinoma progression and tumour vascular markers related to apoptotic mechanisms. *Disease markers* 2014; **2014**: 156034.
199. Hansen T, Ingason A, Djurovic S, Melle I, Fenger M, Gustafsson O *et al.* At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia. *Biol Psychiatry* 2011; **70**(1): 59-63.
200. Alkelai A, Greenbaum L, Lupoli S, Kohn Y, Sarner-Kanyas K, Ben-Asher E *et al.* Association of the type 2 diabetes mellitus susceptibility gene, TCF7L2, with schizophrenia in an Arab-Israeli family sample. *PLoS One* 2012; **7**(1): e29228.
201. Winham SJ, Cuellar-Barboza AB, Oliveros A, McElroy SL, Crow S, Colby C *et al.* Genome-wide association study of bipolar disorder accounting for effect of body mass index identifies a new risk allele in TCF7L2. *Mol Psychiatry* 2014; **19**(9): 1010-1016.
202. Iossifov I, O'Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D *et al.* The contribution of de novo coding mutations to autism spectrum disorder. *Nature* 2014; **515**(7526): 216-221.
203. Miller BH, Zeier Z, Xi L, Lanz TA, Deng S, Strathmann J *et al.* MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function. *Proc Natl Acad Sci U S A* 2012; **109**(8): 3125-3130.
204. Dempster EL, Pidsley R, Schalkwyk LC, Owens S, Georgiades A, Kane F *et al.* Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. *Human molecular genetics* 2011; **20**(24): 4786-4796.

205. Ruvolo PP, Deng X, May WS. Phosphorylation of Bcl2 and regulation of apoptosis. *Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, UK* 2001; **15**(4): 515-522.
206. Jain M, Kumar S, Upadhyay R, Lal P, Tiwari A, Ghoshal UC *et al.* Influence of apoptosis (BCL2, FAS), cell cycle (CCND1) and growth factor (EGF, EGFR) genetic polymorphisms on survival outcome: an exploratory study in squamous cell esophageal cancer. *Cancer biology & therapy* 2007; **6**(10): 1553-1558.
207. Portier BP, Taglialatela G. Bcl-2 localized at the nuclear compartment induces apoptosis after transient overexpression. *J Biol Chem* 2006; **281**(52): 40493-40502.
208. Azad N, Vallyathan V, Wang L, Tantishaiyakul V, Stehlik C, Leonard SS *et al.* S-nitrosylation of Bcl-2 inhibits its ubiquitin-proteasomal degradation. A novel antiapoptotic mechanism that suppresses apoptosis. *J Biol Chem* 2006; **281**(45): 34124-34134.
209. Gobe G, Rubin M, Williams G, Sawczuk I, Buttyan R. Apoptosis and expression of Bcl-2, Bcl-XL, and Bax in renal cell carcinomas. *Cancer investigation* 2002; **20**(3): 324-332.
210. Yin XM, Oltvai ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. *Nature* 1994; **369**(6478): 321-323.
211. Smalla KH, Mikhaylova M, Sahin J, Bernstein HG, Bogerts B, Schmitt A *et al.* A comparison of the synaptic proteome in human chronic schizophrenia and rat ketamine psychosis suggest that prohibitin is involved in the synaptic pathology of schizophrenia. *Mol Psychiatry* 2008; **13**(9): 878-896.
212. Glatt SJ, Stone WS, Nossova N, Liew CC, Seidman LJ, Tsuang MT. Similarities and differences in peripheral blood gene-expression signatures of individuals with schizophrenia and their first-degree biological relatives. *Am J Med Genet B Neuropsychiatr Genet* 2011; **156B**(8): 869-887.
213. Gottschalk MG, Wesseling H, Guest PC, Bahn S. Proteomic enrichment analysis of psychotic and affective disorders reveals common signatures in presynaptic glutamatergic signaling and energy metabolism. *Int J Neuropsychopharmacol* 2014; **18**(2).
214. Bychkov ER, Ahmed MR, Gurevich VV, Benovic JL, Gurevich EV. Reduced expression of G protein-coupled receptor kinases in schizophrenia but not in schizoaffective disorder. *Neurobiology of disease* 2011; **44**(2): 248-258.

215. Focking M, Lopez LM, English JA, Dicker P, Wolff A, Brindley E *et al.* Proteomic and genomic evidence implicates the postsynaptic density in schizophrenia. *Mol Psychiatry* 2015; **20**(4): 424-432.
216. Matuzany-Ruban A, Golan M, Miroshnik N, Schreiber G, Avissar S. Normalization of GRK2 protein and mRNA measures in patients with depression predict response to antidepressants. *Int J Neuropsychopharmacol* 2010; **13**(1): 83-91.
217. Maestrini E, Pagnamenta AT, Lamb JA, Bacchelli E, Sykes NH, Sousa I *et al.* High-density SNP association study and copy number variation analysis of the AUTS1 and AUTS5 loci implicate the IMMP2L-DOCK4 gene region in autism susceptibility. *Mol Psychiatry* 2010; **15**(9): 954-968.
218. Noor A, Lionel AC, Cohen-Woods S, Moghimi N, Rucker J, Fennell A *et al.* Copy number variant study of bipolar disorder in Canadian and UK populations implicates synaptic genes. *Am J Med Genet B Neuropsychiatr Genet* 2014; **165B**(4): 303-313.
219. Vawter MP, Tomita H, Meng F, Bolstad B, Li J, Evans S *et al.* Mitochondrial-related gene expression changes are sensitive to agonal-pH state: implications for brain disorders. *Mol Psychiatry* 2006; **11**(7): 615, 663-679.
220. Yuan P, Zhou R, Wang Y, Li X, Li J, Chen G *et al.* Altered levels of extracellular signal-regulated kinase signaling proteins in postmortem frontal cortex of individuals with mood disorders and schizophrenia. *J Affect Disord* 2010; **124**(1-2): 164-169.
221. Nabi MO, Mirabzadeh A, Feizzadeh G, Khorshid HR, Karimlou M, Yeganeh MZ *et al.* Novel mutations in the calreticulin gene core promoter and coding sequence in schizoaffective disorder. *Am J Med Genet B Neuropsychiatr Genet* 2010; **153B**(2): 706-709.
222. Martins-de-Souza D, Guest PC, Harris LW, Vanattou-Saifoudine N, Webster MJ, Rahmoune H *et al.* Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients. *Transl Psychiatry* 2012; **2**: e87.
223. Novak G, Seeman P, Tallerico T. Increased expression of calcium/calmodulin-dependent protein kinase IIbeta in frontal cortex in schizophrenia and depression. *Synapse* 2006; **59**(1): 61-68.
224. Chan MK, Tsang TM, Harris LW, Guest PC, Holmes E, Bahn S. Evidence for disease and antipsychotic medication effects in post-mortem brain from schizophrenia patients. *Mol Psychiatry* 2011; **16**(12): 1189-1202.

225. Lehrmann E, Colantuoni C, Deep-Soboslay A, Becker KG, Lowe R, Huestis MA *et al.* Transcriptional changes common to human cocaine, cannabis and phencyclidine abuse. *PLoS One* 2006; **1**: e114.
226. Zarif Yeganeh M, Mirabzadeh A, Khorram Khorshid HR, Kamali K, Heshmati Y, Gozalpour E *et al.* Novel extreme homozygote haplotypes at the human caveolin 1 gene upstream purine complex in sporadic Alzheimer's disease. *Am J Med Genet B Neuropsychiatr Genet* 2010; **153B**(1): 347-349.
227. Nakatani N, Hattori E, Ohnishi T, Dean B, Iwayama Y, Matsumoto I *et al.* Genome-wide expression analysis detects eight genes with robust alterations specific to bipolar I disorder: relevance to neuronal network perturbation. *Human molecular genetics* 2006; **15**(12): 1949-1962.
228. Wang C, Tao B, Li S, Li B, Wang X, Hu G *et al.* Characterizing the role of PCDH9 in the regulation of glioma cell apoptosis and invasion. *Journal of molecular neuroscience : MN* 2014; **52**(2): 250-260.
229. Kuzman MR, Medved V, Terzic J, Krainc D. Genome-wide expression analysis of peripheral blood identifies candidate biomarkers for schizophrenia. *J Psychiatr Res* 2009; **43**(13): 1073-1077.
230. Maes OC, Xu S, Yu B, Chertkow HM, Wang E, Schipper HM. Transcriptional profiling of Alzheimer blood mononuclear cells by microarray. *Neurobiology of aging* 2007; **28**(12): 1795-1809.
231. Peirce TR, Bray NJ, Williams NM, Norton N, Moskvina V, Preece A *et al.* Convergent evidence for 2',3'-cyclic nucleotide 3'-phosphodiesterase as a possible susceptibility gene for schizophrenia. *Arch Gen Psychiatry* 2006; **63**(1): 18-24.
232. Flynn SW, Lang DJ, Mackay AL, Goghari V, Vavasour IM, Whittall KP *et al.* Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins. *Mol Psychiatry* 2003; **8**(9): 811-820.
233. McCullumsmith RE, Gupta D, Beneyto M, Kreger E, Haroutunian V, Davis KL *et al.* Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia. *Schizophr Res* 2007; **90**(1-3): 15-27.
234. Etheridge N, Lewohl JM, Mayfield RD, Harris RA, Dodd PR. Synaptic proteome changes in the superior frontal gyrus and occipital cortex of the alcoholic brain. *Proteomics Clinical applications* 2009; **3**(6): 730-742.

235. Aston C, Jiang L, Sokolov BP. Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. *Mol Psychiatry* 2005; **10**(3): 309-322.
236. Sibille E, Wang Y, Joeyen-Waldorf J, Gaiteri C, Surget A, Oh S *et al.* A molecular signature of depression in the amygdala. *Am J Psychiatry* 2009; **166**(9): 1011-1024.
237. Fernandez SV, Huang Y, Snider KE, Zhou Y, Pogash TJ, Russo J. Expression and DNA methylation changes in human breast epithelial cells after bisphenol A exposure. *International journal of oncology* 2012; **41**(1): 369-377.
238. Maron E, Hettema JM, Shlik J. Advances in molecular genetics of panic disorder. *Mol Psychiatry* 2010; **15**(7): 681-701.
239. Domschke K, Kuhlenbaumer G, Schirmacher A, Lorenzi C, Armengol L, DiBella D *et al.* Human nuclear transcription factor gene CREM: genomic organization, mutation screening, and association analysis in panic disorder. *Am J Med Genet B Neuropsychiatr Genet* 2003; **117B**(1): 70-78.
240. Hill EJ, Nagel DA, O'Neil JD, Torr E, Woehrling EK, Devitt A *et al.* Effects of lithium and valproic acid on gene expression and phenotypic markers in an NT2 neurosphere model of neural development. *PLoS One* 2013; **8**(3): e58822.
241. Meda SA, Ruano G, Windemuth A, O'Neil K, Berwise C, Dunn SM *et al.* Multivariate analysis reveals genetic associations of the resting default mode network in psychotic bipolar disorder and schizophrenia. *Proc Natl Acad Sci U S A* 2014; **111**(19): E2066-2075.
242. Bowden NA, Scott RJ, Tooney PA. Altered gene expression in the superior temporal gyrus in schizophrenia. *BMC genomics* 2008; **9**: 199.
243. Guilloux JP, Douillard-Guilloux G, Kota R, Wang X, Gardier AM, Martinowich K *et al.* Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression. *Mol Psychiatry* 2012; **17**(11): 1130-1142.
244. Sainz J, Mata I, Barrera J, Perez-Iglesias R, Varela I, Arranz MJ *et al.* Inflammatory and immune response genes have significantly altered expression in schizophrenia. *Mol Psychiatry* 2013; **18**(10): 1056-1057.

245. Glatt SJ, Tylee DS, Chandler SD, Pazol J, Nievergelt CM, Woelk CH *et al.* Blood-based gene-expression predictors of PTSD risk and resilience among deployed marines: a pilot study. *Am J Med Genet B Neuropsychiatr Genet* 2013; **162B**(4): 313-326.
246. Tylee DS, Chandler SD, Nievergelt CM, Liu X, Pazol J, Woelk CH *et al.* Blood-based gene-expression biomarkers of post-traumatic stress disorder among deployed marines: A pilot study. *Psychoneuroendocrinology* 2015; **51**: 472-494.
247. Wang N, Zhang CQ, He JH, Duan XF, Wang YY, Ji X *et al.* MiR-21 down-regulation suppresses cell growth, invasion and induces cell apoptosis by targeting FASL, TIMP3, and RECK genes in esophageal carcinoma. *Digestive diseases and sciences* 2013; **58**(7): 1863-1870.
248. Lit L, Sharp FR, Bertoglio K, Stamova B, Ander BP, Sossong AD *et al.* Gene expression in blood is associated with risperidone response in children with autism spectrum disorders. *Pharmacogenomics J* 2012; **12**(5): 368-371.
249. Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 schizophrenia-associated genetic loci. *Nature* 2014; **511**(7510): 421-427.
250. Chen Z, Shen BL, Fu QG, Wang F, Tang YX, Hou CL *et al.* CUL4B promotes proliferation and inhibits apoptosis of human osteosarcoma cells. *Oncology reports* 2014; **32**(5): 2047-2053.
251. Bruneau EG, McCullumsmith RE, Haroutunian V, Davis KL, Meador-Woodruff JH. Increased expression of glutaminase and glutamine synthetase mRNA in the thalamus in schizophrenia. *Schizophr Res* 2005; **75**(1): 27-34.
252. Shao L, Vawter MP. Shared gene expression alterations in schizophrenia and bipolar disorder. *Biol Psychiatry* 2008; **64**(2): 89-97.
253. Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP *et al.* Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. *Proc Natl Acad Sci U S A* 2005; **102**(43): 15653-15658.
254. Bernard R, Kerman IA, Thompson RC, Jones EG, Bunney WE, Barchas JD *et al.* Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. *Mol Psychiatry* 2011; **16**(6): 634-646.
255. Novikova SI, He F, Cutrufello NJ, Lidow MS. Identification of protein biomarkers for schizophrenia and bipolar disorder in the postmortem prefrontal cortex using SELDI-TOF-MS

- ProteinChip profiling combined with MALDI-TOF-PSD-MS analysis. *Neurobiology of disease* 2006; **23**(1): 61-76.
256. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL *et al.* Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. *Mol Psychiatry* 2004; **9**(7): 684-697, 643.
 257. Beech RD, Leffert JJ, Lin A, Sylvia LG, Umlauf S, Mane S *et al.* Gene-expression differences in peripheral blood between lithium responders and non-responders in the Lithium Treatment-Moderate dose Use Study (LiTMUS). *Pharmacogenomics J* 2014; **14**(2): 182-191.
 258. Mamdani F, Berlim MT, Beaulieu MM, Labbe A, Merette C, Turecki G. Gene expression biomarkers of response to citalopram treatment in major depressive disorder. *Transl Psychiatry* 2011; **1**: e13.
 259. Papiol S, Rosa A, Gutierrez B, Martin B, Salgado P, Catalan R *et al.* Interleukin-1 cluster is associated with genetic risk for schizophrenia and bipolar disorder. *Journal of medical genetics* 2004; **41**(3): 219-223.
 260. Papiol S, Molina V, Desco M, Rosa A, Reig S, Sanz J *et al.* Gray matter deficits in bipolar disorder are associated with genetic variability at interleukin-1 beta gene (2q13). *Genes Brain Behav* 2008; **7**(7): 796-801.
 261. Hanninen K, Katila H, Saarela M, Rontu R, Mattila KM, Fan M *et al.* Interleukin-1 beta gene polymorphism and its interactions with neuregulin-1 gene polymorphism are associated with schizophrenia. *European archives of psychiatry and clinical neuroscience* 2008; **258**(1): 10-15.
 262. Saiz PA, Garcia-Portilla MP, Florez G, Corcoran P, Arango C, Morales B *et al.* Polymorphisms of the IL-1 gene complex are associated with alcohol dependence in Spanish Caucasians: data from an association study. *Alcohol Clin Exp Res* 2009; **33**(12): 2147-2153.
 263. Luciano M, Houlihan LM, Harris SE, Gow AJ, Hayward C, Starr JM *et al.* Association of existing and new candidate genes for anxiety, depression and personality traits in older people. *Behavior genetics* 2010; **40**(4): 518-532.
 264. Katsuura S, Kamezaki Y, Yamagishi N, Kuwano Y, Nishida K, Masuda K *et al.* Circulating vascular endothelial growth factor is independently and negatively associated with trait anxiety and depressive mood in healthy Japanese university students. *International journal of psychophysiology : official journal of the International Organization of Psychophysiology* 2011; **81**(1): 38-43.

265. Colangelo V, Schurr J, Ball MJ, Pelaez RP, Bazan NG, Lukiw WJ. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. *Journal of neuroscience research* 2002; **70**(3): 462-473.
266. Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. *Mol Psychiatry* 2010; **15**(4): 384-392.
267. Qi XR, Kamphuis W, Wang S, Wang Q, Lucassen PJ, Zhou JN *et al.* Aberrant stress hormone receptor balance in the human prefrontal cortex and hypothalamic paraventricular nucleus of depressed patients. *Psychoneuroendocrinology* 2013; **38**(6): 863-870.
268. Noto CS, Gadelha A, Belangero SI, Smith MA, de Aguiar BW, Panizzuti B *et al.* Association of biomarkers and depressive symptoms in schizophrenia. *Neurosci Lett* 2011; **505**(3): 282-285.
269. Liu L, Jia F, Yuan G, Chen Z, Yao J, Li H *et al.* Tyrosine hydroxylase, interleukin-1beta and tumor necrosis factor-alpha are overexpressed in peripheral blood mononuclear cells from schizophrenia patients as determined by semi-quantitative analysis. *Psychiatry Res* 2010; **176**(1): 1-7.
270. Chavushyan A, Hovsepyan M, Boyajyan A. Cryoglobulins as potential triggers of inflammation in schizophrenia. *Schizophrenia research and treatment* 2013; **2013**: 125264.
271. Soderlund J, Schroder J, Nordin C, Samuelsson M, Walther-Jallow L, Karlsson H *et al.* Activation of brain interleukin-1beta in schizophrenia. *Mol Psychiatry* 2009; **14**(12): 1069-1071.
272. Belzeaux R, Bergon A, Jeanjean V, Lloriod B, Formisano-Treziny C, Verrier L *et al.* Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. *Transl Psychiatry* 2012; **2**: e185.
273. Rethorst CD, Toups MS, Greer TL, Nakonezny PA, Carmody TJ, Grannemann BD *et al.* Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder. *Mol Psychiatry* 2013; **18**(10): 1119-1124.
274. Tucker P, Ruwe WD, Masters B, Parker DE, Hossain A, Trautman RP *et al.* Neuroimmune and cortisol changes in selective serotonin reuptake inhibitor and placebo treatment of chronic posttraumatic stress disorder. *Biol Psychiatry* 2004; **56**(2): 121-128.

275. Schwarz E, Guest PC, Rahmoune H, Wang L, Levin Y, Ingudomnukul E *et al.* Sex-specific serum biomarker patterns in adults with Asperger's syndrome. *Mol Psychiatry* 2011; **16**(12): 1213-1220.
276. Todorova VK, Elbein AD, Kyosseva SV. Increased expression of c-Jun transcription factor in cerebellar vermis of patients with schizophrenia. *Neuropsychopharmacology* 2003; **28**(8): 1506-1514.
277. Aston C, Jiang L, Sokolov BP. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. *Journal of neuroscience research* 2004; **77**(6): 858-866.
278. Cattane N, Minelli A, Milanesi E, Maj C, Bignotti S, Bortolomasi M *et al.* Altered gene expression in schizophrenia: findings from transcriptional signatures in fibroblasts and blood. *PLoS One* 2015; **10**(2): e0116686.
279. Malki K, Pain O, Tosto MG, Du Rietz E, Carboni L, Schalkwyk LC. Identification of genes and gene pathways associated with major depressive disorder by integrative brain analysis of rat and human prefrontal cortex transcriptomes. *Transl Psychiatry* 2015; **5**: e519.
280. Jin EH, Zhang E, Ko Y, Sim WS, Moon DE, Yoon KJ *et al.* Genome-wide expression profiling of complex regional pain syndrome. *PLoS One* 2013; **8**(11): e79435.
281. Kirov G, Zaharieva I, Georgieva L, Moskvina V, Nikolov I, Cichon S *et al.* A genome-wide association study in 574 schizophrenia trios using DNA pooling. *Mol Psychiatry* 2009; **14**(8): 796-803.
282. Jurata LW, Bukhman YV, Charles V, Capriglione F, Bullard J, Lemire AL *et al.* Comparison of microarray-based mRNA profiling technologies for identification of psychiatric disease and drug signatures. *Journal of neuroscience methods* 2004; **138**(1-2): 173-188.
283. Bowden NA, Weidenhofer J, Scott RJ, Schall U, Todd J, Michie PT *et al.* Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia. *Schizophr Res* 2006; **82**(2-3): 175-183.
284. Pandey GN, Dwivedi Y, Ren X, Rizavi HS, Roberts RC, Conley RR *et al.* Altered expression and phosphorylation of myristoylated alanine-rich C kinase substrate (MARCKS) in postmortem brain of suicide victims with or without depression. *J Psychiatr Res* 2003; **37**(5): 421-432.

285. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD *et al.* Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. *Proc Natl Acad Sci U S A* 2001; **98**(8): 4746-4751.
286. Pinner AL, Haroutunian V, Meador-Woodruff JH. Alterations of the myristoylated, alanine-rich C kinase substrate (MARCKS) in prefrontal cortex in schizophrenia. *Schizophr Res* 2014; **154**(1-3): 36-41.
287. Redei EE, Andrus BM, Kwasny MJ, Seok J, Cai X, Ho J *et al.* Blood transcriptomic biomarkers in adult primary care patients with major depressive disorder undergoing cognitive behavioral therapy. *Transl Psychiatry* 2014; **4**: e442.
288. Baruch K, Silberberg G, Aviv A, Shamir E, Bening-Abu-Shach U, Baruch Y *et al.* Association between golli-MBP and schizophrenia in the Jewish Ashkenazi population: are regulatory regions involved? *Int J Neuropsychopharmacol* 2009; **12**(7): 885-894.
289. Chambers JS, Perrone-Bizzozero NI. Altered myelination of the hippocampal formation in subjects with schizophrenia and bipolar disorder. *Neurochemical research* 2004; **29**(12): 2293-2302.
290. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB *et al.* Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. *Lancet* 2003; **362**(9386): 798-805.
291. Matthews PR, Eastwood SL, Harrison PJ. Reduced myelin basic protein and actin-related gene expression in visual cortex in schizophrenia. *PLoS One* 2012; **7**(6): e38211.
292. Wang DS, Bennett DA, Mufson EJ, Mattila P, Cochran E, Dickson DW. Contribution of changes in ubiquitin and myelin basic protein to age-related cognitive decline. *Neuroscience research* 2004; **48**(1): 93-100.
293. Stelzhammer V, Alsaif M, Chan MK, Rahmoune H, Steeb H, Guest PC *et al.* Distinct proteomic profiles in post-mortem pituitary glands from bipolar disorder and major depressive disorder patients. *J Psychiatr Res* 2015; **60**: 40-48.
294. Li T, Li D, Sha J, Sun P, Huang Y. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. *Biochemical and biophysical research communications* 2009; **383**(3): 280-285.

295. Choi KH, Elashoff M, Higgs BW, Song J, Kim S, Sabuncuyan S *et al.* Putative psychosis genes in the prefrontal cortex: combined analysis of gene expression microarrays. *BMC Psychiatry* 2008; **8**: 87.
296. Wockner LF, Noble EP, Lawford BR, Young RM, Morris CP, Whitehall VL *et al.* Genome-wide DNA methylation analysis of human brain tissue from schizophrenia patients. *Transl Psychiatry* 2014; **4**: e339.
297. Niculescu AB, Levey D, Le-Niculescu H, Niculescu E, Kurian SM, Salomon D. Psychiatric blood biomarkers: avoiding jumping to premature negative or positive conclusions. *Mol Psychiatry* 2015; **20**(3): 286-288.
298. Arion D, Unger T, Lewis DA, Levitt P, Mirnics K. Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. *Biol Psychiatry* 2007; **62**(7): 711-721.
299. Chu TT, Liu Y, Kemether E. Thalamic transcriptome screening in three psychiatric states. *Journal of human genetics* 2009; **54**(11): 665-675.
300. Nantel F, Monaco L, Foulkes NS, Masquillier D, LeMeur M, Henriksen K *et al.* Spermiogenesis deficiency and germ-cell apoptosis in CREM-mutant mice. *Nature* 1996; **380**(6570): 159-162.
301. Sassone-Corsi P. Regulating the balance between differentiation and apoptosis: role of CREM in the male germ cells. *J Mol Med (Berl)* 1998; **76**(12): 811-817.
302. Sassone-Corsi P. CREM: a master-switch governing male germ cells differentiation and apoptosis. *Seminars in cell & developmental biology* 1998; **9**(4): 475-482.
303. Pan H, Ren SC, He XL, Wei YX, Wang RH, Yang Y *et al.* [The effects of human 21.5 kDa MBP gene on HepG-2 proliferation and apoptosis]. *Sichuan da xue xue bao Yi xue ban = Journal of Sichuan University Medical science edition* 2009; **40**(5): 775-779.
304. Castelli J, Wood KA, Youle RJ. The 2-5A system in viral infection and apoptosis. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie* 1998; **52**(9): 386-390.
305. Malathi K, Paranjape JM, Ganapathi R, Silverman RH. HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2',5'-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand. *Cancer research* 2004; **64**(24): 9144-9151.

306. Asselin-Labat ML, David M, Biola-Vidamment A, Lecoecueche D, Zennaro MC, Bertoglio J *et al.* GILZ, a new target for the transcription factor FoxO3, protects T lymphocytes from interleukin-2 withdrawal-induced apoptosis. *Blood* 2004; **104**(1): 215-223.
307. Costas J, Gratacos M, Escaramis G, Martin-Santos R, de Diego Y, Baca-Garcia E *et al.* Association study of 44 candidate genes with depressive and anxiety symptoms in post-partum women. *J Psychiatr Res* 2010; **44**(11): 717-724.
308. Lintas C, Sacco R, Garbett K, Mirnics K, Militeri R, Bravaccio C *et al.* Involvement of the PRKCB1 gene in autistic disorder: significant genetic association and reduced neocortical gene expression. *Mol Psychiatry* 2009; **14**(7): 705-718.
309. Philippi A, Roschmann E, Tores F, Lindenbaum P, Benajou A, Germain-Leclerc L *et al.* Haplotypes in the gene encoding protein kinase c-beta (PRKCB1) on chromosome 16 are associated with autism. *Mol Psychiatry* 2005; **10**(10): 950-960.
310. Pandey GN, Ren X, Dwivedi Y, Pavuluri MN. Decreased protein kinase C (PKC) in platelets of pediatric bipolar patients: effect of treatment with mood stabilizing drugs. *J Psychiatr Res* 2008; **42**(2): 106-116.
311. Koenigsberg HW, Yuan P, Diaz GA, Guerreri S, Dorantes C, Mayson S *et al.* Platelet protein kinase C and brain-derived neurotrophic factor levels in borderline personality disorder patients. *Psychiatry Res* 2012; **199**(2): 92-97.
312. Silver H, Susser E, Danovich L, Bilker W, Youdim M, Goldin V *et al.* SSRI augmentation of antipsychotic alters expression of GABA(A) receptor and related genes in PMC of schizophrenia patients. *Int J Neuropsychopharmacol* 2011; **14**(5): 573-584.
313. Galindo CL, Gutierrez C, Jr., Chopra AK. Potential involvement of galectin-3 and SNAP23 in *Aeromonas hydrophila* cytotoxic enterotoxin-induced host cell apoptosis. *Microbial pathogenesis* 2006; **40**(2): 56-68.
314. Wong ML, Dong C, Maestre-Mesa J, Licinio J. Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. *Mol Psychiatry* 2008; **13**(8): 800-812.
315. Wong ML, Dong C, Andreev V, Arcos-Burgos M, Licinio J. Prediction of susceptibility to major depression by a model of interactions of multiple functional genetic variants and environmental factors. *Mol Psychiatry* 2012; **17**(6): 624-633.

316. Arion D, Corradi JP, Tang S, Datta D, Boothe F, He A *et al.* Distinctive transcriptome alterations of prefrontal pyramidal neurons in schizophrenia and schizoaffective disorder. *Mol Psychiatry* 2015.
317. Zhang S, Liu J, MacGibbon G, Dragunow M, Cooper GJ. Increased expression and activation of c-Jun contributes to human amylin-induced apoptosis in pancreatic islet beta-cells. *Journal of molecular biology* 2002; **324**(2): 271-285.
318. Duan L, Sterba K, Kolomeichuk S, Kim H, Brown PH, Chambers TC. Inducible overexpression of c-Jun in MCF7 cells causes resistance to vinblastine via inhibition of drug-induced apoptosis and senescence at a step subsequent to mitotic arrest. *Biochemical pharmacology* 2007; **73**(4): 481-490.
319. Dass CR, Friedhuber AM, Khachigian LM, Dunstan DE, Choong PF. Downregulation of c-jun results in apoptosis-mediated anti-osteosarcoma activity in an orthotopic model. *Cancer biology & therapy* 2008; **7**(7): 1033-1036.
320. Wong CC, Meaburn EL, Ronald A, Price TS, Jeffries AR, Schalkwyk LC *et al.* Methyloomic analysis of monozygotic twins discordant for autism spectrum disorder and related behavioural traits. *Mol Psychiatry* 2014; **19**(4): 495-503.
321. Kanazawa T, Glatt SJ, Faraone SV, Hwu HG, Yoneda H, Tsuang MT. Family-based association study of SELENBP1 in schizophrenia. *Schizophr Res* 2009; **113**(2-3): 268-272.
322. Kanazawa T, Chana G, Glatt SJ, Mizuno H, Masliah E, Yoneda H *et al.* The utility of SELENBP1 gene expression as a biomarker for major psychotic disorders: replication in schizophrenia and extension to bipolar disorder with psychosis. *Am J Med Genet B Neuropsychiatr Genet* 2008; **147B**(6): 686-689.
323. Murata-Ohsawa M, Tohda S, Kogoshi H, Nara N. The Notch ligand, Delta-1, reduces TNF-alpha-induced growth suppression and apoptosis by decreasing activation of caspases in U937 cells. *International journal of molecular medicine* 2004; **14**(5): 861-866.
324. Fan Q, Chen M, Zuo L, Shang X, Huang MZ, Ciccarelli M *et al.* Myocardial Ablation of G Protein-Coupled Receptor Kinase 2 (GRK2) Decreases Ischemia/Reperfusion Injury through an Anti-Intrinsic Apoptotic Pathway. *PLoS One* 2013; **8**(6): e66234.
325. Gardiner EJ, Cairns MJ, Liu B, Beveridge NJ, Carr V, Kelly B *et al.* Gene expression analysis reveals schizophrenia-associated dysregulation of immune pathways in peripheral blood mononuclear cells. *J Psychiatr Res* 2013; **47**(4): 425-437.

326. Yi Z, Li Z, Yu S, Yuan C, Hong W, Wang Z *et al.* Blood-based gene expression profiles models for classification of subsyndromal symptomatic depression and major depressive disorder. *PLoS One* 2012; **7**(2): e31283.
327. Schmidt F, Kunze M, Looock AC, Dobbelstein M. Screening analysis of ubiquitin ligases reveals G2E3 as a potential target for chemosensitizing cancer cells. *Oncotarget* 2015; **6**(2): 617-632.
328. Brooks WS, Helton ES, Banerjee S, Venable M, Johnson L, Schoeb TR *et al.* G2E3 is a dual function ubiquitin ligase required for early embryonic development. *J Biol Chem* 2008; **283**(32): 22304-22315.
329. Ryan MM, Lockstone HE, Huffaker SJ, Wayland MT, Webster MJ, Bahn S. Gene expression analysis of bipolar disorder reveals downregulation of the ubiquitin cycle and alterations in synaptic genes. *Mol Psychiatry* 2006; **11**(10): 965-978.
330. Williams KH, Vieira De Ribeiro AJ, Prakoso E, Veillard A, Shackel NA, Brooks B *et al.* Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study. *Journal of diabetes* 2014.
331. Qian Q, Zhou H, Chen Y, Shen C, He S, Zhao H *et al.* VMP1 related autophagy and apoptosis in colorectal cancer cells: VMP1 regulates cell death. *Biochemical and biophysical research communications* 2014; **443**(3): 1041-1047.
332. Shi Z, Hou W, Hua X, Zhang X, Liu X, Wang X. Overexpression of calreticulin in pre-eclamptic placentas: effect on apoptosis, cell invasion and severity of pre-eclampsia. *Cell biochemistry and biophysics* 2012; **63**(2): 183-189.
333. Stein S, Thomas EK, Herzog B, Westfall MD, Rocheleau JV, Jackson RS, 2nd *et al.* NDRG1 is necessary for p53-dependent apoptosis. *J Biol Chem* 2004; **279**(47): 48930-48940.
334. Liang Y, Liu M, Wang P, Ding X, Cao Y. Analysis of 20 genes at chromosome band 12q13: RACGAP1 and MCRS1 overexpression in nonsmall-cell lung cancer. *Genes, chromosomes & cancer* 2013; **52**(3): 305-315.
335. Flatscher-Bader T, van der Brug M, Hwang JW, Gochee PA, Matsumoto I, Niwa S *et al.* Alcohol-responsive genes in the frontal cortex and nucleus accumbens of human alcoholics. *Journal of neurochemistry* 2005; **93**(2): 359-370.

336. Stewart SE, Yu D, Scharf JM, Neale BM, Fagerness JA, Mathews CA *et al.* Genome-wide association study of obsessive-compulsive disorder. *Mol Psychiatry* 2013; **18**(7): 788-798.
337. Damgaard T, Knudsen LM, Dahl IM, Gimsing P, Lodahl M, Rasmussen T. Regulation of the CD56 promoter and its association with proliferation, anti-apoptosis and clinical factors in multiple myeloma. *Leukemia & lymphoma* 2009; **50**(2): 236-246.
338. Ersland KM, Christoforou A, Stansberg C, Espeseth T, Mattheisen M, Mattingsdal M *et al.* Gene-based analysis of regionally enriched cortical genes in GWAS data sets of cognitive traits and psychiatric disorders. *PLoS One* 2012; **7**(2): e31687.
339. Oved K, Morag A, Pasmanik-Chor M, Rehavi M, Shomron N, Gurwitz D. Genome-wide expression profiling of human lymphoblastoid cell lines implicates integrin beta-3 in the mode of action of antidepressants. *Transl Psychiatry* 2013; **3**: e313.
340. Sun C, Zhang YY, Tang CL, Wang SC, Piao HL, Tao Y *et al.* Chemokine CCL28 induces apoptosis of decidual stromal cells via binding CCR3/CCR10 in human spontaneous abortion. *Molecular human reproduction* 2013; **19**(10): 676-686.
341. Gao B, Sun W, Wang X, Jia X, Ma B, Chang Y *et al.* Whole genome expression profiling and screening for differentially expressed cytokine genes in human bone marrow endothelial cells treated with humoral inhibitors in liver cirrhosis. *International journal of molecular medicine* 2013; **32**(5): 1204-1214.
342. Iwamoto K, Kakiuchi C, Bundo M, Ikeda K, Kato T. Molecular characterization of bipolar disorder by comparing gene expression profiles of postmortem brains of major mental disorders. *Mol Psychiatry* 2004; **9**(4): 406-416.
343. Chen TY, Hwang TL, Lin CY, Lin TN, Lai HY, Tsai WP *et al.* EMR2 receptor ligation modulates cytokine secretion profiles and cell survival of lipopolysaccharide-treated neutrophils. *Chang Gung medical journal* 2011; **34**(5): 468-477.
344. Treutlein J, Cichon S, Ridinger M, Wodarz N, Soyka M, Zill P *et al.* Genome-wide association study of alcohol dependence. *Arch Gen Psychiatry* 2009; **66**(7): 773-784.
345. Sebastiani P, Solovieff N, Dewan AT, Walsh KM, Puca A, Hartley SW *et al.* Genetic signatures of exceptional longevity in humans. *PLoS One* 2012; **7**(1): e29848.
346. Terracciano A, Sanna S, Uda M, Deiana B, Usala G, Busonero F *et al.* Genome-wide association scan for five major dimensions of personality. *Mol Psychiatry* 2010; **15**(6): 647-656.

347. Erraji-Benchekroun L, Underwood MD, Arango V, Galfalvy H, Pavlidis P, Smyrniotopoulos P *et al.* Molecular aging in human prefrontal cortex is selective and continuous throughout adult life. *Biol Psychiatry* 2005; **57**(5): 549-558.
348. Bielli P, Busa R, Di Stasi SM, Munoz MJ, Botti F, Kornblihtt AR *et al.* The transcription factor FBI-1 inhibits SAM68-mediated BCL-X alternative splicing and apoptosis. *EMBO reports* 2014; **15**(4): 419-427.
349. Claiborn KC, Sachdeva MM, Cannon CE, Groff DN, Singer JD, Stoffers DA. Pcf1 modulates Pdx1 protein stability and pancreatic beta cell function and survival in mice. *The Journal of clinical investigation* 2010; **120**(10): 3713-3721.
350. Stegh AH, Herrmann H, Lampel S, Weisenberger D, Andra K, Seper M *et al.* Identification of the cytolinker plectin as a major early in vivo substrate for caspase 8 during CD95- and tumor necrosis factor receptor-mediated apoptosis. *Mol Cell Biol* 2000; **20**(15): 5665-5679.
351. Sudhakar JN, Chow KC. Human RAD23 homolog A is required for the nuclear translocation of apoptosis-inducing factor during induction of cell death. *Biology of the cell / under the auspices of the European Cell Biology Organization* 2014; **106**(10): 359-376.
352. Ma J, Fang B, Zeng F, Pang H, Zhang J, Shi Y *et al.* Curcumin inhibits cell growth and invasion through up-regulation of miR-7 in pancreatic cancer cells. *Toxicology letters* 2014; **231**(1): 82-91.
353. Dhami GK, Liu H, Galka M, Voss C, Wei R, Muranko K *et al.* Dynamic methylation of Numb by Set8 regulates its binding to p53 and apoptosis. *Molecular cell* 2013; **50**(4): 565-576.
354. Riaz SK, Iqbal Y, Malik MF. Diagnostic and therapeutic implications of the vascular endothelial growth factor family in cancer. *Asian Pacific journal of cancer prevention : APJCP* 2015; **16**(5): 1677-1682.
355. Gangula NR, Maddika S. WD repeat protein WDR48 in complex with deubiquitinase USP12 suppresses Akt-dependent cell survival signaling by stabilizing PH domain leucine-rich repeat protein phosphatase 1 (PHLPP1). *J Biol Chem* 2013; **288**(48): 34545-34554.
356. Le-Niculescu H, Balaraman Y, Patel S, Tan J, Sidhu K, Jerome RE *et al.* Towards understanding the schizophrenia code: an expanded convergent functional genomics approach. *Am J Med Genet B Neuropsychiatr Genet* 2007; **144B**(2): 129-158.

357. Metkus TS, Timpone J, Leaf D, Bidwell Goetz M, Harris WS, Brown TT. Omega-3 fatty acid therapy reduces triglycerides and interleukin-6 in hypertriglyceridemic HIV patients. *HIV medicine* 2013; **14**(9): 530-539.
358. Le-Niculescu H, Case NJ, Hulvershorn L, Patel SD, Bowker D, Gupta J *et al.* Convergent functional genomic studies of omega-3 fatty acids in stress reactivity, bipolar disorder and alcoholism. *Transl Psychiatry* 2011; **1**: e4.
359. Hammonds MD, Shim SS. Effects of 4-week treatment with lithium and olanzapine on levels of brain-derived neurotrophic factor, B-cell CLL/lymphoma 2 and phosphorylated cyclic adenosine monophosphate response element-binding protein in the sub-regions of the hippocampus. *Basic Clin Pharmacol Toxicol* 2009; **105**(2): 113-119.
360. McQuillin A, Rizig M, Gurling HM. A microarray gene expression study of the molecular pharmacology of lithium carbonate on mouse brain mRNA to understand the neurobiology of mood stabilization and treatment of bipolar affective disorder. *Pharmacogenetics and genomics* 2007; **17**(8): 605-617.
361. Ahmed MR, Gurevich VV, Dalby KN, Benovic JL, Gurevich EV. Haloperidol and clozapine differentially affect the expression of arrestins, receptor kinases, and extracellular signal-regulated kinase activation. *The Journal of pharmacology and experimental therapeutics* 2008; **325**(1): 276-283.
362. Rushlow WJ, Seah C, Sutton LP, Bjelica A, Rajakumar N. Antipsychotics affect multiple calcium calmodulin dependent proteins. *Neuroscience* 2009; **161**(3): 877-886.
363. Meffre D, Massaad C, Grenier J. Lithium chloride stimulates PLP and MBP expression in oligodendrocytes via Wnt/beta-catenin and Akt/CREB pathways. *Neuroscience* 2015; **284**: 962-971.
364. Youngs RM, Chu MS, Meloni EG, Naydenov A, Carlezon WA, Jr., Konradi C. Lithium administration to preadolescent rats causes long-lasting increases in anxiety-like behavior and has molecular consequences. *J Neurosci* 2006; **26**(22): 6031-6039.
365. Bosetti F, Seemann R, Bell JM, Zahorchak R, Friedman E, Rapoport SI *et al.* Analysis of gene expression with cDNA microarrays in rat brain after 7 and 42 days of oral lithium administration. *Brain research bulletin* 2002; **57**(2): 205-209.